



License to krill 
A fundamental valuation of Aker BioMarine 
 
Amund Kleven Rasmussen & Eirik Lindberg 
Supervisor: Tommy Stamland 
 
Master thesis, Economics and Business Administration, 
Financial Economics 
NORWEGIAN SCHOOL OF ECONOMICS 
 
 
This thesis was written as a part of the Master of Science in Economics and Business 
Administration at NHH. Please note that neither the institution nor the examiners are 
responsible − through the approval of this thesis − for the theories and methods used or results 
and conclusions are drawn in this work. 
Norwegian School of Economics  




In this master thesis, we have conducted an extensive strategic and financial analysis of Aker 
BioMarine. The thesis aims to estimate the fair intrinsic value of the equity and share price as 
of October 30, 2020. The fundamental valuation technique has been chosen as the preferred 
method and is supplemented with a relative valuation. The final estimation of the stock price 
was compared with the closing price on October 30 to find the appropriate trading strategy.  
The thesis can be divided into two parts: The first part introduces the industry and its 
companies, along with an in-depth presentation of Aker BioMarine. After presenting the 
industry and the company, the frameworks and theories adopted in the thesis are presented. 
Further, the strategic analysis is conducted. The analysis includes both external industry 
analyses and an internal resource-based analysis complemented with an ESG assessment. The 
external analysis discovered that the industry has high entry barriers with a moderately 
competitive environment, indicating the possibilities to sustain a long-term competitive 
advantage. The internal resource-based analysis indicates that the brand name, value chain, 
patents, and strategic collaborations represent the vital competitive advantages Aker 
BioMarine possesses. However, the analyses suggest that competitive advantages will be 
decreasing in the long run. The first part of the thesis concludes with reorganizing and 
analyzing the company's historical financial performance. The analyses are key for 
understanding the investment case of Aker BioMarine but have their limitations for future 
projections as Aker BioMarine is a high-growth case.  
The second part of the thesis commences with a forecast of the future performance of Aker 
BioMarine based on the strategic and financial analyses conducted in the first part. Further, 
the company's cost of capital and capital structure is forecasted to find the dynamic weighted 
average cost of capital. The fundamental valuation is presented after the cost of capital is 
presented using discounted cash flows, and economic value added. The last chapter before the 
conclusion of the thesis is the relative valuation.  
Based on the analyses in the first part and the projections in the second part, we have valued 
the fair market value of the equity to be NOK 101.67 per share, indicating a potential upside 
of 23.98% as of October 30, 2020. The thesis concludes with a “BUY” recommendation and 
ends with comparing our valuation and the investment banks' estimates.  
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In the first chapter, the motivation for the topic, industry, and company will be rationalized. 
Further, the purpose of the thesis and its limitations is presented. Lastly, the thesis' structure 
and composition is presented so that the reader can navigate the thesis easier.  
1.1 Motivation and choice of company 
The master thesis is a concluding part of our Master's degree in Economics and Business 
administration at the Norwegian School of Economics. The thesis is based on the knowledge 
acquired through BUS440A Verdsettelse, FIE402 Corporate Finance, FIE437 Venture 
Capital, Private Equity, and IPOs, and FIE443 Mergers and Acquisitions. These courses aim 
to provide one with the knowledge and tools to make extensive and fundamental analyses of 
companies. Combining these courses has provided us with different approaches we can apply, 
which is essential in cases involving a high degree of uncertainty. Throughout the years at 
NHH, the authors have obtained a significant interest in financial statement analysis and 
valuations. We view it to be of high importance to both understand and have the ability to 
analyze complicated cases such as Aker BioMarine when commencing our careers. Lastly, 
concluding our studies at NHH with a valuation allows us to deploy and utilize the tools and 
knowledge acquired throughout our studies in a challenging valuation case.  
There are multiple reasons we decided to write our master thesis about Aker BioMarine. The 
company was listed on Merkur Market, termed Euronext Growth from November 9, on July 
6, 2020. During the first day of trading, the company lost of NOK 1bn in market capitalization 
(Bærland, 2020). Even with the weak opening in the stock market, industry analysts 
proclaimed the stock to be immensely underpriced (figure 40). The company is frequently 
mentioned in the media, and the potential of the company is vast, which makes an analysis of 
the company even more compelling and challenging. Before settling on a company, it was 
agreed that we wanted a challenging valuation case in an industry none of us were familiar 
with, as it is both motivating and fascinating to acquire new knowledge about an unacquainted 
industry. Aker BioMarine was a company that the analysts stated was trading for pennies on 
the dollar, which caught our interest. Was the company as underpriced as the equity 
researchers asserted?  
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1.2 The objective of the thesis 
The master thesis aims to estimate the intrinsic value of Aker BioMarine's equity by deploying 
a fundamental valuation, supported by relative valuations. The estimation of the equity's fair 
market price reflects the company's fundamental economic qualities and future aspects. The 
thesis aims to represent the intrinsic value of Aker BioMarine, as the authors consider it to be. 
The valuation is based on projections and forecasts of an uncertain future, which is greatly 
influenced by the assumptions, expectations, and simplifications of the reality taken by the 
authors. To add more weight to our valuation, we utilized a relative valuation to support our 
final estimate of the intrinsic value. The valuation of Aker BioMarine is based on publicly 
available information, including everything up until October 30, 2020. Lastly, our estimation 
of the stock price's fair market value is compared to the closing price on October 30, 2020, to 
assess whether the stock is overpriced (underpriced) and recommend a trading strategy based 
on the findings. The thesis's research question is: 
“What is the intrinsic value of Aker BioMarine's equity on October 30, 2020?” 
1.3 Limitations 
The information treated in the master thesis is exclusively based on publicly available 
information. This includes quarterly reports, annual reports, market data, and other available 
information for every external third-party. No information in the thesis is acquired from an 
insider or employee of the company. The only exception is the annual report of 2017, which 
was missing from the website. The cut-off date is set to October 30, 2020, and the estimated 
value of the equity will be compared with the closing price on the same date. Thus, we have 
utilized the Q3 report in the thesis, but the launch of their new segment, “Lysoveta,” is not 
considered as it happened in late November 2020. 
The thesis focused on two valuation methods: fundamental and relative valuation. 
Fundamental valuation is chosen as the primary technique and is only supplemented by the 
comparative method. Further, we have selected peers based on what we deem to be of future 
peers that are publicly available. The companies operating in the krill industry are largely 
private companies, making it difficult to assess their financial position. We needed to look 
outside the krill industry to find suitable peers to implement a relative valuation. The selected 
peers are Glanbia Plc, Midsona AB, Probi Plc, and DSM.  
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These companies will be analyzed together with Aker BioMarine in the thesis. Aker 
BioMarine is valued as a stand-alone company, even with Aker ASA being the majority owner 
with 77.8% (Aker BioMarine 2020a). 
1.4 Structure of the thesis 
The thesis consists of two parts: the first part consists of chapters 2, 3, 4, and 5. In the second 
chapter, the industry is presented together with Aker BioMarine and close competitors. The 
third chapter is the presentation of the theories and frameworks utilized throughout this thesis. 
The fourth chapter is a qualitative strategic analysis of Aker BioMarine. The chapter 
commences with external industry-oriented analysis where both PESTEL and Porter's five 
forces are employed to assess the macro-environment. The chapter continues with an internal 
resource-based analysis of Aker BioMarine. The chapter concludes with summarization in a 
SWOT analysis. The fifth chapter is the historical financial statement analysis, where the 
company ultimately is compared with the selected peers. 
The second part of the thesis comprises of chapters 6, 7, 8, 9, and 10. The sixth chapter 
introduces the projections and forecasts of Aker BioMarine's financial statements and 
performance in detail. The seventh chapter introduces and computes the frameworks for 
estimating the cost of capital and approximating the company's capital costs. The eight chapter 
is the fundamental valuation, where both discounted cash flows and economic value added 
methods are utilized. The nineth chapter is the relative valuation, where the different multiples 
are implemented to assess Aker BioMarine against peers' selection. The thesis concludes with 
the presentation of a recommended trading strategy as of October 30, 2020.  
It should be noted that all assumptions, expectations, and views presented in the master thesis 
are our own. If otherwise, a source is cited to credit the original author for its views and 
arguments.  
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2. Introduction to Aker BioMarine 
This paper aims to determine the intrinsic and fair share price of Aker BioMarine and provide 
a buy/hold/sell recommendation. Before analyzing the company, it is vital to have a sound 
understanding of the industry in which Aker BioMarine operates. This chapter aims to provide 
the reader with a solid foundation of both the industry and Aker BioMarine's operations. This 
chapter will commence with the introduction of the industry before presenting the company. 
Lastly, we will give a brief introduction to the main competitors to understand the competitive 
environment. 
2.1 Market introduction 
The paper commences with an overview of the past, present, and future of the krill market, 
focusing on Aker BioMarine. The development of the market and its characteristics are 
essential in understanding how the company will develop further and grow. Antarctic krill 
(Euphasia Superba) are small crustaceans that live in the Antarctic Ocean. Although difficult 
to measure, krill's biomass is reported to be the largest on earth, with an estimated 350 to 400 
million metric tons (MT) located in the Antarctic Ocean (CCAMLR, 2018). The market has 
an annual quota of 620 000MT, which is less than 1% of the estimated biomass. Today, the 
market operates as an “Olympic fishery,” meaning the season is over when the quota is 
reached. The players in the market are few but large. Aker BioMarine is the industry's definite 
leader as they expect to catch ~63% of the quota by the end-2020 leaving the remaining 37% 
to the remaining competitors (Aker BioMarine, 2020b). 
It is an industry with high entry barriers, and large capital bases are a requirement to play. The 
significant players embrace a rapid expansion in production capacity and manufacturing 
locations to gain a stronghold. Further, the industry is increasing its research and development 
(“R&D”) efforts to expand its presence and maintain its market position according to 
consumer needs. In addition to high efforts in R&D, the industry has undergone significant 
consolidation in the past decade, with large players engaging in mergers and acquisitions 
(“M&A”). They acquire smaller players to consolidate their position in the krill oil market, 
and the increasing strategic alliances among players may intensify the competitive 
environment (Mordor Intelligence, 2020). 
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The harsh competitive environment in the market has incentivized product development to 
find new ways to monetize krill. For instance, Aker BioMarine recently introduced the 
powdered form of krill and is expected to launch a gummy paste of krill oil soon (Mordor 
Intelligence, 2020). The industry is also looking to leverage krill by creating food for the global 
population as the carbon footprint per gram of protein is amongst the lowest discovered 
(Figure 1). Since the beginning of the century, there have been significant R&D efforts to 
create both human and pet food out of krill, whereas only the latter is greenlighted for 
commercial production (Aker BioMarine, 2020b). 
2.1.1 The market for human nutrition 
The Sustainable Development Goals (“SDGs”) presented by the United Nations are the 
blueprint for achieving a better and more sustainable future for the entire world. However, all 
the SDGs have one thing in common; they are indirectly affected by nutrition and food 
security. According to the Global Nutrition Report (2020), on a global scale, 1 in 9 people is 
malnourished, and 1 in 3 people is overweight or obese. The growing population and middle 
class disrupt the way people eat, and the food industry is already accounting for close to a 
quarter of global greenhouse gas emissions (Poore et al. 2018). Thus, it is necessary with 
actions by the industry and the population to reach the SDGs. Improving the wellbeing and 
nourishment of people and animals through sustainable development in products and 
supplements containing key nutrients is a considerable element to a healthy and prosperous 
life for us all. 
Figure 1: Protein sources CO2 emissions: t Co2 C/t edible protein 















Krill Salmon Poultry Pork Beef
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The existing food system will struggle to deliver enough protein and nourishment to the 
growing population. The need for sustainable development is imminent, and krill could be a 
part of the solution. Krill has a low greenhouse gas intensity per edible protein, being only 
1.48% and 50% of what beef and salmon require, respectively (Figure 1). The market 
participants are looking to solve these problems by introducing krill-based dietary 
supplements and upcoming protein foods for humans, primarily in oil or meal. The krill-based 
omega-3 has already been introduced to the market, but the potential for further expansion is 
vast as ~70% of the current global population is in a state of omega-3 deficiency (Hamilton et 
al., 2020). The market for omega-3 reached ~USD 4.1bn in 2019 and is expected to surge to 
USD 8.5bn in 2025. Implying a CAGR of 13.1%, according to Research and Markets (2019). 
In terms of the market share, the global omega-3 ingredients market for human consumption 
in 2018 was 111 210MT, where krill only held the fraction of 0.8% (859MT) in terms of 
volumes, but a significantly higher value at 7.4% (USD 102mn) (Research and Markets, 2019). 
Figure 2: Sales of EPA and DHA acids - market share per region (2018) 
Source: Research and Markets (2019) 
There is an increased demand for high concentrated krill oil in omega-3 supplements, as it is 
beneficial to the general health and reduces the dosage of the capsule intake due to more potent 
antioxidants. Krill oil contains a potent antioxidant called "astaxanthin," which has been used 
to promote hearth health benefits, and various studies have proved better absorption of krill 
oil than fish oil (Mordor Intelligence, 2020). With the rise of nutraceuticals in the past decade, 















Krill is not only a good source of protein and omega-3 but has also shown signs to combat 
several health problems. Since the beginning of the century, there has been a noticeable 
increase in krill oil research and promotion for its benefits (Kwantes et al., 2015). The research 
includes areas of management and treatment of conditions such as hyperlipidemia (Bunea et 
al., 2004), chronic inflammation (Banni et al., 2011 & Ulven et al., 2011), arthritis (Deutsch, 
2007), and premenstrual syndrome (Sampalis et al., 2003). The focus of the research of krill 
oil has evolved around the content and form of the EPA and DHA acid (Bunea et al., 2004; 
Banni et al., 2011; Deutsch, 2007; Krill oil, 2010; Ulven et al., 2011; Sampalis et al., 2003; 
Maki, Reeves, & Farmer 2009). Using krill oil as a dietary supplement could be a cost-
effective and organic way for patients to relieve symptoms without employing prescription 
drugs. 
2.1.2 The market for pet nutrition 
Krill is a relatively new ingredient in pet foods but brings healthy nutrients and fats to its meal. 
The nutrition market is traditionally a lesser value category than human foods, but it has 
experienced significant growth in the past years. The food ingredient in the production market 
for animal consumption has been dominated by soybean. The krill market is mostly untapped, 
and it could prove to be an attractive alternative to the soybean, given its high levels of protein 
and fatty acids. Pet feed is a new market for the industry, which is yet to be fully taken 
advantage of, and the global pet food market has grown by nearly 3.5% over the past years 
(Euromonitor, 2020a). Euromonitor (2020a) forecasts it to expand its growth to 4.2% per year 
from 2020 through 2025e globally. These numbers imply opportunities to monetize in this 
market, and players such as Aker BioMarine has already begun to tap into the market.  
2.1.3 Recent developments 
During the past decade, the health industry has introduced a broad, holistic approach to health 
and prevention, which has encouraged consumers to purchase vitamins and dietary 
supplements (Euromonitor, 2020b). Access to more information and constant connectivity is 
changing both the ways consumers purchase and what they demand. For instance, the US retail 
sales of omega-3 plunged between 2012-2014, following a 2012 study claiming an association 
between omega-3 fatty acid supplementation and the increased risk of major cardiovascular 
diseases, compounded by the 2013 Brasky prostate cancer paper.  
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The adverse combination of this sparked a market drop of 25-30% in the sales. Though, the 
conclusion of the 2012 report was proven misleading, and the sales recovered to an annual 
growth rate of 5% in the US (Euromonitor, 2020b). This supplement hype has been a vital part 
of the continued growth of krill companies. Looking at the global Google search activity, 
omega-3 has been steadily increasing since 2004, reaching an all-time high in 2020. However, 
the search activity for "krill" and "krill oil" has stayed constant in the past decade. 
Figure 3: Google search history – Global results 
Source: Google Analytics (2020) 
The krill industry has experienced a high consolidation level with considerable R&D efforts 
to develop new products to penetrate new markets. The efforts have resulted in the recent 
entrance to the market for pet foods. The industry leader, Aker BioMarine, recently 
collaborated with the largest dog sledding race, The Iditarod, and other races. Their goals are 
to help the sport and community to grow, strengthen the race organizations, and showcase the 
world-class dog food they produce. The company uses the races to showcase how their dog 
food affects a dog's performance and health. According to Aker BioMarine, the nutritional 
ingredients have positive health benefits for dogs resulting in reduced muscle damage and 
inflammation.  
Aker BioMarine became the first player in the industry with a fully integrated value chain in 
2016, and the results have proven to be unmatched by any other competitor. Various Antarctic 
krill fisheries have been looking to expand their value chain to catch up with Aker BioMarine, 
and the increased R&D and capital expenditures (“Capex”) efforts have been deployed to do 
so. Due to the longevity of the R&D and capex deliveries, it may take years before the 























Omega-3 Fish oil Krill oil Krill
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2.1.4 Going forward 
Typically, a few vessels have entered the market every year, but the added capacity has been 
offset by an equivalent number of vessels leaving the market, keeping the overall capacity 
almost constant. Aker BioMarine's new vessel, Antarctic Endurance, delivered in 2019, has 
demonstrated a significant capacity increase in the market. The significant scale advantage has 
led to the expected catch of 388 000MT in 2020, nearly 129 000MT per vessel, compared to 
competitors 17 000MT per vessel (Aker BioMarine, 2020b). There is now a pipeline of new 
vessels potentially entering the market over the coming years – where the first deliveries were 
in May 2020. 
There are signals from the market that various players are increasing their efforts to catch up 
with Aker BioMarine's superior position. Shanghai Chonghe Marine Industry (CMI) placed 
an order for a krill-harvesting vessel in March 2020, the second krill trawler designed by 
Wärtsilä for CMI and considerably more extensive than the first one launched in Shanghai in 
2020 (Wärtsilä, 2020). According to Wärtsilä, 2-3 vessels are now under construction or 
design in China, but no further information has been disclosed. Another large Norwegian 
player is Rimfrost, which entered a NOK 1bn agreement with Westcon to build a new krill 
fishing vessel (Rimfrost, 2019).  
The global population is expected to reach ten billion by 2050, and the global demand for 
protein will double. We note that 70% of the earth's surface is oceans, and 11% of the landmass 
is farmed, while only 2% of food consumption stems from the ocean (FAO, 2017). We believe 
this creates a beneficial foundation and backdrop for growth in the aquaculture market. 
2.2 Aker BioMarine 
Aker BioMarine was established as an independent enterprise in 2006, after being a business 
unit in the Aker Group focusing on deep-water fishing. The previous business activities were 
organized under Aker Seafoods Holding (100% subsidiary of Aker ASA), apart from the 
biotech company Natural. Today, the company is a full-service marine biotechnology 
company and was relisted on Merkur Market July 6, 2020, after the 2012 delisting. Aker 
BioMarine is the industry leader within krill harvesting and processing, accounting for nearly 
70% of all krill harvesting in Antarctica and 80% of the krill oil production (Aker BioMarine, 
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2020b). Globally, they operate 3 out of 13 krill harvesting vessels and owns a krill oil 
extraction facility in Houston, Texas.  
Over the past decade, they have invested over USD 600mn to build up their industry leadership 
through an aggressive M&A strategy and large investments in new vessels. The group has four 
large vessels (three for harvest and one support), with another support vessel expected for 
delivery in 2021. The combination has yielded a superior position in terms of capacity, scale, 
and unit costs, with reduced earnings volatility backed by a strong portfolio of contracts that 
are decoupled from commodity prices (Aker BioMarine, 2020b). The majority of revenue 
come from long-term contracts (57%) or 1-year contracts or predictable volumes (33%), with 
only the remaining 9% of revenues from the spot market (Aker BioMarine, 2020b). The fully 
integrated value chain has resulted in an excellent position concerning efficiency, as the 
younger and more massive fleet has ~7-8x that their peers possess (Aker BioMarine, 2020b). 
Lastly, the biotech company also has 76 patents and more than 1 200 patent claims gained 
through 15 years with intensive R&D investments.  
Aker BioMarine has also dedicated itself to four of the UN's sustainable development goals 
(2, 3, 12, and 14), and the company is highly dedicated to a sustainable agenda (Aker 
BioMarine, 2020b). Its core focus lies in preventing lifestyle diseases, increase resource 
utilization, and promoting sustainable fishery practices. Further, the company has kept a 
constant and close dialogue with environmental organizations such as WWF Norway and the 
Commission for the Conservation of Antarctic Marine Living Resources (“CCAMLR”) to 
ensure its operations have a low impact on both the climate and ecosystem in the Antarctic 
ocean.  
One of the patents they hold is the so-called 'eco harvesting' technology, which reduces the 
by-catch and stress on the krill. Krill has traditionally been viewed as commercially inviable 
and environmentally challenging to sustain, but the company solved this through the new eco 
harvesting technology. Aker BioMarine is also regarded best-in-class for their management of 
the krill fishery, in an industry that has exceptionally well-managed fisheries (MSC, 2018). 
Acquisition of Lang Pharmaceuticals 
The 2019 acquisition of Lang paved the way for Aker BioMarine to gain access to 
pharmaceutical production capabilities and nearly 85% of retail stores in the US (Aker 
BioMarine, 2020b). Lang is a full service, mass-market private label, and corporate-brand 
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manufacturer. The firm produces 146 products across 15 categories for all major US retailers. 
By leveraging Lang's expertise, they established the fast-moving consumer goods (“FMCG”) 
company Epion in 2020, intending to build a USD 100mn brand by 2025. Its strategy is to 
reinvest EBITDA in marketing, allowing for market development to deliver the targeted USD 
100mn by end-2025. In Q2 2020, Epion launched a new brand: 'Kori,' a krill oil supplement 
for humans. The product has been rolled out to close to half of the targeted 85% of relevant 
US retail stores. It is a high gross margin product, and with full effects of Kori, it may deliver 
Aker BioMarine's targeted gross margin of >70% for Epion. 
2.2.2 Segments 
Aker BioMarine's two primary segments are “Ingredients” and “Brands.” Ingredients 
primarily produce and market ingredients for humans, pet feed, and aquaculture. Its “Qrill” 
products range consists of krill meals, oils, and high-protein specialty meals. This segment 
also includes its wholesale B2B brand “Superba,” which produces high-quality krill oil for 
human consumption.  
Exhibit 1: Overview of Aker BioMarine’s divisions (All numbers from FY2019) 
Source: Aker BioMarine (2020a&b) and own creation 
The segment accounted for ~ 70% of sales and 75% of the 2019 EBITDA. The latter segment 
results from the 2019 acquisition of Lang for USD 91.1mn, with an earnout of USD 60mn, 
and the segment experienced an 89% year-on-year (“YoY”) growth in Q1 2020. 
The acquisition provided direct access to the US retail market and strong relationships with its 
largest retailers. Aker BioMarine also produces its new krill oil supplement through its new 
FMCG company Epion. In the past years, the group has focused on its B2B operations to drive 
Ingredients Brands
Share of revenue:Share of revenue: 68% 32%
Revenue: USD 82mn






- First brand ‘Kori’ was 
launched in 2020
- All EBITDA will be 
reinvested for growth
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- Superba: 54%
- Qrill Aqua: 39%
- Qrill high-protein:          5%






revenues. However, with the recent Lang acquisition and the new Epion brand, there will be 
an increased focus on B2C to drive the margins going forward. The revenue split between the 
two segments is expected to be nearly 50%< Brands and 50%> Ingredients in 2024 (Aker 
BioMarine, 2020b). 
2.2.3 Revenue and production growth 
Aker BioMarine's revenue growth averaged at nearly 11% between 2012 and 2016 (Aker 
ASA, annual reports 2012-2016) before it augmented 30% in 2017 – 2019 (Aker BioMarine, 
annual reports 2017-2019). The significant boost can be attributed to the Lang acquisition in 
2019, which contributed with ~USD 90mn. The organic growth in 2019 was 15% YoY, and 
in April 2019, the firm reported revenues of USD 24.5mn, up 31% from USD 18.7mn in 2018. 
The adjusted EBITDA margin averaged 16% in 2012 – 2016 and 20% in 2017 - 2019.  
Figure 4: Aker BioMarine's revenue development 
Source: Aker ASA annual reports and Aker BioMarine annual reports 
Aker BioMarine owns and operates the purpose-built plant for krill oil production in Houston, 
Texas. The plant produces 85% of all krill oil globally, and can with its “Flexitech” 
technology, produce krill oil with high quality and a high content of beneficial compounds 
without any off-putting taste or scent. Aker BioMarine grew its total krill oil sales from USD 
59mn in 2017 to USD 96mn in 2019, representing 63% growth. Lastly, they also presented a 
YoY growth of 63% of krill oil in Q1 2020.  
Aker BioMarine has grown its production volume by nearly 40% from 29 200MT in 2017 to 
40 900MT in 2019, lifted by delivering the new vessel “Antarctic Endurance.” The production 
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averaged 20 fewer fishing days in Q1 2020 YoY due to adverse weather conditions in 
Antarctica (Aker BioMarine, 2020b). It is important to note that the large discrepancies 
between the total catch volume and production are explained by the krill's large water content 
(~85%), which evaporates when the krill is processed (Aker BioMarine, 2020b). 
2.3 Other significant players in the krill industry 
To wrap up the introduction, we will briefly present the main competitors in the krill industry. 
These firms harvest krill and produce krill oil but do not operate the whole value chain as Aker 
BioMarine does. We do believe it is essential to present these firms to give the reader a better 
understanding of the industry dynamics and the competitive environment. When selecting 
peers, one wants to choose companies comparable with Aker BioMarine along dimensions 
such as business characteristics and operations. However, the krill industry is a relatively 
young industry where the companies' different characteristics are vast, making it difficult to 
find perfect peers. Further, most companies are either private or a subsidiary of a 
conglomerate, making it difficult to derive the financials. Thus, the peers presented in the 
following subchapter is only to gain a better understanding of the industry and not for 
comparing financial- or operating metrics. 
Rimfrost AS  
Rimfrost is a private Norwegian vertical integrated biotech company based in Ålesund, 
established in 2001 by Stig Rune Remøy. Today, the firm only employs 11 people but has 
intentions to expand as the new vessel is delivered (Rimfrost, 2020a). Its core operations are 
krill-harvesting and production of krill derived products. Rimfrost is the second-largest 
producer in Norway and a significant player in the industry that produces both krill oil and 
omega-3 powder for humans and animal feed. They are also a pioneer within the R&D of krill 
products, as they have developed quality markers to test the krill oil for its quality. Lastly, 
Rimfrost was one of the first players to develop powder-based krill products for human 
consumption (Rimfrost, 2020b). Rimfrost presented negative revenues in 2016, which stem 
from a lawsuit from a customer in the US, which resulted in a reversing of the sales.   
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Figure 5: Rimfrost AS’ revenue development 
Source: Proff.no (2020) 
Dongwon Industries (“DWI”) 
Dongwon industries CO is a South Korean deep-sea fishing company that produces and 
distributes fish, shellfish, crustaceans, and processed seafood. The company was founded in 
1969 and has grown to be a significant player in the seafood industry. In 2009, the company 
acquired E. Farm Inc, a wholly-owned subsidiary of the company. The company recently 
invested NOK 50mn in the Norwegian on-land salmon farming company Salmon Evolution 
(Salmon Evolution, 2020). Dongwon Industries has three different divisions: Fisheries 
division, which catches, processes, and transports the marine products. Distribution division: 
which distributes the marine produces to Japan, the US, and Europe. Lastly, the logistics 
division is engaged in the transportation, warehousing, and shipping services.  
The conglomerate does not operate the whole value chain in its krill operations. They only 
harvest the krill from Antarctica and produce krill oil. The company has no in-house R&D 
department for its krill operations or ingredient productions. Its sale of krill oil is wholesaled 
to department outlets, nor do they have their sales and marketing department. 
Figure 6: Dongwon Industries revenue development 
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Shanghai Chonghe Marine Industry (“CMI”) 
Shanghai Chonghe Marine Industry Co., Ltd. is the parent company of Jiangsu Sunline Deep 
Sea Fishery Co., Ltd. (“Sunline Fishery”). It is a comprehensive enterprise with diversified 
business. Since its establishment, CMI has been focusing on shipbuilding and marine industry 
and has invested in ship repair, ship design, ship trading, ship financial leasing, ship 
management, marine mining, offshore wind power, polar fishing, marine aquaculture, 
environment, and other fields. 
Sunline Fishery, managed by CMI, specializes in the development and utilization of Antarctic 
krill resources. Sunline is invested in an Antarctic krill fishing vessel called “Shen Lan,” 
meaning “Deep Blue,” launched from Shanghai previously this year. It is the world's largest 
krill fishing vessel, which uses onboard processing technology and is the only one in China. 
Deep Blue's goal is to sail in Antarctica by the end of 2020 and harvest krill. Sunline Fisheries 
is the leader of China's fully integrated Antarctic krill resources. 
China has a set goal to become a global leader in the krill industry, and CMI has commenced 
the journey in 2020. CMI has planned its entry in the krill industry for years, as it already in 
2017 entered a joint venture with Neptune Technologies and Bioresources Inc. to accelerate 
the sale of omega-3 products in China (Reuters, 2017). The company expects to be one of the 
industry leaders once the delivery of their ordered vessel arrives. 
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3. Choice of the valuation frameworks 
By an in-depth examination of the highly influential theoretical valuation frameworks of 
Koller et al. (2020), Damodaran (2012), and related finance literature, we identify three 
valuation techniques of particular importance in modern valuation theory. The first approach 
is the discounted cash flow ("DCF")-based model, which has its foundation in the present 
value ("PV") rule and prices an asset based on its expected future cash flows. Secondly, the 
relative valuation approach values assets based on the market values of similar assets. The 
final method is the contingent claim approach to valuation, in which option pricing models are 
utilized to calculate the value of assets with option characteristics. Although these approaches 
have the same end goal of valuing an asset, the outcomes and applications can vary. In the 
following sections, we will discuss these models' attributes and our choice of methodology in 
greater detail. The chapter will be closed off with an introduction to the step-by-step approach 
that we will utilize to derive our final valuation estimate. 
3.1 DCF-based valuation approach 
The discounted cash flow valuation methodology focuses on an asset's fundamentals to derive 
an estimate of the asset's intrinsic value. DCF involves taking the expected future cash flows 
of an asset and discounting them with the right discount rate to arrive at the present value of 
cash flows (Damodaran, 2012). The general DCF model is expressed through the following 
equation: 






Where,  𝑛 = Asset life 
  𝐶𝐹𝑡 = Period t cash flow 
  𝑟 = Discount rate 
While a range of discounted cash flow approaches exists in today's financial literature, the 
literature is generally divided between four commonly used DCF-based methods (Koller et 
al., 2020): the equity valuation method, the enterprise discounted cash flow method, the 
 26
discounted economic profit method, and the adjusted present value method. Appropriately 
implemented, all the methods mentioned in this sub-chapter will yield the same value. 
3.1.1 The equity valuation approach 
The equity valuation method is used to value only the equity claims on the business. The equity 
cash flows show the expected amount of additional cash the firm will have on-hand to conduct 
repurchases of shares or to pay dividends within each given year. Given that these projected 
cash flows represent payments to equity holders, the correct discount rate should be the equity 
cost of capital (Berk & DeMarzo, 2020). The discounted cash flow to equity formula is 
presented below: 







Where,  𝑛 = Asset life 
  𝐶𝐹 𝑡𝑜 𝑒𝑞𝑢𝑖𝑡𝑦𝑡 = Period t cash flow to equity 
  𝑘𝑒 = cost of equity 
Although the firm and equity models use different cash flow definitions and discount rates, 
both models should produce the same output in terms of equity value as long as the valuation 
assumptions are used consistently. Cash flow to equity is calculated by adding non-cash 
expenses to net income to determine the gross cash flow. Working capital investment is then 
subtracted, along with fixed assets and non-operating assets. To this, debt increases and 
increases other non-equity claims are added, whilst any decreases in debt or other non-equity 
claims are subtracted to finally arrive at the cash flow to equity (Koller et al., 2020). 
In the discounted cash flow to equity formula, the cost of equity is used as the correct discount 
rate, as this method does not adjust for non-operating assets or debt contrary to the WACC-
based enterprise model. This is frequently pointed out as one of the model's risk aspects, as it 
does not take into account any potential changes in the debt-to-equity ratio unless the cost of 
equity is adjusted accordingly to mirror the risk inflicted on equity holders. Moreover, the 
equity model is also problematic because it prices non-operating assets, as the non-operating 
and operating cash flows are incorporated in the cash flow to equity and are discounted at the 
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same discount rate. Consequently, the equity methodology can be challenging to implement 
correctly in certain investment cases (Koller et al., 2020). 
3.1.2 The enterprise discounted cash flow model 
In the enterprise DCF approach to valuation, the firm's entire value is estimated by discounting 
the cash flows to all firm claim holders at the weighted average cost of capital (“WACC”) rate. 
By doing this, the value effect of the debt tax benefits and debt risk is incorporated into the 
firm valuation. Although the firm and equity models use different cash flow definitions and 
discount rates, both models should produce the same output in terms of equity value as long 
as the valuation assumptions are used consistently. Koller et al. (2020) describe a four-step 
process in order to derive the value of a company's equity using the enterprise DCF approach: 
Estimation of the value of the firm's operations 
The value of the operating assets of a firm is estimated by discounting the free cash flow to 
the firm at the cost of capital. This value estimate represents the value of all firm investors' 
claims independent of company financing, including debt holders and equity holders. In the 
most general case, the model can be written as follows (Damodaran, 2012): 






Where, 𝑛 = Asset life 
  𝐹𝐶𝐹𝐹𝑡 = Period t free cash flow to the firm 
  WACC = weighted average cost of capital 
Identification and valuation of non-operating assets 
Further, to arrive at the enterprise value, the value of non-operating assets is added to the firm's 
discounted free cash flow. These non-operating assets are assets that possess value but are 
valued separately and are not enclosed in regular operating profits or accounting revenues. 
Among the most frequently encountered non-operating assets, we have marketable securities, 
excess cash, investments in public firms and private firms, and tax loss carryforwards.  
As these non-operating assets all have different characteristics, individual asset characteristics 
will have to be considered when valuing them (Koller et al., 2020). 
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Identification and valuation of debt and other non-equity claims 
Before extracting the enterprise DCF approach's equity value, the value of all non-equity 
claims needs to be calculated. Although non-equity claims are a broad concept, it can be 
divided into four categories (Koller et al., 2020). The first category is traditional corporate 
debt, which can be raised directly as private debt from banks or groups of investors or public 
debt in the public marketplace. Standard corporate debt instruments include mortgage bonds, 
debentures, notes, and asset-backed bonds (Berk & DeMarzo, 2020). The second one, debt 
equivalents, is the same as regular debt but without the same formal requirements. Debt 
equivalents encompass operating leases, provisions, contingent liabilities, and preferred stock. 
Further, the portion of the minority interest in other entities must also be identified and valued. 
Lastly, hybrid financial claims such as convertible bonds and stock options should also be 
considered when valuing non-equity claims. 
Extraction of the shareholder's equity value 
Finally, once a value is attached to the non-equity claims, the shareholder equity value can 
now be calculated by deducting the value of non-equity claims from the firm value. Although 
the enterprise DCF model and equity model use different cash flow definitions and discount 
rates, both models should produce the same output in terms of shareholder's equity value as 
long as the valuation assumptions are used consistently. The price per share can be calculated 
by dividing the total shareholder's equity value by the firm's most recent number of undiluted 
shares outstanding. Using the undiluted shares outstanding is essential to avoid a double-
counting problem, as we remember having already subtracted the stock options and 
convertible debt from firm value by the deduction of non-equity claims. 
The enterprise discounted cash flow is the preferred valuation method among both academia 
and practitioners as it builds upon a company's cash flow, contrary to the accounting-based 
earnings in the economic profit model (Koller et al., 2020). Although the firm and equity 
models use different cash flow definitions and discount rates, both models should produce the 




3.1.3 The discounted economic profit model 
While the enterprise discounted cash flow builds upon a company's cash flows, the discounted 
economic profit model, or economic value added (“EVA”) model, spotlights the origin and 
timing of value creation through the use of accounting-based earnings. It uses the DCF 
methodology explained in the previous subchapters and will, through proper implementation, 
yield the same shareholder's equity value as Eq.2 and Eq.3. It is based on the economic profit 
measure, which is expressed through the following equation (Koller et al., 2020): 
 𝐸𝑐𝑜𝑛𝑜𝑚𝑖𝑐 𝑝𝑟𝑜𝑓𝑖𝑡 =  𝐼𝑛𝑣𝑒𝑠𝑡𝑒𝑑 𝑐𝑎𝑝𝑖𝑡𝑎𝑙 ×  (𝑅𝑂𝐼𝐶 −  𝐶𝑜𝑠𝑡 𝑜𝑓 𝑐𝑎𝑝𝑖𝑡𝑎𝑙) Eq.4 
Where, ROIC = Return on invested capital 
Now, by making use of the general DCF model, as illustrated in Eq.1 along with algebraic 
transformations, we end up with the following general formula for discounted economic 
profits: 






Economic profit is a measure of a company's value creation in a single period. This valuation 
measure is beneficial when examining if value creation in specific businesses has changed 
from one year to the next. However, one issue is that it does not do an outstanding job 
describing variation in economic profit for different size businesses. Nonetheless, since the 
discounted economic profit model is derived from the DCF formula, both models' valuation 
output should be identical when implemented correctly (Koller et al., 2020). 
3.1.4 The adjusted present value model 
The adjusted present value model ("APV") is a flexible valuation method with a particular 
focus on considering corporate tax and financing side-effects. The APV is calculated by 
combining the levered firm's value with the present value of tax benefits and deducting the 
present value of financial distress costs. The APV is expressed through the following equation: 
 𝐴𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝑝𝑟𝑒𝑠𝑒𝑛𝑡 𝑣𝑎𝑙𝑢𝑒 = 𝑉𝑈 + 𝑃𝑉(𝐼𝑇𝑆) − 𝑃𝑉(𝐶𝐹𝐷) Eq. 6 
Where, 𝑉𝑈 = Unlevered value 
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𝑃𝑉(𝐼𝑇𝑆) = Present value of interest tax shield 
𝑃𝑉(𝐶𝐹𝐷) = Present value of costs of financial distress 
To arrive at the adjusted present value using the equation shown in Eq.6, we estimate the firm's 
value in three steps (Damodaran, 2012). 
Value of the unlevered firm 
The first part of the APV approach requires estimating the firm value with no leverage, 
essentially valuing the firm as if it had no debt. To complete this step, the free cash flows will 
have to be discounted by the firm's cost of capital if it was without debt financing, known as 
the unlevered cost of capital (or "pre-tax WACC"). The following equation returns the 
unlevered cost of capital: 







Where, 𝐸 = Market value of equity 
  𝐷 = Market value of debt 
  𝑟𝐸 = cost of equity 
  𝑟𝐷 = cost of debt 
Further, the expected free cash flows of the firm are discounted at the unlevered cost of capital 
as follows to arrive at the value of the unlevered firm: 






The present value of interest tax shield 
After calculating the value of the unlevered firm, the next step is to examine today's value of 
the interest savings from debt financing. The benefit of the interest tax shield is calculated by 
multiplying the interest payments with the firm's corporate tax rate. The interest tax shield is 
discounted by the appropriate cost of capital to reflect the riskiness of interest payments.  
To provide a general example, a firm that manages a target leverage ratio will have to apply a 
cost of capital that reflects the risk of the firm's cash flows, that is, the unlevered cost of capital. 
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Vice versa, if debt-levels are fixed in advance, the interest tax shield should be discounted 
using the cost of debt (Berk & DeMarzo, 2020). 
Effect of borrowing and expected cost of bankruptcy 
The third and final step is to examine the effect of bankruptcy costs. There are three key 
components in evaluating bankruptcy costs: The first is the probability of bankruptcy, the 
second is the expected cost in the case of bankruptcy, and the third is the appropriate discount 
rate for bankruptcy costs (Berk & DeMarzo, 2020). In practice, calculating the components 
mentioned above is considered challenging, and most practitioners ignore the use of expected 
bankruptcy costs due to various reasons (Koller et al., 2020). Meanwhile, the APV approach 
is appreciated by many due to its flexibility in considering side-effects from tax and financing. 
When these three steps are concluded, the adjusted present value can be determined using 
Eq.8. 
3.2 The relative valuation approach 
The previous subchapter explained the discounted cash flow-based model's recognition among 
investors as a flexible and insightful valuation methodology. For a simpler and easier-to-
understand approach to valuing an asset, an investor may look to relative valuation instead. In 
relative valuation, an investor deploys a relatively quick and easy method of evaluating an 
asset by comparing the asset in question with similar assets already priced in the marketplace. 
One of the critical aspects of successful relative valuation is transforming prices into 
standardized ratios and multiples of firm measures such as sales, earnings, and book values. 
Damodaran (2012) lists four different categories of standardized multiples: 
Multiples of earnings 
As the most common group of multiples in relative valuation, earning multiples take use of 
the earnings measures such as earnings, EBITDA, and EBIT to measure relative value. The 
most well-known of these ratios is the price-earnings ("P/E") multiple, in which market price 
per share is the numerator and earnings per share is the denominator. The P/E multiple can be 
derived from both historical earnings, known as a trailing multiple, and forward-looking 
estimates of earnings, which is defined as a forward multiple (Gaughan, 2017).  
Earnings multiples based on enterprise value ("EV") are also common, such as the EV-to-
EBITDA and EV-to-EBIT multiple. The latter is perceived to be a more reliable guide to a 
 32
firm's relative value than P/E multiples since it allows for a better comparison of firms with 
different capital structures (Koller et al., 2020). The valuation outcome of different earnings 
multiples may vary significantly. The various earnings measures are affected by accounting 
rules and principles to a lesser or greater degree. As one goes further down on the income 
statement, the probability increases that special non-recurring effects may distort the multiple 
(Kaldestad & Møller, 2016). 
Multiples of book values 
In the relative valuation universe, book value multiples are based on values recognized in 
financial statements are historical, and not market values. The most recognized book value 
multiple is the price-to-book ratio ("PB"), which is defined as the market price per share 
divided by the book value of equity per share. This metric's general investor perception may 
be useful in revealing undervalued and overvalued stocks in the market. That is, firms trading 
in the market at less than their book value or firms trading higher than their book value, 
respectively. 
While easy to understand, comparing the book values ratios across firms may prove to be 
challenging. Damodaran (2012) addresses three challenges one might face when conducting 
relative valuation using book value multiples. The first reason is that book values are based 
on financial statements and accounting principles, which may differ between firms. Following, 
firms in specific asset-light sectors, such as information technology, may not be meaningful 
to assess based on their tangible assets' value. Lastly, as equity book value can potentially 
become negative, the metric may not come out as meaningful. 
Multiples of revenue 
In the preceding categories, the focus has been on financial measures based on accounting 
principles. For revenue multiples, the presence of implications due to accounting practices is 
lower. In particular, the general literature on revenue multiples is split between the ratios Price-
to-Sales ("P/S") and EV-to-Sales, defined as price divided by sales and EV divided by sales, 
respectively. As mentioned, under the prior relative valuation methods, some firms may have 
negative earnings or negative book values.  
In some instances, comparable analysis using sales as the denominator may provide a more 
meaningful outcome as a revenue figure is present for firms in all stages of a business cycle. 
Despite its upside of being applicable to most firms, the use of revenue multiples is not free 
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from complications. To exemplify this, using revenue multiples can easily lead to high 
valuations for firms that are creating high revenues but at the same time are losing money over 
a more extended period and that are inevitably destroying shareholder value. 
Sector-specific multiples 
For some sectors, the broad scope of the earnings, book value, and revenue multiples will 
cause valuation estimates to not become meaningful for companies in that specific sector. The 
reasons for this can vary, but generally, new or specific sectors with financial characteristics 
such as negative earnings, negative book values, and negligible revenues may need sector-
specific multiples. However, as these multiples apply only to the companies in the sector, they 
could potentially cause substantial over-or undervaluation of specific sectors compared to the 
overall market. Moreover, controlling for differences across firms could prove problematic 
when using such multiples (Damodaran, 2012). 
3.3 The contingent claim approach 
The contingent claim approach, also known as option-based valuation, is based on using 
financial option theory to derive a firm's value with optionlike qualities (Damodaran, 2012). 
Black & Scholes (1972) popularized a financial option is defined as a right, but not an 
obligation, to buy or sell a stock at a given price. This same methodology has later been 
translated for use on operational assets, which is called real options in today's financial theory. 
Central to this theory's wide-spread recognition is the presumption that a contingent claim 
approach will value assets with payoffs dependent on specific events better than valuation 
methods such as the DCF-based models. I.e., such methodology will be beneficial for the 
valuation of assets such as patents and unexploited attractive natural resources. 
One challenge in option-based valuation is that there is high uncertainty attached to the 
variables that are to be estimated. First, there is no liquid market for the real option as there is 
for traditional financial options. Some of these challenges are also caused by estimating the 
value of the exercise price and challenges in applying a correct volatility and estimating the 
asset's useful life. 
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3.4 Choice of valuation methodology 
As showcased in preceding subchapters, any choice of valuation methodology has its positives 
and negatives. While the three main valuation frameworks we presented all share the same 
end-goal of valuing an asset, they are still doubtful to produce the same valuation output in 
the end. Thus, selecting an appropriate valuation methodology for the asset in question is 
considered a critical step in the process of valuing an asset. Damodaran (2012) points out three 
business characteristics that are essential in choosing the right valuation approach: the 
marketability of assets, the firms' cash flow generating capacity, and its uniqueness. 
Firstly, Aker BioMarine possesses many traits usually seen in businesses that are considered 
growth businesses and expect growth both in the short and long term. The firm intends to have 
a long-term position as the krill industry leader, and using a discounted cash flow analysis is 
fitting as such. As a publicly-traded company, it fits into Damodaran's category of firms with 
a cash flow generating capacity suitable for a valuation using DCF methodology. In addition 
to this, Aker BioMarine operates in a specific segment where a limited amount of similar assets 
are trading. Although the company is comparable to a range of firms through its activity in 
end-markets such as human nutrition, aquaculture, and pet food, a limited number of firms are 
available for direct comparison. In such cases, discounted cash flow valuation may also be 
preferred to arrive at better value estimates (Damodaran, 2012). 
Based on relevant theory combined with our reasoning, we assign the enterprise DCF model 
and the economic profit model to derive our fundamental valuation estimate of Aker 
BioMarine. Since the FCFE model may be sensitive to errors in estimating leverage changes, 
we deem this model less relevant for our valuation (Damodaran, 2012). Besides, we also 
exclude the APV method due to its more complicated nature and less insightful methodology. 
Furthermore, we recognize multiples as a practical approach to provide a complementary view 
and validation of our DCF valuation analysis. This can be a great check on our principal 
valuation analysis and may potentially give us clues if there is something wrong with our 




A relative valuation approach would require a selection of directly comparable firms with 
similar firm characteristics to Aker BioMarine to provide us with a meaningful value estimate. 
No other krill firms with a fully integrated value chain are trading in the market today, making 
a multiple-based valuation less applicable for Aker BioMarine. However, since multiple firms 
operating in the same end markets and similar sectors are listed in the marketplace, these could 
provide much insight as a supplement to a DCF or option-based approach. Therefore, we 
decided to complement the fundamental valuation with a relative valuation estimate based on 
relevant peers. While a contingent claim approach may be suitable to value assets with growth 
options and promising underlying, Kaldestad & Møller (2016) argue that there are 
considerable challenges linked with the option-based method's assumptions. Building on this, 
our view is that an option-based approach may not be the aptest tool in the case of Aker 
BioMarine. 
3.5 Valuation framework 
As mentioned, our valuation approach will be based on the discounted enterprise model and 
the discounted economic profit model, with a supplemental relative valuation. To execute this 
analysis, it will require us to do an in-depth examination of Aker BioMarine's fundamental 
information extracted from all publicly available sources, such as annual and quarterly reports, 
admission documents, historical financial information, and company presentations. This 
information will be examined in five steps, which will ultimately result in a fundamental 
valuation of the company and our recommended investment action choice. The steps are 
summarized below. 
3.5.1 Selected step-by-step valuation approach 
1. Strategic analysis 
As a first step toward our valuation analysis, we will conduct a qualitative analysis of Aker 
BioMarine's business model's market and firm-specific elements. By utilizing publicly 
available information, we will understand the company's operational performance, its 
surroundings, and its crucial value drivers. This analysis will be split between an internal 
analysis of the company’s competitive position and an external analysis of macro factors 
affecting industry performance.  
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Also, we have included an analysis of internal and external ESG factors to provide context as 
to how this may affect the valuation of the company both in the marketplace and in the 
valuation performed in this thesis. 
2. Financial statement analysis 
Our financial statement analysis is a quantitative analysis of Aker BioMarine’s historical 
financial information, with the overall goal of understanding the firm's past to successfully 
forecast its future (Koller et al., 2020). This will include a reorganization and adjustments of 
financial statements to prepare them for the investment analysis, and an in-depth examination 
of historical performance. 
3. Forecasting and cost of capital 
On the basis of our findings in the strategical financial statement analysis in the two precedent 
steps, we will perform forecasting of financial statements and estimate the future cost of 
capital. We do this by following relevant valuation guidelines to produce estimates of Aker 
BioMarine's free cash flows, economic profits, and the weighted average cost of capital. 
4. Valuation analysis 
Our selected approach for deriving an estimate of Aker BioMarine's equity value is the 
enterprise discounted cash flow model and the discounted economic profit model. Ultimately, 
this will enable us to derive our fair value of the company’s stock. Moreover, we will also test 
how specific input variables will impact our valuation estimate by means of a sensitivity 
analysis. As a supplement to our fundamental valuation analysis, we will also perform a 
relative valuation of the firm using multiples. 
5. Recommended investment action 
After arriving at our fair price of Aker BioMarine's stock, we will discuss our recommended 
investment action for the stock and form a conclusion of our valuation analysis. This involves 
an assessment of our findings and our valuation estimate against the price at which the 
company’s share is trading in the marketplace and our recommended investment strategy in 
the form of either a BUY, HOLD or SELL recommendation. We conclude the final part with 
an overview of analysts’ target prices and a short note on the company’s share price 
development after our analysis. 
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3.6 Visualization of the valuation framework 
Exhibit 2 gives a visual presentation of the structure of our thesis based on the step-by-step 
valuation framework presented above: 
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This analysis is conducted in two parts, namely through external and internal analysis. The 
external analysis will be performed utilizing two widely recognized frameworks, the PESTEL 
framework and Porter's five forces. Following an analysis of Aker BioMarine's macro 
environment and industry-specific factors, we utilize VRIO analysis as our tool to uncover the 
company's internal strategic capability. The VRIO analysis is followed by a SWOT analysis, 
where we summarize the findings in our internal and external analysis and determine how the 
underlying factors affect the company's competitive position. On top of this, we will perform 
an ESG assessment of Aker BioMarine and explain how we see this to play a vital role in our 
valuation analysis. 
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4.1 Key drivers and risk in the krill industry 
Deploying the PESTEL framework, we will analyze the external factors affecting Aker 
BioMarine and the krill industry. A PESTEL analysis intends to help uncover macroeconomic 
aspects crucial to the firm's competitive environment both today and in the future (Løwendahl 
& Wenstøp, 2010). The framework is based on six categories of factors affecting a firm's 
macroclimate: political, economic, sociocultural, technological, environmental, and legal 
aspects. In this chapter, we dive into each of these categories and discuss how they affect Aker 
BioMarine and the krill industry. 
4.1.1 Political and legal factors 
Licenses and quotas 
Krill fishing operators in Antarctica are dependent on regulations from national authorities in 
the company's country of origin, in addition to regulations set by CCAMLR, and the 
international treaty includes 25 member states. An operator first needs to receive a krill fishing 
license issued by its home authorities. In the case of a Norwegian operator, a license is to be 
issued by Norwegian authorities. It will include certain country-specific conditions and 
regulations, such as minimum ownership requirements from Norwegian investors and 
compliance with Antarctic krill fisheries' regulations. Any breach of these conditions may 
result in permanent or temporary suspension or modification of current license agreements. 
Moreover, all krill harvesting operators must also adhere to rules and regulations imposed by 
the CCAMLR. This includes the CCAMLR's current annual quota restriction of 620 000 MT, 
resembling >1% of the total krill biomass of 379 million tons (CCAMLR, 2018b). As with 
country-specific regulations, any operator breaking with the CCAMLR regulations may face 
the consequences in the form of restriction on fishing activity or even withdrawal of licenses. 
Despite the fact that today's harvest limit has never been reached before, this quota may still 
be subject to future changes. The quota limit is conditional to recommendations issued by 
CCAMLR's Scientific Committee, which is derived from the leading scientific data and 
research available. On top of this, the Antarctic ecosystem is considered vulnerable, and 
potential political pressure may force regulators to impose further regulation on krill fisheries 
in the Antarctic (Norwegian Ministry of Foreign Affairs, 2015). 
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International trade wars and regulations 
In recent years, the international trade war has impacted the state of global trade and 
regulations dramatically. After decades of increasing international trade and acceleration of 
free-trade agreements, the focus has been shifting towards more restrictions and re-negotiation 
of existing international trade deals among the world's biggest economies. Most prominently, 
the recent US-China trade war initiated by the Donald Trump administration has caused the 
US and China to impose stricter regulations and tariffs on each other. Although a "first-phase" 
trade deal was struck between the US and China in early 2020, considerable uncertainty is still 
present in the trade relationship between the two economic superpowers (Donnan et al., 2020). 
While this conflict is mostly a matter of tension between the US and China, the rising US 
protectionism has also sparked fears of a more widespread de-globalization trend affecting 
international trade and regulations (Steinbock, 2018). Today, the krill industry depends on 
global trade and exports to grow and increase total krill demand. Factors such as adverse 
changes in international trade and de-globalization are viewed as scenarios that could 
potentially damage the industry. 
COVID-19 policymaking 
The ongoing coronavirus ("COVID-19") pandemic poses several risk factors to all global 
business operations, including the krill industry. Since the virus was recognized as a pandemic 
on March 11, 2020, global trade has been falling dramatically, with the October 2020 trade 
volume forecast indicating a fall of 9.2% in world merchandise trade volume in 2020, 
according to the World Trade Organization (2020). The pandemic does not only pose a global 
health threat and causes financial market uncertainty, but it also managed to bring attention to 
stricter international trade regulation by policymakers worldwide (Jean, 2020). 
Even though it may be too early to determine the long-term effects of COVID-19 on global 
trade policies, some experts assert that the coming months will be crucial for global 
policymakers in shaping the global trade landscape going forward. More so, they claim that if 
the right actions are not taken, the world might be facing longer-lasting consequences in the 
form of a slower than expected economic recovery, political tension, and increased social 
differences, which may ultimately affect economic growth and global trade (Rogoff, 2020). 
The future development of the krill industry is likely to be affected by the political and 
regulatory outcome of the COVID-19 pandemic, as such. 
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4.1.2 Economic factors 
Macroeconomic aspects: GDP Growth 
As of October 30, 2020, over 46.1 million people have been infected, and more than 1.2 
million people have lost their lives due to the novel coronavirus (Johns Hopkins University, 
2020). While the outbreak of the virus has not only turned into a global health crisis, it has 
also had an enormous impact on the global economy and GDP growth. This economic impact 
is attributable primarily to the far-reaching measures introduced by governing powers 
worldwide, including travel bans, social distancing measures, and lockdowns. In turn, this has 
had a direct negative impact on activity in industries such as airlines, hotels, and restaurants, 
with indirect adverse effects on many more. Moreover, although this crisis has prompted 
record-breaking economic measures and stimulus from governments worldwide, it has also 
caused record-breaking job loss numbers and a historically steep fall in GDP growth (Gambino 
& Singh, 2020). 
As illustrated in figure 7, GDP growth has been stable in the last years, following a drop after 
the financial crisis of 2008-2009. In this same period, emerging economies have had the 
highest annual GDP growth, performing above the world average, followed by advanced 
economies posing a slightly lower GDP growth. From this graph, the coronavirus's 
macroeconomic impact is evident, with real GDP growth forecasted by The World Bank to be 
negative in 2020. Yet, they expect GDP growth to be back to normalized levels already in 
2021, with the world economy envisioned to recover moderately (The World Bank, 2020a). 
Figure 7: Real GDP growth 
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Macroeconomic aspects: Interest rates 
In Norway, the Central bank’s policy rate is viewed as the main instrument in monetary policy 
and is defined as the interest rate on deposits from banks in the Central bank up until a certain 
amount (Norges Bank, 2020b). The rate is set based on an assessment of economic 
development, and a decision on whether to change it or not is typically made eight times a 
year. The interest rate can be significant for businesses considering whether to undertake 
investment or not, and a lower interest rate environment may provide an attractive opportunity 
to fund specific investments. As observed from figure 8, the policy rate fell from a 5.75% level 
in 2008 to a near 1% level in the years following the financial crisis of 08/09. The rate has 
been falling further in recent years, breaking the 1% and further-reaching a historical 0% in 
2020 due to the abrupt fall in activity due to COVID-19. As of September 2020, the Norwegian 
Central bank predicts that the policy rate will remain at the 0% level in some time going 
forward to stimulate activity during the crisis (Norges Bank, 2020c). 
Figure 8: The Norwegian Central bank’s policy rate 
Source: Norges Bank (2020a) 
Exchange rates 
Krill companies operating in an international market will be impacted by currency fluctuation, 
both directly and indirectly. They are affected directly through sales of krill, ingredients, and 
end-products to the global market and investment in new vessels and equipment. For 
Norwegian krill companies, many products are exported to the US, Europe, and APAC, 
making changes in exchange rates of importance for the krill industry's economic 
performance. The krill industry is mainly affected by fluctuations in the major currencies, such 
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A weak Norwegian krone (NOK) is favorable for Norwegian businesses exporting to other 
countries. The significant effect of the weak NOK is confirmed in a Nofima report from 2016, 
showcasing that out of an increase in NOK 22.4bn seafood exports in 2012-2015, NOK 14.1bn 
was attributable to a weaker Norwegian krone (Nofima, 2016). 
Figure 9: NOK exchange rate development (EUR/GBP/USD) 
Source: Norges Bank (2020d) 
Oil price 
A sizeable amount of a vessel's operating expenses are attributable to fuel costs. I.e., fuel costs 
contributed to ~30% of Aker BioMarine's offshore operating expenses in 2019. Each vessel 
expects to consume ~35,000 metric tons of fuel annually going forward (Aker BioMarine, 
2020b). While limited data is available for fuel consumption for other companies in the krill 
industry, we expect that fuel cost is just as crucial in the krill industry overall as it is for Aker 
BioMarine, given that all competitors have considerably older fleets. Thus, increases in oil 
prices could put noticeable pressure on the profitability of the krill industry. 
Figure 10: Crude oil price development (USD/bbl) 




























4.1.3 Sociocultural factors 
Demographic aspects 
According to The World Bank, the world's population was at a staggering 7.67 billion by the 
end of 2019. From a total population of 6.11bn in 2000, today's population represents more 
than a 25% growth in population since the 2000s (The World Bank, 2020b). Furthermore, the 
population growth is not expected to come to a halt any time soon, as the Food and Agriculture 
Organization of the United Nations ("FAO") expects the world population to reach almost ten 
billion by 2050. This does not come without implications for the world's food security, with 
food production expected to grow by 70% by 2050, and the demand for protein anticipated to 
double in the same period (FAO, 2019). For the krill and seafood industry, this leaves 
considerable opportunities to be a part of the solution in meeting the expected increase in 
demand. 
Another demographic trend shaping the demand is the middle class’ growth in emerging 
markets, particularly in the rapidly growing BRIC countries, Brazil, Russia, India, and China. 
With a total population of close to 3.1 billion people (Statista, 2019), shifting demographics 
in these markets may enable significant changes in demand for various goods and services, 
including foods and proteins. As the middle class is expanding in these sizeable markets, it 
shifts eating habits towards more nutritious, healthy, and protein-rich foods, such as seafood, 
eggs, and meat. Consumption of high-quality proteins is expected to increase, as such (Mowi, 
2020). 
Moreover, an increasingly aging population is placing healthy eating and living on the agenda 
for an increasing number of people. Estimates released by the World Health Organization in 
2018 predict that the global population over 60 years of age will almost double between 2015 
and 2050, from 12% up to 22% (Word Health Organization, 2018). In such an environment, 
an industry with a value proposition such as the krill industry may play a critical role in the 
increasing health focus among the aging population. 
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Figure 11: Population (billion) and % of the population above 65 years 
Source: The World Bank (2020b) 
Consumer consciousness concerning health and wellbeing 
Through a vast amount of research and studies over the last years, various types of seafood 
have been recognized as healthy due to their high content of specific nutrients. Research shows 
that intake of fish, fish oil, EPA, and DHA (or so-called "essential fatty acids") is known to 
reduce the risk of death due to heart diseases and reduce the risk of other forms of heart failure 
(Helsedirektoratet, 2018).  
As a consequence of the build-up of research and evidence in recent years and the increased 
focus on healthy food intake, public health authorities worldwide are increasingly promoting 
the intake of fish and seafood. In a report from 2019, the EAT-Lancet Commission advocated 
that seafood is to be an auspicious source of protein in the coming years. This was validated 
due to seafood's broad health benefits as a dietary component and its high nutritional 
properties, with the unique attributes of omega-3 fatty acids being stressed (Troell et al., 2019).  
As krill is loaded with omega-3 fatty acids (EPA & DHA), phospholipids, astaxanthin, and 
choline, the krill industry could find itself in an attractive position as public health authorities 
are putting healthy living on the agenda and as the general consumer focus on health and 
wellness increases. 
Change in consumer trends due to negative research  
Another sociocultural aspect that we consider relevant to the krill industry's future 
development is changing consumer trends due to negative news and research. However, the 
positive health effects of omega-3 are considered well documented by many. Historical 
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the past as an effect of negative news, new studies, and opposing researcher views (GOED, 
2017). As seen in the graph below, omega-3 sales in the US fell steadily from 2012-2014 on 
the back of various studies scrutinizing the health effects of omega-3, such as the ORIGIN 
study in 2012 which concluded that daily supplements of omega-3 did not reduce the rate of 
cardiovascular events (The ORIGIN Trial Investigators, 2012).  
This is not a new phenomenon in the seafood industry, and in recent years the Norwegian 
salmon industry has been subject to negative media coverage on several occasions. While the 
exact impact of this sort of coverage has not been straightforward to measure, we find 
examples where researchers have raised the question of whether negative media attention may 
have caused reduced demand for Norwegian salmon in specific countries (Nofima, 2019). 
Krill oil has a different delivery form from traditional fish oil, phospholipids, which also 
provides an opportunity to differentiate. The different delivery may allow krill oil to be either 
more or less affected by news and studies on the health effects of omega-3, as such. 
Figure 12: US omega-3 retail sales and media sentiment 
Source: GOED Analysis of Meltwater and Factiva data (2017) 
4.1.4 Technological factors 
Vessel and fishery technology 
Out of the 13 krill fishing vessels operating globally today, the median time since the vessels' 
build year is over 30 years. Only three vessels operating in the market today were built after 
1995 (CCAMLR, 2020). While some vessels have been rebuilt and refit with new technology 
in more recent years, the current krill fleet is still ripe for renewal, at least in the latest 
technological advances in newbuilds. With a relatively old fleet operating in the krill industry, 
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technological innovation in fishery management, CO2 emission, cost, krill welfare, and more 
may significantly reshape the industry from how we know it today. Since fisheries in a 
vulnerable environment such as the Antarctic are subject to strict regulations and standards, 
adapting to such regulations whilst still bolstering profitability will be a vital issue in the bigger 
picture. 
The technological innovation has been limited in the krill industry, although several 
technological and innovative practices are currently considered today. The push toward 
innovation is predominantly coming from nations such as Norway and China, who in recent 
years have been vocal about their ambitions to lead the krill industry going forward (Godfrey, 
2020). Out of several significant projects in the works today, projects involving big data and 
artificial intelligence ("AI") are anticipated to increase knowledge and carry the krill fishing 
industry into the data-driven era. 
The technological advances involve large-scale data analysis of information collected through 
monitoring technology such as drones and echo sounding to collect a vast amount of data on 
the krill's location and behavior. In turn, analysis through big data and AI may significantly 
increase the effectiveness, accuracy, fuel efficiency, and sustainability of krill fisheries 
(Orlowski, 2020).  
Technological development in krill product offerings 
Another central part of the krill industry's future development is technological development 
and innovation in end-markets and product categories where its raw material may be 
applicable. For the demand for Antarctic krill to increase, demand in end-markets such as in 
the omega-3 supplement industry, the aquaculture industry, and the pet food industry is key. 
In recent years, several R&D initiatives have been set out to life to elevate the krill oil market. 
As the clear market leader in this segment, Aker BioMarine has continuously tried to reshape 
and innovate krill oil product offerings. Recent initiatives such as its ongoing pilot-scale 
protein powder factory and newly developed Flexitech technology (Aker BioMarine, 2020b). 
In addition to this, R&D and technological advances are likely to become a critical issue in 
the future as competing companies, industries, and segments battle for consumer demand and 
attention. 
 48
4.1.5 Environmental factors 
Climate impact on krill stocks 
The focus on the environmental issues that the seafood industry is facing is more significant 
than ever before. Today, seafood industries undermining the environmental challenges the 
world is facing may be held accountable in numerous ways. Climate issues are no longer just 
a priority for environmentalists and scientists but also high on the agenda for consumers, 
investors, and governments. 
Climate change is also putting the current krill biomass and life in the Antarctic Ocean at risk. 
Atkinson et al. (2019) claimed in a report released last year that several Antarctic species, 
including krill, are increasingly impacted by global warming. More specifically, krill has 
moved approximately 440 kilometers southward during the last 90 years, with most of this 
contraction believed to have taken place since the 1970s. The study concludes that "rapid 
climate change, with associated nonlinear adjustments in the roles of keystone species, poses 
challenges for the management of valuable polar ecosystems" (Atkinson et al., 2019, p. 1). 
Further, if this contraction process continues, it may have disastrous consequences for the 
Antarctic krill stock as we know it today, and businesses operating in this environment will 
have to take necessary measures to comply. 
Overfishing and depletion of marine stocks 
On several occasions in the last 50 years, krill fisheries in the Antarctic have been scrutinized 
by researchers, environmentalists, and various climate initiatives. This scrutiny comes even 
though Antarctic krill fishery at present is the only fishery globally to be classified "in 
excellent condition" by the Sustainable Fisheries Partnership, is reported to have had a biomass 
increase of ~10 million in the past ten years (Havforskningsinstituttet, 2019) and is subject to 
a much stricter catch limit relative to other less sustainable fisheries.  
It should be noted that fishing in the Antarctic is subject to hefty surveillance due to several 
reasons. Krill plays an important part in the Antarctic ecosystem, as several Antarctic species 
depend on it as its primary source of food, such as seals, seabirds, and whales. Naturally, this 
means that considerable interference with the current krill biomass may constitute a threat to 
the broader wildlife in Antarctica. This raises concerns among several scientists and 
environmentalists, and some researchers have even argued that the present allowed krill 
fishing limits might increase the risk for the depletion of numerous predator populations in the 
 49 
Southern Ocean (Klein et al., 2018). According to the CCAMLR, today's quota is based on 
current leading research and is consensus-based, meaning that the quota today should represent 
a limit that is not considered harmful for the krill biomass (CCAMLR, 2018).  
Depletion of wild fish stocks has been an issue of global magnitude for decades. Since the 
1970s, overfished fish stocks have steadily increased year by year. According to the FAO 
(2020b), fisheries in the Mediterranean and the Black Sea have the highest percentage share 
of unsustainable fishing activity. While krill fishing in Antarctica does not contribute to these 
unsustainable fishing practices, the global overfishing trend may contribute risk to the future 
practices of the krill fishing operators. 
Figure 13: Global trends in the state of the world’s marine fish stocks (1974-2017) 
Source: FAO (2020b) 
4.2 Porter's five forces analysis 
Porter's five forces is an analytical framework consisting of five external elements related to 
competitiveness utilized to better understand the competitive dynamics in an industry. Porter 
refers to these forces as the microenvironment and that they are forces that affect a company's 
ability to serve its customers and generate a profit. The industry dynamics are integral for a 
company when deciding how to position themselves (Roos et al., 2014).  
The cumulative intensity of the external aspects is what decides the profit potential in the 
industry. The five forces are threats from new entrants, threats of substitutes, customers' 
bargaining power, suppliers' bargaining power, and competitive rivalry. If an industry has a 





















operate within. Industries with a lack of these forces will be more profitable and more 
comfortable to operate in (Roos et al., 2014). 










Source: Marketinfo Group (2020) 
4.2.1 Threats from new entrants 
Barney (2011) defines new entrants as companies that have recently established themselves in 
an industry or threaten to establish themselves in one within a short period. New entrants 
usually have to employ many resources and capacity to capture market shares in the industry. 
When there is a new entrant in an industry, it is often followed by downward pressure on prices 
or increased investments as the competitive situation is intensified. The result is often a 
reduction in the industry's profit potential (Roos et al., 2014). The threat from the 
establishment of new entrants is determined by entry barriers in that specific industry, such as 
government policies, capital requirements, economies of scale, and extensive knowledge of a 
product. 
Government policies 
All aquaculture activities require licenses, and no company can harvest krill from the Antarctic 












entry in the krill industry. The government assigns krill harvest licenses if the companies that 
have applied for them fulfills the requirements. In 2019, it was opened for companies to apply 
for krill harvesting licenses, which was the first time since 2007. Only three Norwegian firms 
applied, Aker BioMarine, Rimfrost, and Fish Group of Norway AS. The latter was initially 
denied a license before but won the appeal case and received a license. To receive a license, 
one needs to comply with strict requirements regarding technology and environmental 
standards. 
On a global scale, there is a fixed annual quota for krill harvesting set by CCAMLR. When an 
operator has received a license to harvest, one can harvest until the annual quota is fulfilled. 
The quota is industry-specific and not company-specific, such that the industry operates as an 
Olympic pool where the operators try to catch as much krill before the cumulative quota is 
met, as clarified in the PESTEL analysis.  
These attributes imply that the threats from new entrants as of today are medium. These high 
demands to acquire a license in Norway do not reflect what is required in every country. 
Consequently, it might be easier to acquire a license through another country, and as the 
industry quota is set for the industry as a whole – it is a zero-sum game for the participants. 
China has a stated goal to become the number one nation in krill harvesting, and this may 
challenge Aker BioMarine's position as the industry leader in the future.  
Capital requirements 
The krill industry is capital intensive as there are high requirements for the harvesting vessels, 
production, R&D efforts, and licenses. It takes time to create customer relationships, develop 
their products, and penetrate new markets. Hence, new entrants need robust financial resources 
that allow the investors to wait for years before generating returns on their investments. Even 
though a company may have enough resources for necessary investments, it may take time to 
generate profits. Even the industry leader, Aker BioMarine, has experienced a negative net 
profit the past three years. The massive economic barriers in the establishing phase make it 
somewhat challenging for new entrants to establish themselves.  
Economies of scale 
A large part of the operating expenses (“Opex”) is tied to offshore production and fuel cost. 
Participants can take advantage of economies of scale to obtain a competitive benefit. It is 
instinctive to assume that large companies can gain quantum discounts regarding fuel. Fuel 
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made up ~15% of the total opex in 2019 (Aker BioMarine, 2020a). Implying, it is a significant 
expense for krill harvesting companies. 
Moreover, a lot of the production of the krill takes place offshore on the vessels. Once the 
vessels are launched from the port, a lot of the costs are fixed. It is necessary to harvest and 
process as much krill as possible. There is no 1-to-1 relationship between the vessel's size and 
fuel consumption and crew members' need so that the larger vessels can process krill for a 
lower cost per kilo than the smaller vessels. The economies of scale make it difficult for new 
entrants to establish themselves in the industry. 
Extensive knowledge 
Already established industry participants will have a competitive advantage with their 
extensive knowledge of the dynamics and requirements to run the operations efficiently 
compared to new entrants. Thus, the established companies will have a competitive edge. In 
addition, advanced and valuable technology makes the entrance ever more problematic as this 
takes time to develop and acquire. Accordingly, we deem that the established participants' 
advantages make it complicated for new companies to establish themselves in the krill 
industry. 
4.2.2 Threats from substitutes 
Substitutes are products that cover the same function and needs as the product the initial 
industry does. Substitutes reduce the industry's potential for profits as they cap their products' 
prices (Roos et al., 2014). Factors such as product differentiation, price, and the cost of 
changing the products are central in the substitution assessment in each industry. What 
substitutes are considered alternatives to krill products vary a lot. Krill products are the ones 
who are new on the block, trying to capture market shares. As of today, it is primarily used to 
produce omega-3 oils for human nutrition. Omega-3s come in several forms today and are 
found in fish, green-lipped mussels, mammalians, algal, and alpha-linolenic acids. The aspects 
that differ from the individual capsules are omega-3, amount and form of omega-3, freshness, 
and sustainability. The average individual perhaps does not view the difference between the 
source of the omega-3 as important but looks at all omega-3 supplements as equal. As a result, 
it might be difficult for omega-3 companies to differentiate their products.  
Today, fish oil is the most common way of consuming omega-3 supplements, either through 
capsules or liquid form. Natural fish oil contains the fatty acids EPA and DHA and vitamins 
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A and D. This type of fish oil is better for the consumers than the processed fish oil that is 
vulnerable to oxidation, and is more problematic for the body to absorb. This is where krill oil 
differs from its leading rival, the fish oil, as krill oil is naturally low in contaminants and 
contains potent antioxidants easily absorbed in the body. Even though there are distinct 
differences between the omega-3 supplements, the everyday consumer does not necessarily 
possess this information or is unwilling to pay a premium for these features. We consider fish 
oil to be a nearly perfect substitute for krill oil, which impedes the industry to charge a 
considerably higher price for their products even though it is healthier than other sources.   
Further, the industry is currently penetrating the market for pet and aquaculture feed. Pet feed 
made from krill is, again, the new contestant on the market and the threats of substitutes are 
high. Numbers from Aker BioMarine indicate that dog feed made of krill can significantly 
reduce inflammation and muscle damage after sled racing. The everyday dog does not require 
these features, and the research itself was performed with a small sample and cannot be 
considered absolute truth. Krill is also used to supply the seafood industry with feed for the 
fish. The fish feed may be an essential input factor for the industry, and krill has proven to be 
superior, looking at growth, yield, and fish heart health (Aker BioMarine, 2020b). However, 
only a minority portion of the total fish feed in the industry is from krill, which implies that 
other alternatives are employed. 
The threats from substitutes are reasonably high at this time. This can be ascribed to the other 
omega-3 oil supplements, pet feed products, and aquaculture feed at the market. As the public 
interest in health and health supplements increases, we believe the people will recognize krill 
oil to be superior and distinguish itself more from the others. 
Figure 15: Qrill Pet reduces muscle damage: Control group (left) vs. Qrill Pet (right) 


































Figure 16: Qrill Pet reduces inflammation: Control group (left) vs. Qrill Pet (right) 
Source: Aker BioMarine (2020b) 
4.2.3 Bargaining power of buyers 
The buyer power represents a threat towards the profitability potential in an industry as the 
consumers are interested in putting pressure downwards on the prices and increasing the 
products' quality. The costumers enjoy a strong position if the costumers of the product are 
concentrated, purchase large quantities, if the total costs of the products represent a significant 
fraction of the customers' total costs, or if the product is standardized or there are numerous 
suppliers (Roos et al., 2014). 
In this industry, the customers are frequently brand-owners and contract manufacturers that 
buy oil in bulk to encapsulate the oil in soft gels before sold as dietary supplements. When the 
manufacturers face more demand in the market, they order from their suppliers who stock the 
krill oil. The krill industry is a relatively new and small industry that presently experience 
more supply than demand, which provides the customers of the krill oil with enhanced 
bargaining power. The oil from the supplier is sold in the same way as most other natural 
resources, where the price is set per kilo and fluctuates and reflects the market tensions. When 
the demand for krill oil is low, downwards pressure is put on the oil suppliers while the 
customers enjoy the upper hand. There are few exclusive relationships and contracts in the 
industry as lots of the relationships are trust-based, which further strengthens the customers' 
position as they already face a surplus of krill oil.  
Further, the cost of switching a supplier is low in the industry as the harvested krill and 
produced oil all origins from the same place. The difference between the various suppliers is 
low, and the production sites are primarily on the vessels found in the Antarctic ocean. The 
customers are a growing market for the suppliers of omega-3 oil as we focus on health and 


































new products and innovations to solve diseases and similar issues, and it is now utilized for 
more than only human consumption. The customers' bargaining power is enhanced as they can 
decide what supplier they want to work with to achieve the best price and quality on their krill. 
Looking at the fish- and pet feed market, we have two completely different situations. Firstly, 
krill is an established alternative in the fish feed market, and Norway's Aker BioMarine has a 
market share between 22% ~ 32% in Norway (Marine Harvest, 2017).  
This contrasts with the new pet feed market that krill just entered. In this market, krill is the 
challenger with lots of substitutes, and the buyers are limited. These attributes of the buyer's 
bargaining power make it rational to categorize it as moderate to high. If the demand for krill 
increases amongst the end-consumers, it is natural to believe that the manufacturers will 
require larger margins, and there are few indications that this would benefit the krill harvesting 
companies. Subsequently, there is a real threat to the harvesting companies that their customers 
will hijack parts of the value creation, affecting the industry's real profitability potential.  
4.2.4  Bargaining power of suppliers 
Suppliers in an industry may affect the potential for earnings if they can squeeze the profits. 
Reduced profitability may happen in increased prices or reduced quality of the supplies or 
services delivered. The bargaining power of suppliers is dependent on multiple factors such 
as the number of participants in the industry, how easy it is to change suppliers, and the 
importance of the product the supplier delivers to the companies (Roos et al., 2014).  
The krill industry differs from other industries because they are the first part of the value chain 
and have few suppliers. The leading suppliers to the krill industry consist of fuel suppliers and 
the shipyards that construct and build the vessels. Crude oil is refined to make fuels like petrol 
and diesel for machines and other vessels. Today, fuel makes up roughly ~30% of the opex in 
the krill industry, a significant portion (Aker BioMarine, 2020a). The price of oil is merely 
conditional on the supply and demand from investors, and the only way a company may 
position itself is with hedging. A krill harvesting company knows it needs fuel in the coming 
years, and a way to lock in a price is to buy futures contracts in the market. This is a free 
market, and the supplier-buyer relationship is purely transactional. The only discount they 
achieve is a quantum discount, but it is unlikely to vary between suppliers. 
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The second significant supplier is the shipyards when the harvesting companies decide to 
expand or modernize their fleet. It is challenging to analyze the relationship between the krill 
harvesting companies and the shipyards as there is not much publicly available information. 
It would not be unreasonable to assume that the harvesting companies will shop around 
amongst the shipyards with proper competency to create and manufacture the vessels. In this 
way, they may achieve a better price and quality and have the upper hand in the negotiations. 
The suppliers' bargaining power might be the most problematic factor to analyze in Porter's 
five forces as there is inadequate public information about the suppliers. We still contend that 
the relationship favors the krill harvesting companies that can shop around with the shipyards 
when deciding to order a new vessel. The way the oil market is constructed makes it hard to 
gain the upper hand. Larger fleets may achieve a quantum discount, but the differences 
between suppliers are implausible to be sizeable. 
4.2.5  Competitive rivalry 
Competitive rivalry is related to how companies in an industry chose to position themselves 
to capture market shares. Product launches, guarantees, and low prices are methods companies 
use to attract customers. A high degree of competition will create uncertain outlooks for the 
industry and make it less profitable. The degree of competition in an industry is decided by 
growth prospects, the level of concentration and competition, and how complicated a potential 
liquidation would be (Roos et al., 2014). 
Industry growth 
If the degree of growth in an industry is low, the competitive environment will limit itself to 
acquire market shares from each other. Limited growth represents a threat to the industry's 
profitability (Roos et al., 2014). The demand for krill products globally is growing, and the 
total krill harvest is at its highest since 1991 (Aker BioMarine, 2020b). Further, Tharos, a 
world-known krill consultancy, estimates that the Chinese demand for krill oil will exceed the 
current global production by 250% and 300% for krill meal production in the coming decade 
(Godfrey, 2019). If the krill market has a growth outlook and CCAMLR inflates the total catch 
quota, the industry participants do not have to limit the competition to acquire market shares 
from each other. Increased demand for krill products and a potential expansion of the quota, 
as the current quota is <1% of the total biomass and UN believes ~10% are sustainable (Aker 
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BioMarine 2020b), would indicate that competitive rivalry between the participants is 
moderate. This can partly be attributed to the Olympic pool quota system in the industry.  
Level of concentration and competition  
If many companies operate in the same industry or enough participants are the same size, the 
industry's degree of rivalry is enhanced. Still, if a few large players dominate the industry, the 
rivalry is lessened (Roos et al., 2014). Aker BioMarine chiefly dominates the krill industry, 
the company harvest ~63% of all krill (Aker BioMarine, 2020b), and the remaining ~37% are 
caught by the remaining companies. The degree of concentration is therefore significant, and 
the development of the past years is trending towards further concentration with M&A activity 
consolidating the industry. The recent development converges towards fewer but larger 
participants in the industry, which indicates an immense potential for earnings in the industry.  
Liquidation possibilities 
The liquidation possibilities in the industries are viewed to be moderate, which indicates 
modest competitive rivalry. The limited number of purpose-built krill vessels and support 
crafts makes them sought resources, and if a participant wants out of the industry, it will likely 
be straightforward to unload these vessels to competitors. The industry players are currently 
expanding their operations and investing in new resources to meet the future demand for krill. 
We view the liquidation possibilities in the industry to be reasonable, which indicates a softer 
competitive rivalry. 
The analysis of these three characteristics indicates that the competitive rivalry in the industry 
is limited. The dominance of Aker BioMarine, the current consolidation trend, and the 
adequate liquidation possibilities indicate low rivalry. The industry is regulated in a way that 
encourages a highly competitive environment with the Olympic pool model. Nevertheless, in 
the past years, the quota has not been covered, and the humble quota is expected to be 
increased with the global surge in demand for krill products. Hence, we argue the competitive 
rivalry in the industry to be limited. 
4.3 Summary of external industry analysis 
The external industry analysis has mapped and assessed external factors that create potential 
advantages in the krill industry. Both the PESTEL analysis and Porter's five forces contributed 
to analyzing any competitive advantages in the krill industry that can be utilized. Together 
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with Aker BioMarine's internal resources advantages, the advantages presented are an 
estimation of Aker BioMarine’s combined competitive advantage in the global economy. In 
the PESTEL analysis, we identified and presented various macroeconomic factors that affect 
the krill industry's earnings.   
We consider political, sociocultural, and technological aspects of playing the most critical role 
in the industry's performance in the foreseeable future. Political factors such as trade barriers 
and political decisions on the allowed krill fishing volumes in the Antarctic may have the 
ability to drastically change the “rules of the game” for the krill operators. Moreover, we also 
perceive sociocultural developments in population growth, public health, and consumer 
perception on omega-3 and the industry, in general, to be of substantial strategic importance, 
as we expect these factors to be some of the critical drivers of krill demand in the future. 
Evolution in efficiency, productivity, and accuracy due to technological advances and 
innovation could also play out as critical factors in shaping the industry's future. More so, 
advances in technology have the potential to increase competition and drive profits 
remarkably. 
While economic factors such as GDP growth and interest rates are likely to be closely linked 
with consumer spending and business prosperity, we believe it will have a more bounded 
impact on the krill industry in the foreseeable future. This is mainly due to our belief that the 
krill industry is somewhat cyclical and that economic factors such as fuel prices are of 
significant effect. In terms of legal factors, we expect a similar effect, in which we perceive 
legal developments to be relatively predictable and of limited scope. Lastly, the krill fisheries 
are at the forefront of global fisheries in handling environmental factors. Hence, we see a 
relatively little impact of environmental aspects on the future of the industry. 
4.3.1 PESTEL analysis summary 
Exhibit 4: Expected importance of PESTEL factors (1: Low – 5: High) 
Elements 1 2 3 4 5 
Political    X  
Economic   X   
Sociocultural    X  
Technological    X  
Environmental  X    
Legal   X   
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Exhibit 4 summarizes our assessment of each of the PESTEL aspects on the krill industry, 
with ”1” symbolizing a low impact of the external factor and “5” symbolizing a high impact 
of the external factor on the krill industry going forward. 
4.3.2 Porter's five forces summary 
Porter's five forces framework facilitated an industry analysis to identify what characteristics 
affect industry profits and competition. Today, a license is required to operate in the 
aquaculture industries, and it requires significant capital to get started, making the entry 
barriers are substantial. The threats from substitutes are significant as there are multiple 
alternatives for omega-3 sources other than krill. As of today, the most deployed source is fish. 
Further, the animal feed segment is also easily substitutable. We deem it to be a considerable 
threat to the profitability of the industry. The buyers' bargaining power is relatively high today 
as there is more supply than demand for krill, and it is limited how widespread the krill 
products are today. 
The negotiating power from suppliers is limited. This is since krill harvesting is the first stage 
in the value chain, and the suppliers consist of fuel suppliers and shipyards that build the 
vessels. Thus, we believe this to be a low threat to profitability. Finally, the industry's 
competitive rivalry is low as there are few players in a growth industry dominated by one 
larger player. We also maintain that the industry's liquidation possibilities are reliable as the 
need for new vessels has increased, and krill vessels need to be purpose-built. 
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4.4 Internal resource analysis 
The internal resource and competitive advantages are frequently employed as the theoretical 
frameworks used to explain the variation in earnings and profitability between companies in 
the same industry. The analysis identifies and maps out the resources which the company 
disposes of and aims to identify if and how a company may develop and (or) sustain a 
temporary or permanent competitive advantage. A resource is defined as every input factor 
the company uses to generate value for its consumers, including employees, brand name, 
patents, company culture, products, and real capital. Resources can be characterized as 
“strategic resources,” which implies that the resource may be the source of competitive 
advantage, leading to increased earnings.  
Analyzing companies in an industry with this approach may explain some of the differences 
in earnings and profits. Competitive advantages are difficult to quantify, but numerous studies 
have tried finding the link between strategic resources and earnings. The link to profitability 
may also be problematic to measure as strategic resources may only increase their portion of 
the value creation and do not necessarily increase how much value is generated. An increase 
in the captured profitability could be assigned to other parts of the value chain, not the specific 
resource. A company will have a resource-based competitive advantage if they have better 
profitability than the industry. To outline Aker BioMarine’s position in the market, we will 
deploy the VRIO framework. We will use this analysis to forecast what we expect of Aker 
BioMarine compared with the industry. In the external analyses, we investigated how the 
industry is expected to perform compared with other industries while focusing on the 
individual company in this analysis. One of the most frequently used frameworks to identify 
sustained competitive advantages is the VRIO framework. VRIO is an acronym for 
“valuable”, “rare”, “inimitable”, and “organized”.  
The first step in the analysis is to assess if a resource is valuable, meaning it can be used to 
charge premium prices, reduce costs, or increase earnings. If the resource is unable to do any 
of these, - it is not valuable. If the resource passes the first test, it goes through to the second 
stage, which is “rare.” This implies that it is not easy for competitors to get their hands on that 
specific resource. The third stage implies that the resource is difficult to replicate or copied by 
competitors. If the resource passes this stage, it moves on to the final stage. It needs to be 
organized. If the company has not organized it so that it is possible to capitalize on the 
resource, it is considered an unused competitive advantage. Only when the resource has passed 
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all four stages may it be classified as a sustained competitive advantage that the company can 
quickly capitalize on. 
Figure 18: Illustration of the VRIO framework 
Source: Business-to-you (2020) 
4.4.1 Brand name 
Aker BioMarine is one of the companies that focus on building a strong brand in the krill 
product industry. It differentiates itself from its competitors by offering different products 
under unique brand names. The “Qrill” product range offers “Aqua” as nutrition to the 
aquaculture feed segment, “High Protein” is also aquaculture feed, focusing on enhanced 
growth and increased feed uptake. The final product in the Qrill product range is “Pet,” which 
is pet feed, focusing on dogs. Their product ranges are directed towards humans called 
“Superba Krill” and the new “Kori” brand. We believe Aker BioMarine is wise to separate the 
individual brands instead of offering it all underneath its brand. In this way, consumers are not 
thinking of pet feed when they see Superba Krill or Kori as these product lines are directed 
towards the human segment. 
Aker BioMarine has spent a lot on marketing to build these brands, and they may soon be able 
to reap what they have sown as they enter the pet feed market. They have created a responsible 
and trustworthy position for their brands globally. If a company can create a strong brand name 
and reliable reputation in the market, it may lower the risk of a product as it is perceived as 
safe and sound. As more individuals consume a product, the product’s own risk will also be 
lowered as it will be regarded as reliable. Further, a firm brand name might also increase 
customer loyalty and high margins leading to higher profitability. Aker BioMarine’s strong 
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brand appears to be important, rare, and efficiently organized. Even though it is expensive, 
complicated, and time-consuming for other industry players to obtain such a mighty brand 
name and the same level of brand recognition, we cannot argue that it is inimitable. The 
resource will only provide a competitive advantage short-term.  
4.4.2 Product portfolio and development 
In addition to Aker BioMarine’s investments in building strong brands, they have the past 
years invested heavily in product development to enter new markets. The development of new 
products will be a crucial part of securing its future growth and the demand for krill products. 
The acquired pharmaceuticals manufacturer, Lang, produces over 146 products across 15 
different categories for significant retailers, contributes to the well-positioning of Aker 
BioMarine as they now have a close relationship with major retailers. They are now in a good 
position when introducing new products to the market as they already have a well-established 
relationship with all the major retailers and an in-house pharmaceuticals manufacturer. No 
other competitor in the industry has its own fully vertically integrated supply chain, some only 
harvest while some only sell the end-product. It has the whole chain and offers both human 
nutrition in omega-3 tablets and nutrition for aquaculture and animals.  
Today, Aker BioMarine has the broadest product range in the krill industry, with even more 
products under development, such as protein powder for humans. In this way, they cover a 
larger part of the market than what their competitors do and have a better-diversified portfolio 
of products than their rivals can offer. A diversified portfolio of products makes it easier to 
enter new markets as their brand is familiar, and they have loyal customers that are willing to 
embrace their new products. Finally, a broad selection of products will also make Aker 
BioMarine less vulnerable to changes in market preferences, which will mitigate some of the 
company's exposure to risk.  
These attributes do create a strategic resource for Aker BioMarine in the krill industry. Even 
though a broad and diversified portfolio of products is rare and vital, the competitors will 
likely follow. Having a broad product portfolio is not inimitable, although it will be both 
expensive and time-consuming to catch up with Aker BioMarine as none of the industry 
players today has a fully vertical supply chain. We deem this to be a short-term competitive 
advantage as we see the other industry participants following Aker BioMarine, and it is more 
comfortable and less time-consuming to follow up Aker BioMarine’s breakthrough products 
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than it is to innovate new ones. Thus, we do not believe it will be able to hold this competitive 
advantage permanently. 
4.4.3 Ability to innovate 
Since the launch of Aker BioMarine, the biotech company has heavily invested in R&D and 
has been a pioneer in several industrial fields. They have broadened the knowledge about the 
health and nutrition potential of krill. As of today, they hold 76 patents and 1,200 patent 
claims. Aker BioMarine has also been at the forefront of introducing new products and 
penetrating new markets, such as pet feed.  
The best example of its ability to innovate may be the eco-harvesting technology, which 
enables them to harvest the krill with minimum eco-footprints. They are also currently 
developing a new protein powder for humans, which, again, they will be the first to introduce 
to the market. By implementing innovation as a strategy such as Aker BioMarine has done, 
they can improve their core competencies and engineer the business structure to respond to 
new market conditions and customer demands (Evangelista et al., 2010). Besides, companies 
that innovate are better at penetrating new markets, maintain existing market share, and 
increase their competitive advantage. Innovation in the implementation of strategy can act as 
a strategic weapon to achieve a sustainable competitive advantage in the global competition 
(Kuratko et al., 2005). 
Figure 19: Historical development of Aker BioMarine’s intellectual property 
Source: Aker BioMarine (2020b) 
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Aker BioMarine's ability to innovate and create new products are rare. The ability to produce 
patents and innovate is not inevitably rare in the industry, but the ability to produce both so 
many and patents that can be utilized as a resource is rare. The strategic resource is rare, 
valuable, and organized, but again, it is not inimitable in the long run. Competitors can be able 
to catch up with Aker BioMarine with enough R&D investments. The combined portfolio of 
patents has taken ~15 years to create, but it is unlikely that any rival will catch up in the 
foreseeable future. Collectively, the ability to innovate only provides a temporary competitive 
advantage. 
4.4.4 Input factors and value chain 
Aker BioMarine is a vertically integrated company that controls its whole supply chain, from 
harvesting, R&D, and to the production of its end-products. Having absolute control over the 
value chain can increase competitiveness and profitability in the marketplace. They achieve 
economies of scale by lowering their per-unit fixed cost. They can do this to buy supplies in 
bulk and spread the cost over a larger quantity. Further, it may allow them to cut costs by 
eliminating costly markups from intermediaries, consolidating management and staff, and 
optimizing and engineering the operations to their corporate structure. Vertical integration also 
allows Aker BioMarine to quickly expand geographically by adding distribution centers in 
new areas or acquiring a new brand. The recent acquisition of Lang Pharma allowed entering 
the US pharmaceuticals production.  
Further, Aker BioMarine recently opened a new distribution hub in Chennai, India, to keep 
the region well-stocked with its Qrill Aqua products. The new center will strengthen its local 
presence while also enabling it to serve its customers across the region more efficiently. By 
expanding to India, the customers in Asia will benefit from a steady supply of the products, 
from vessel to warehouse delivery-ready and already customs cleared. The increased speed in 
the distribution provides easy access for customers, who can also benefit from the local service 
and support instead of relying on cross-continental support. 
The current structure also allows for more straightforward quality control. If a business is a 
pastry depot getting cake deliveries, one is at the risk of the supplier cutting down or 
substituting the eggs. This would alter the final product, and the pastry depot cannot control it 
without having to temporarily sell substitutions to control it or offer it to customers without 
quality control. Aker BioMarine is the supplier of the needed components to the end-products 
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and is therefore in control of the production process and can maintain a higher quality standard. 
Finally, it is an excellent way to protect proprietary processes and recipes. As stated, it holds 
76 patents and has 1 200 patent claims, which in some cases are secret and valuable. To keep 
these trade secrets, outsourcing their manufacturing would be unthinkable.  
Aker BioMarine is today the only company in the industry that controls the full value chain, 
and we regard this to be rare. Based on the presented arguments, we say that it is valuable to 
control the whole value chain even though it presents some additional risk considerations. The 
value chain is also organized and ready to be capitalized on as it is fully operating. Finally, we 
cannot regard the access to input factors and their value chain to be inimitable as other 
competitors are in the position to develop their integrated value chain. 
4.4.5 Locations 
Aker BioMarine’s supply chain stretches from the krill harvesting vessels in the Antarctic 
waters through the logistics hub in Montevideo, Uruguay, to the krill oil manufacturing plant 
in Houston, Texas. The custom-built krill vessels produce the krill meals instantly after the 
krill has been brought on board from the waters, as it ensures optimal quality. Aker BioMarine 
has a fleet of three harvesting vessels and two support vessels, with a fully equipped 
manufacturing plant. A lot of the production done at the top-modern vessels saves both time 
and costs, compared to having it shipped to a facility to produce the krill meals. In addition to 
the logistics hub in Montevideo, it recently opened a new warehouse in India, which acts as 
India's main distribution center. This effort is increasing its presence and local relationship 
with the Indian population and Asia in general. 
The current locations cannot be scarce, as the on-vessel production is not uncommon in the 
industry. The element that separates it from its industry peers is the production plant in 
Houston, Texas. Nevertheless, again, this must be viewed in the context of the vertically 
integrated supply chain. Some of its peers only sell their harvest, while others also produce 
Omega-3 krill oil. We view the locations of Aker BioMarine only to be valuable and organized 
but not rare and inimitable. Implying the locations alone provide them with a competitive 
parity. 
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4.4.6 Strategic collaborations 
Aker BioMarine has multiple strategic collaborations with various allies throughout its supply 
chain. In Q1 2019, Aker BioMarine and Cognite, an IT company with Aker ASA as its 
majority owner, signed an agreement to digitalize the harvesting and manufacturing operations 
to enhance the sustainability efforts already implemented. Similarly, the data science company 
NextBridge analytics also joined forces in a strategic alliance. The initial goal for Aker 
BioMarine is to use data contextualization with AI to increase the vessels' efficiency, including 
the reduction of fuel consumption. To optimize the harvesting patterns, production flow, and 
maintenance, the company hopes the deployment of live data and machine learning will be of 
value. 
Further down the supply chain, Aker BioMarine has entered an R&D collaboration with Lupus 
Research Alliance when launching a new clinical study in 2018. The goal is to examine how 
phospholipid-rich krill oil can benefit individuals with lupus can lessen the severity of the 
symptoms associated with chronic disease. If the study results proved to help people affected 
by this illness, it would be great news for both the individuals and Aker BioMarine, who profits 
a new segment. With the ongoing penetration of the pet feed market, Aker BioMarine teamed 
up with the world's largest dog sledding race, The Iditarod, as well as other races in Minnesota 
(John Beargrease), Norway (Femund Race), and Russia (Volga Quest) to create a new 
championship. QRILLPAWS (Qrill Pet Arctic World Series) is the new championship aimed 
to help the sport and community grow and showcase and market their new world-class dog 
feed (Aker BioMarine, 2020b). The event was broadcasted on CBS Sports Network, and 
according to Aker BioMarine, it has more than 9.5mn views on YouTube and aired four hours 
of highlights on both CBS and in Russia. Aker BioMarine also used the races to test their feed 
to determine if it affected the dog's health and performance – meaning it does not test on dogs 
in cages. 
These strategic collaborations throughout the value chain with different allies that all enable 
Aker BioMarine to generate value through either exposure and marketing or cost-cutting. The 
collaboration with the dog sledding community may prove to be especially important as this 
is a new market for the industry, and it is critical to get a good foothold in the market to become 
the preferred krill pet feed. The ability to map out and create the right strategic collaborations 
is both time and resource-demanding and challenging to find good allies. We deem this to be 
difficult to imitate short-term. It should be noted that it is rational to assume the competition 
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will create valuable relations. All this combined, we consider this to be a temporary 
competitive advantage.  
4.4.7 Financial position 
The industry is capital intensive and requires the operating companies to make significant 
investments in licenses, harvesting vessels, and equipment. To follow the development in the 
industry, it is vital to have a robust financial position. In the fiscal year of 2019, Aker 
BioMarine had an equity ratio of 22.46%, and a high equity ratio lowers the risk of default as 
the firm can withstand losses in a more extended period. 62.8% of the assets are also property, 
plant, and equipment (“PPE”), which are favored over intangible assets by debt holders and 
lending institutions, as it holds value. However, as 37.2% are intangible assets implies that 
when Aker BioMarine encounters hard times, the intangible assets can be at risk for a 
significant decline as they would have to depreciate. The equity would suffer the same destiny 
in that case. An integral part of the assessment of the financial strength also revolves around 
who the shareholders are. Today, Aker ASA is the majority owner, and which is a powerful 
financial conglomerate with stable profits and balance sheet.  
Aker BioMarine would operate and expand its operations with losses for years to come if Aker 
is backing the decision and looking at it as an investment in the future. We contend that the 
financial position is valuable for Aker BioMarine, but as the other peers are private, we cannot 
go through the financial position to determine whether it is rare. We note that other krill 
harvesting companies are backed by large conglomerates as well, so we cannot conclude that 
it is in a rare position for now. Thus, we consider the financial position of Aker BioMarine to 
give them a competitive parity. 
4.4.8 Conclusion 
The VRIO analysis illustrates that Aker BioMarine's brand name, ability to innovate, product 
portfolio, access to input factors, and strategic collaborations represent some of the company's 
essential competitive resources. These are also rare to possess in the same volume and extent 
as Aker BioMarine has today, and with a short-term view, they are challenging for peers to 
copy. The resources are also considered to be organized in such a manner that they are fully 
exploited. Aker BioMarine separates itself from its peers as it is the industry giant capturing 
most of the harvest and market shares, but they have not differentiated themselves in a way 
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that no peer will ever be able to copy with enough time and capital. All their resources are, 
with adequate capital and time, possible to imitate. 
Looking at all the analyzed aspects of the VRIO analysis demonstrates that Aker BioMarine 
has internal resources, which gives them a temporary competitive advantage, but not a 
permanent one. We expect Aker BioMarine to perform better and grow faster than the rest of 
the industry. This is an industry with enormous growth potential and many investments 
currently going into it, it is problematic to say something about the long-term competitive 
situation. We argue that Aker BioMarine’s current internal resources will give them a 
competitive advantage going forward but expect it only to provide competitive parity looking 
long-term.  
Exhibit 5: Summary of VRIO analysis 
4.5 ESG assessment 
The ESG assessment is based on the framework of Schoenmaker et al. (2019) and the 
knowledge acquired from FIE459 Sustainable Finance. Environmental, social, and 
governance (“ESG”) criteria are a set of standards for a company's operations that socially 
conscious investors employ when screening for potential investments, and these standards 
vary a lot from industry to industry. The environmental criteria consider how a company 
performs as a steward of nature. This may include a company's carbon footprint, waste 
management, natural resource conservation, and animal treatment. It may also be used in 
Resource Valuable Rare Inimitable Organized Competitive implications   
Brand name X X  X  
Short-term competitive 
advantage 
       
Product portfolio X X  X  
Short-term competitive 
advantage 
       
Ability to innovate X X  X  
Short-term competitive 
advantage 
       
Input factors and 
value chain 
X X  X  
Short-term competitive 
advantage 
       
Locations X   X  Competitive parity  
 
         
Strategic 
collaborations 
X X  X  
Short-term competitive 
advantage 
       
Financial position X   X  Competitive parity   
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evaluating any environmental risks a company might face and how it manages those risks. The 
social criteria assess how the company manages its relationships with employees, suppliers, 
customers, and its communities. Lastly, the governance criteria deal with a company's 
management, corruption, audits, internal control, and shareholder rights. Investors want to 
know that a company uses accurate and transparent accounting methods and that stockholders 
are given the right to vote on important issues. No single company may have a top score in 
every category, so investors and companies need to decide what is important for them. 
4.5.1 Context 
It all began with the call to action in 2004 by then-UN Secretary-General Kofi Annan, who 
wrote to the CEOs of considerable financial intuitions to take part in an initiative to integrate 
ESG into capital markets. Since then, ESG has moved and evolved from the sidelines to the 
forefront of decision-makers for asset managers, institutional investors, and corporate 
management. ESG considerations are being integrated into the charter of a growing number 
of entities, included in their practice, and applied to due diligence when assessing investments. 
In 2015, the global ESG investments were ~USD 18.4 trillion, growing by 25% to USD 23 
trillion in 2017, accounting for one-quarter of all professionally managed investments globally 
(Colby, 2017).   
World economies face a growing indebtedness and unsustainable asset prices as we have 
entered a disconcerting geopolitical reality where nationalism and populism are on the rise, 
leading to alleviate the escalating military, economic, and commercial tensions. 
Simultaneously, the world is failing to mitigate climate change and global warming, which 
continues to grow as it threatens global stability. As we enter this grim reality, it is clear that 
the ESG criteria are well-suited to effectively assess a company's resilience, adaptability, long-
term sustainability, social-awareness, and capacity for growth. All of this requires a forward-
looking, qualitative, expansive approach for corporate governance and investing that examines 
what-if scenarios and relies less on past performance and historical data as a prophet of future 
performance.  
Aker BioMarine has an outspoken mission to continue being the ESG-leader in the krill 
industry as the first Marine Stewardship Council (“MSC”)-certified krill supplier (Aker 
BioMarine, 2020e). The certification is only given to the fisheries that comply with the most 
stringent sustainability standards. Before throwing the first fishing net, they initiated a 
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dialogue with WWF Norway to ensure the operations would have a low impact on the 
Antarctic ecosystem. They have set ambitious goals to overcome the global challenges the 
world faces, such as loss of biodiversity, resource scarcity, lifestyle disease threats, and climate 
change. Aker BioMarine intends to be a part of the solution to these challenges with its eco-
harvesting technology and marine conservation practices (Aker BioMarine 2020b). With the 
rising importance of a company's ESG standards, an ESG assessment is an essential step in 
the strategic analysis. 
4.5.2 Environment ("E") 
Several environmental factors are critical when assessing the seafood industry. We will 
highlight what we argue are the most significant elements, describe risks the industry is facing, 
and potential risk mitigation measures.  
Fleet and production 
Like most other industries, the seafood industry is pushed towards reduced its CO2 emissions 
and carbon footprint. Seafood's carbon footprint is primarily affected by fuel consumption. 
The reality is that large vessels traveling the high seas to catch krill will burn a lot more fuel 
than vessels traveling less distance to catch local species. The further the vessels travel from 
the port to the catch, the larger gas consumption and emissions. As the krill are found in 
Antarctica, it is not easy to do something about the port's distance if we exclude the option to 
relocate. The key driver to lower the emissions can be found in new and modern vessels and 
higher catch volumes per day/vessel, as this will reduce the CO2 emission for the end-product. 
Further, the tools utilized to catch the krill does also have a variable climate impact. So, 
another element in classifying seafood as climate-friendly involves how it was caught. Finally, 
where the catch is processed and the end-product produced will also affect the carbon 
footprint. Even if caught without large distances, shipping product for foreign processing and 
importing it for sale may skyrocket fuel and energy consumption, leading to higher emission 
rates. 
Aker BioMarine has the newest and most modern fleet in the industry, with an additional 
expected delivery of a support vessel in 2021 (Aker BioMarine, 2020b). Their modern fleet 
catches far more krill per vessel than the competitors. Further, with the new support vessel's 
delivery, the need for krill vessels to go to the port will be eliminated as the support vessels 
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will bring supplies, new crew, and fuel to the krill vessels. This will enhance the catch volumes 
per vessel and reduce the combined end-CO2 emissions per end-product. 
The patented eco-harvesting technology developed by Aker BioMarine secures the krill to be 
caught with an environmentally friendly method and protects the Antarctic fishery from 
disadvantageous environmental impacts. Traditional trawling is not considered suitable for 
krill, as the enzymes will “self-destruct” before they can be processed. However, the eco-
harvesting system allows the fishing net to stay in the water during the whole operation, with 
the krill being pumped up through a hose live to the vessel for instant processing. 
This increases the catch's quality, which has more fat and oil collected during the processing, 
consequently preserving vital nutrients in the end-product and preventing enzymatic 
degradation. Thus, the method is the most sustainable and efficient way to catch krill and 
almost eliminates any by-catch. 
Figure 20: Aker BioMarine’s eco-harvesting 
Source: Repstad, T. Superba Krill (2018) 
The company’s purpose-built manufacturing facility in Houston, Texas, is a complete-chain 
operation, implying it does not ship and distribute parts of the production elsewhere, which 
would significantly increase the end-product's carbon footprint. The facility itself is also 
highly sustainable, recycling and re-using the vast majority of ethanol and water need for the 
production. As presented in Figure 1, krill only emits half of the CO2 per MT of edible protein 
as salmon and only 1.48% of what requires for beef (Aker BioMarine, 2020b). So, krill is a 
low-intensity greenhouse gas product, but the way of harvesting and production to end-product 
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matters a lot in the ESG assessment. Aker BioMarine has executed various measures to 
increase efficiency and lower emissions, which is reflected in the certifications they have 
attained.  
Overfishing 
Sustainable fisheries leave enough fish and crustaceans in the ocean, respecting the habitats 
without disrupting the ecosystem and ensuring people who depend on fishing can maintain 
their livelihood. A fishery's sustainability can be assessed regardless of its size, geography, or 
the harvesting method employed. In the process of assessing the sustainability of a fishery, 
three main principles are deployed. The first thing to consider is the krill stock, the harvesting 
must be at a level that ensures it can continue to live indefinitely, and the krill population can 
remain productive and healthy. Krill harvesting appears to be operating sustainably, as the 
cumulative annual catch is well below the conservative set quotas target, according to Lloyd's 
Register (Chu, 2020). The organization also granted the company a certificate stating its krill 
harvest is sustainable and well-managed and meets the requirements set out by the MSC. 
According to Sustainable Fisheries, Antarctic krill is the only fishing industry ranked “A” for 
its sustainability, with best-in-class supervision and stock status (MSC, 2019). 
Secondly, sustainable fisheries must minimize their environmental impact. The harvesting 
activity must be managed carefully so that other species and habitats within the ecosystem 
remain healthy and in large enough stock to reproduce. The wild catch's environmental impact 
is predominantly related to potential damage caused by dredging, bottom trawling, or 
unintended harvest of vulnerable species. Aker BioMarine has addressed this with the 
invention of eco-harvesting. Finally, to be viewed as a sustainable fishery, the operations must 
be well-managed and transparent. The company must comply with relevant laws and be able 
to adapt to changing environmental circumstances and standards. We will dive deeper into this 
when we present the “governance” aspect of the ESG assessment. 
4.5.3 Social ("S") 
Assessing the social aspect of the seafood industry, we chose to elevate four considerations.  
Occupational safety  
Health and safety are paramount as the occupation is one of the most dangerous occupations 
globally, supported by high rates of accidents and fatality rates in most countries (FAO, 
2020a). Aquaculture processing has been highlighted as one of the vital hazardous industries, 
 73 
and the industry is taking significant steps in generating awareness and building capacity for 
workspace health and safety measures. In addition to safety hazards, workers in the industry 
are often exposed to high noise levels resulting in hearing loss, ergonomic hazards causing 
musculoskeletal disorders, and chemicals that increase the threat to satisfactory occupational 
health. The industry is operating in harsh conditions, and a key focus for companies is to 
reduce the number of accidents by having top-quality equipment and strict policies.  
Aker BioMarine possesses the newest and most modern fleet in the industry, which is outfitted 
with top-modern equipment that reduces the risk of fatal work-related accidents and long-term 
damages coming from the usage of older and inferior equipment. Further, its Houston-plant 
was awarded the “Platinum Safety Partner Award” by Texas Mutual Insurance Company in 
2017, which only 0.29% of all Texas-companies possess (Aker BioMarine, 2017). The award 
is presented to companies that demonstrate their commitment to occupational safety by 
implementing safety programs and measures and controlling their worker's compensation 
losses. The management has stated that they go “far and beyond” to provide training and 
resources necessary to protect their employees from workplace hazards, reflected in safety 
records (Aker BioMarine, 2017). 
Social dumping and local initiatives 
The EEA agreement has created the opportunity for easy employment of foreign workers 
within the economic area, unlocking the possibility of social dumping. In the past years, there 
have been numerous instances with fisheries breaking the labor law and utilizing workers from 
low-wage countries (Lysvold et al., 2019). Violations like these are quite frowned upon by 
both the public and investors, such that it is crucial to create and maintain the image that shows 
that Aker BioMarine does not exploit low-wage blue-collar workers. In late 2019, it was 
discovered that one of the MSC-certified fisheries Aker BioMarine employed to process the 
catch was involved in social dumping (Thorenfeldt et al., 2019). Aker BioMarine took 
immediate distance from it and suggested that assessment the work environment should be a 
criterion of the MSC-certification (Thorenfeldt et al., 2019).  
We consider local initiatives to be essential to maintain a positive impression by the public 
and thereby continue to have the license to operate in the common areas. Through the Antarctic 
Wildlife Research Fund, Aker BioMarine is contributing to Antarctic science. The company 
is contributing to new technology to improve fishery management in the polar circle. As it is 
with all businesses, it is crucial to have a diverse base of employees. This is true for the whole 
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organization, from top management and board of directors to the vessels' staff. Today, the firm 
also has diverse top management, with 4 out of 9 (44.4%) being women (Aker BioMarine 
2020a). It should be compared with the rest of the industry to benchmark the performance. 
Researching the rest of the seafood industry, Aker BioMarine comes out in the high end 
compared with the industry. There is only one woman on the board, which consists of 6 
directors (16.6%). We were unable to obtain any numbers regarding the diversity on the 
vessels, but men frequently dominate these positions, so we do not expect the same diversity 
in these positions (OECD, 2020). 
Food safety and quality assurance  
Food safety and quality is also a key factor for the industry. The importance and knowledge 
that the end-product is safe and healthy for the consumers are paramount. Consumers require 
full transparency when it comes to the origin of their product choices and, in particular, when 
the product sources from the ocean. Aker BioMarine has since the launch offered the 
customers the actual harvesting location for every krill oil batch. The harvesting location 
information is both a differentiator and for the consumers, which makes them stand out as an 
attractive, trustworthy, and responsible brand delivering high-quality products. Traceability is 
needed to guarantee food safety, deliver products that responsibility produced, and build trust. 
As the customers can follow the whole production circle of the products Aker BioMarine 
offers, the competitors cannot offer the same level of quality assurance and ownership in the 
product line. 
4.5.4 Governance ("G") 
Our final aspect is the governance characteristic. Governance is a vital part of all operating 
companies. The seafood industry is especially relevant due to the strong relationship between 
the businesses, the government, and the public. It is, therefore, of great significance that these 
companies have an open and transparent reporting policy. Several of the industry companies 
are also family-controlled, which also holds other businesses in different parts of the supply 
chain and other sectors, and good corporate governance is therefore key for not damaging the 
family name. We have chosen to investigate three different aspects of corporate governance, 
explicitly reporting standards, political accountability, and corporate control.  
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Reporting standards 
The seafood industry is obligated to report on several factors, and we argue the reporting 
standard will be stricter and stricter going forward. The companies are operating in the 
common areas, and both the public and governing organs will require companies to disclose 
more information going forward with regards to the origin of the product. We consider 
companies like Aker BioMarine, which have numerous studies documenting the positive 
health effects, will be more willing and forward-leaning in their reporting standards.  
As a listed company, we expect high reporting standards of both catch-volumes, by-catch, 
vessel positions, and production processes. Today, Aker BioMarine reports following both the 
Global Reporting Initiative (“GRI”) core level guidelines and meeting the requirements by the 
Norwegian Accounting Act. As a part of its strategic reporting project, initiated in November 
2019, it developed targets and baseline tracking for selected key performance indicators 
(“KPIs”) relevant to the corporate structure. The company is now evaluating relevant standards 
currently applied by well-performing listed companies as a part of the strategy but will develop 
and apply a reporting regime tailored for its scope and context (Aker ASA, 2020). 
Political accountability and corporate control 
For the seafood industry to operate sustainably, rules and regulations must be in place. 
Historically, we have seen that when the industry is under-regulated, it has led to overfishing. 
Therefore, we assert that having stable and reliable regulations is fundamental for the industry 
to thrive in the future. Aker BioMarine relies on continued strong regulation of the krill 
biomass to continue the harvest profitably and sustainably in the unforeseeable future. They 
currently operate in Antarctica, where the quotas are determined by the 26 nations who operate 
under the Antarctic Treaty.  
The final part of the governance facet is corporate control. Aker BioMarine is ~78% held by 
Aker ASA, which is controlled by The Resource Group (“TGR”), owned by Kjell Inge Røkke. 
Potential transactions between the company and other portfolio companies in the Aker system 
must be done at an arm-length distance to keep good corporate governance. The group will 
also need to establish a strong board to ensure the rights of the minority owners. As the 
situation is today, it is sub-optimal for the minority owners regarding the board of directors 
and the measures taken by TGR to ensure transactions and corporate decisions at Aker ASA 
are taken to improve Aker BioMarine’s position and no other portfolio companies of TGR. 
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4.5.5 Conclusion on ESG assessment 
Aker BioMarine ranks high on the environmental factors as the end-products it produces have 
a low carbon footprint, and the krill harvesting is performed in a sustainable manner. We also 
insist that the company has a high ranking on the social criteria as a decisive contribution to 
local communities, and the end-product has high quality and offers several health benefits. 
Lastly, when rating the corporate governance, we cannot claim it scores high but rather 
average. We see needs for improvements with a strong board and the risk of potential 
transactions and major decisions between the company and its largest owners. These 
transactions and decisions must be made at an arm's length distance and with the best 
intentions for Aker BioMarine. Good political accountability and reporting standards impact 
the rating positively, but we cannot rate it high as the situation is today.  
Assessing Aker BioMarine's ESG initiatives and status today with a holistic approach, they 
score well. As stated in the beginning, very few companies achieve a top score on all the 
aspects of the ESG, and the individual investors or asset managers must assess themselves 
what is important for them. We believe Aker BioMarine scores high on essential 
considerations when investors are assessing the ESG, but they should take measures to 
improve the corporate control and ensure that every decision taken is in the best interest of all 
Aker BioMarine shareholders – and not only the majority holder. 
Figure 21: Potential pathway from ESG focus to ESG premium 
Source: Own creation, Schoenmaker & Schramade (2019) 
ESG 
integration
The pathway to 
achieving an ESG 
premium starts with 
the business’ 
integrating ESG 

























The ideology is that 
high performance on 
ESG factors will 
warrant an ESG 
premium in the 
marketplace, 
meaning that 
investors are willing 
to pay a higher price 
for companies that 
are mitigating ESG 
risk factors
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Figure 21 summarizes how the focus on ESG factors may lead to a premium valuation in the 
marketplace. This pathway is inspired by Schoenmaker & Schramade’s (2019) theoretical 
frameworks, which elaborates on how to focus on ESG factors that may lead to several 
operational and reputational benefits that in turn warrants an ESG premium in the marketplace. 
While the in-practice existence and implication of an ESG valuation premium has long been 
debated, the view on this matter has been changing drastically in the last decade.  
As governments and regulators are putting increasing pressure on the sustainability of 
businesses and ESG issues, investors are now paying increasing attention to these factors and 
their implications on a company's financial valuation. In fact, in a recent McKinsey Global 
Survey on ESG programs, as many as 83% of senior executives and investment professionals 
that responded to the survey stated they anticipate ESG programs to add increased shareholder 
value in five years than today. Further, these same respondents indicated that they were 
prepared to pay a median of 10% premium on companies that performed well on ESG issues 
compared to companies that perform poorly on ESG issues (Delevingne et al., 2020). 
4.6 SWOT analysis 
A SWOT analysis examines four unique elements: strengths, weaknesses, opportunities, and 
threats. The first two features assess the internal resources of the company. It builds on the 
VRIO analysis and ESG assessment. The latter two elements investigate the opportunities and 
threats in the environment the company operates within. The SWOT analysis combines the 
internal and external analysis to evaluate whether the company's strategy is relevant and 
feasible in combination with the changing macro environment (Roos et al., 2014). A 
combination of the previous analyses is utilized to acquire a holistic view of Aker BioMarine.  
We primarily want to answer how the industry's profitability is going to develop going forward 
and how the profitability of Aker BioMarine will develop compared with the industry. The 
first question will be answered with assistance from PESTEL and Porter's five forces. The 
latter question will be answered centered around the VRIO analysis and ESG assessment, but 
some industry analysis aspects can also be deployed. Some of the factors influencing the 
industry will probably impact some companies more than others. Hence, we examine the 
likeliness that Aker BioMarine is more affected than the industry average. 
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4.6.1 Strengths 
Perhaps the greatest strengths of Aker BioMarine are its sheer size and the integrated vertical 
value chain. No one in the industry is even close to its size and value chain today, as the others 
are mostly pure harvesting companies. This provides more significant economies of scale than 
their peers, with a 2020e catch of 388 000MT of krill, which is ~129 000MT per vessel 
compared to competitors ~17 000MT per vessel (Aker BioMarine, 2020b).  
Further, it also allows for rapid expansion to new markets and makes them better equipped for 
entrance into new markets as swift changes can be made without making significant changes 
in their supply chain. Having control over the entire supply chain allows them to reduce 
operating costs to intermediaries and mediators and have superior quality control of their 
products. Another evident strength is the acquisition of Lang that gave Aker BioMarine access 
to pharmaceutical production and ~85% of retail stores in the US. Access to the vast amount 
of retail stores in one of the world's largest markets is an immense advantage, as there is a 
limited need for time and resources to develop the relationship to obtain access to the store 
shelves with their products. 
Finally, sustainability is embedded in the company's strategy, and they have dedicated 
themselves to four of the UN's development goals. The global markets have experienced an 
elevated focus on “green” companies, and these are often traded with a premium compared to 
the low-scoring ESG equities. Our ESG assessment indicates that the company scores well 
above-average in both the environmental and social aspects but may have to improve its 
governance. Aker BioMarine controls the most extensive and greenest fleet in the industry, 
which may also give them an advantage as the consumers are increasingly becoming fixated 
on the origins and sustainability of their products. 
4.6.2 Weaknesses 
The internal resource analysis, VRIO, illustrated the competitive advantage Aker BioMarine 
currently possesses. It also indicated that none of its resources are inimitable and can be 
replicated with enough time and resources. This may prove to be a challenge for the company 
as China has a stated goal to become the number one within the harvesting of krill and 
production of krill oil (Urch, 2015). The Chinese giant, CMI, recently ordered the largest krill 
harvesting vessel ever to be built.  
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Aker BioMarine has substantial financial backing from the Aker conglomerate, but its 
financial muscles cannot be matched with the second-largest economy in the world. Aker 
BioMarine should focus on and dedicate resources to acquire and develop resources that prove 
to be unique. As presented in the ESG assessment, the company still has issues regarding its 
corporate governance. The company needs to take measures to guarantee the arm-length 
between Aker BioMarine and the rest of the Aker portfolio to ensure investors that decisions 
are taken with the best interest of Aker BioMarine in mind. Lastly, the company also needs to 
improve the female representation on the board to comply with the regulations of Oslo Børs, 
which is the listing Aker BioMarine aims for (Bjergaard, 2020). The increased female 
representation on the board will also improve the company's governance element and may 
further attract ESG-investors. 
4.6.3 Opportunities 
The rapid technological development will help Aker BioMarine conduct its operations more 
efficiently. The new agreement with Cognite may help and improve harvesting and fuel 
consumption. Thus, reduce both the operational costs and emission footprint. This will 
increase resource efficiency by minimizing the environmental impact and input factors 
contributing to climate change. 
Aker BioMarine is also entering the animal feed market, with a particular focus on dogs and 
aquaculture. With Kori's experience, the company is developing a new dog food that is planned 
to hit the market in 2022. The global pet food market is an attractive market worth ~USD 90bn 
in 2018, with an expected 7% 2018-2023 CAGR, and the US accounts for 39% (Nestle, 2019). 
Further, there is also an immense potential in the aquaculture feed market to capture market 
shares and expand operations. According to FAO (2019), the seafood market is expected to 
grow by an average of 2.6% per year, as the global population keeps on rising, and the need 
for aquaculture feed increases as the demand for fish is on the rise.  
In the past decades, there has been a significant rise in deaths from chronic diseases globally, 
and the demand for health supplements, such as omega-3, could consequently increase. In 
2020, annual global health care costs of high BMI are estimated to reach USD 945bn (Aker 
BioMarine, 2020b). Aker BioMarine is already in the process of developing more krill-based 
products through the newly established Epion subsidiary. Today, despite the benefits, less than 
1% of the US population buys omega-3 supplements, which creates an untapped opportunity 
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for growth. Additionally, a greater focus on plant-based diets increases the need for omega-3 
supplements. Plant-based alternatives include omega-3 only in the form of ALA or SDA, while 
the beneficial biological effect has only been documented from the EPA and DHA's fatty acids. 
This may also generate an untapped opportunity to expand the consumer base.  
4.6.4 Threats 
Climate change is a significant threat to the krill industry. Climate change and increasing 
temperatures of the oceans might move warmer water towards the poles, resulting in more 
impoverished living conditions and reduced krill stock in the Antarctic ecosystem. More 
frequent extreme weather, such as cold snaps and intense storms, may become more frequent 
in the future. This may affect the company's harvesting vessels. As described, the CCAMLR 
establishes an annual maximum permitted catch of krill. If climate development continues to 
proceed in the wrong direction, krill harvesting could become subject to tighter regulations.  
Further, China's goal to become the global leader in the krill industry may shake up the whole 
industry. China has all the power and resources needed to become so if wanted. Aker 
BioMarine does not have the capital or resources to outcompete China if they decide to achieve 
its goals. Lastly, the internal resource-based analysis, VRIO, discovered that the company had 
zero sustainable long-term competitive advantages. The risk of competitors developing more 
efficient and sustainable methods of harvesting and production techniques is present and poses 
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Strength 1: Fully integrated value chain 
Strenght 2: In-house pharma production 
and close links to US retailers 
Strenght 3: Strong ESG brand  
O Opportunities 
Opportunity 1: AI and technological 
advances to improve efficiency 
Opportunity 2: Entering the animal feed 
market 
Opportunity 3: Increased demand for 
health supplements and omega-3 
Weaknesses W 
Weakness 1: All its resources are 
imitable 
Weakness 2: Limited financial backing 
from its owners 
Weakness 3: The corporate governance 
structure is in need for reorganization to 
protect minority shareowners 
Threats T 
Threat 1: Climate change may change 
the outlook of the industry dynamics 
Threat 2: The rise of China and its stated 
goals to become the global leader 
Threat 3: The development of more 
efficient and sustainable production 
techniques by competitors 
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In this chapter, the historical financial information of Aker BioMarine is collected and 
analyzed to lay much of the quantitative groundwork for the forecasts and forward-looking 
assumptions that will be drawn later in our valuation analysis. In this paper, we have adopted 
the reorganization framework of Koller et al. (2020), complemented by insight from 
Damodaran (2012), Kaldestad & Møller (2016), and Kjell Henry Knivsflå's BUS440 course 
material. The historical financial statement analysis is conducted in two parts: first, a 
reorganization of the company's financial statements, and second, an analysis of historical 
financial performance. 
The reorganization of the financial statements is a vital step in any valuation analysis. The 
regular financial statements presented in a company's annual report typically lack some 
simplicity and do not provide the necessary understanding of the firm's performance if viewed 
as presented. Therefore, after first untangling each financial statement, a clearer picture of the 
company's operational performance can be obtained by reassembling and splitting financial 
statements into those that are core items to the business' operation and those that are not. 
Further, after the financial statements are restructured, an analysis of the company's historical 
performance can be conducted. More specifically, we do this by analyzing historical return on 
invested capital ("ROIC") and by examining historical revenue growth, as they are 
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5.1 Framework 
Exhibit 7 gives a visual presentation of the overall framework of our historical financial 
statement analysis. This follows Koller et al.'s (2020) methodology, where the financial 
statements as presented in the company's annual reports are presented in part 1, followed up 
by a reorganization of the financial statements in part 2. Finally, in part 3, Aker BioMarine's 
performance is analyzed based on the historical developments in ROIC and revenue growth. 
The final part will be concluded with an analysis of the firm’s credit health and capital 
structure. 










5.1.1 Framework for the reorganization of financial statements 
To capture the differences between operating and non-operating elements described in the 
chapter introduction, Koller et al. (2020) divides each financial statement's reorganization into 
three fundamental categories: invested capital, net operating profit after taxes, and free cash 
flow. Below we provide a brief explanation of how we will use this methodology to restructure 
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Reorganizing to calculate invested capital 
Invested capital represents all invested capital into a company regardless of investor source, 
from shareholders or debtholders. While it is a relatively simple concept in theory, the invested 
capital is much more than just a company's invested equity and debt, and understanding its 
components is key to understanding how a company's operations are financed. Invested capital 
encompasses operating working capital, fixed assets, net other long-term operating assets, and 
sometimes also intangibles such as other intangibles and goodwill if applicable (Koller et al., 
2020). Invested capital is seldom expressed directly in traditional financial reports and must 
be extracted by reorganizing its financial statements. In practice, this involves examining the 
notes in each annual report of the company to untangle balance sheet items to calculate 
invested capital. 
To paint a picture of how the traditional balance sheet mixes operating liabilities and sources 
of financing on the right-hand side of the equation, we illustrate an expansion of the traditional 
balance sheet equation to uncover total funds invested and invested capital (Koller et al., 
2020): 
 𝐴𝑠𝑠𝑒𝑡𝑠 =  𝐸𝑞𝑢𝑖𝑡𝑦 +  𝐿𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑖𝑒𝑠 Eq.9 
Eq.9 can then be expanded into Eq.10, as illustrated below:  
  
𝑂𝑝𝑒𝑟𝑎𝑡𝑖𝑛𝑔 𝑎𝑠𝑠𝑒𝑡𝑠 + 𝑁𝑜𝑛 − 𝑜𝑝𝑒𝑟𝑎𝑡𝑖𝑛𝑔 𝑎𝑠𝑠𝑒𝑡𝑠
= 𝑂𝑝𝑒𝑟𝑎𝑡𝑖𝑛𝑔 𝑙𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑖𝑒𝑠 + 𝐷𝑒𝑏𝑡 𝑎𝑛𝑑 𝑒𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡𝑠
+ 𝐸𝑞𝑢𝑖𝑡𝑦 𝑎𝑛𝑑 𝑒𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡𝑠 
Eq.10 
Further, Eq.10 can then be rearranged to Eq.11 by subtracting operating liabilities from 
operating assets, which equals invested capital: 
  
𝐼𝑛𝑣𝑒𝑠𝑡𝑒𝑑 𝑐𝑎𝑝𝑖𝑡𝑎𝑙 +  𝑁𝑜𝑛 − 𝑜𝑝𝑒𝑟𝑎𝑡𝑖𝑛𝑔 𝑎𝑠𝑠𝑒𝑡  
=  𝑇𝑜𝑡𝑎𝑙 𝑓𝑢𝑛𝑑𝑠 𝑖𝑛𝑣𝑒𝑠𝑡𝑒𝑑 
=  𝐷𝑒𝑏𝑡 𝑎𝑛𝑑 𝑒𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡𝑠 +  𝐸𝑞𝑢𝑖𝑡𝑦 𝑎𝑛𝑑 𝑒𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡𝑠 
Eq.11 
Moreover, Eq.11 will be the conceptual basis for our calculation of invested capital through 
the rearrangement of Aker BioMarine's balance sheet later in this chapter. 
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Reorganizing to calculate net operating profit after tax 
Net operating profit after tax ("NOPAT"), which sometimes is referred to as "unlevered net 
income," is calculated as follows (Berk & DeMarzo, 2020): 
 
𝑁𝑂𝑃𝐴𝑇 = 𝐸𝐵𝐼𝑇 × (1 − 𝑇𝑎𝑥) 
= (𝑅𝑒𝑣𝑒𝑛𝑢𝑒 − 𝐶𝑜𝑠𝑡𝑠 − 𝐷𝑒𝑝𝑟𝑒𝑐𝑖𝑎𝑡𝑖𝑜𝑛) × (1 − 𝑇𝑎𝑥) 
Eq.12 
Eq. 12 illustrates how NOPAT is calculated in simplified terms. On a more general basis, 
NOPAT is referred to as the profit after tax that stems from the business' core operations, while 
non-operating assets or financing-related costs are ignored. One vital aspect of the NOPAT 
calculation is that it needs to be held consistent with the calculation of invested capital, and as 
an effect of this, it should only include those profits created by the invested capital. 
Following Koller et al.'s (2020) theoretical framework, we will derive our estimates of 
NOPAT by reorganizing the income statement through a three-part methodology. Firstly, 
NOPAT is defined as the after-tax operating profit available to all investors. It is kept separate 
from the firm's capital structure by categorizing interest as a financing item. Although Eq. 12 
showcases NOPAT calculated as a product of EBIT, we will instead use earnings before 
interest, taxes, and amortization ("EBITA") proposed by Tim Koller and his co-authors. This 
choice will be explained in greater detail later in this sub-chapter. Further, in line with the 
fundamental principle of keeping NOPAT consistent with invested capital, no income created 
by assets outside of invested capital is included. Finally, taxes should be calculated only as 
operating taxes, and the exclusion of non-operating tax items is required. 
Reorganizing to calculate free cash flow 
The third and final section of our financial statement reorganization calculates the free cash 
flow ("FCF"). A firm's free cash flow is the accumulative effect of the firm's operations on 
available cash, independent from any financing decisions. As with NOPAT, this implies that 
free cash flow is the cash available to all investors, i.e., to both shareholders and debtholders. 
Free cash flow can be calculated as follows: 
 
𝐹𝑟𝑒𝑒 𝑐𝑎𝑠ℎ 𝑓𝑙𝑜𝑤 =  𝑁𝑂𝑃𝐴𝑇 +  𝑁𝑜𝑛 − 𝑐𝑎𝑠ℎ 𝑜𝑝𝑒𝑟𝑎𝑡𝑖𝑛𝑔 𝑒𝑥𝑝𝑒𝑛𝑠𝑒𝑠 −




By reading into Eq.13, the free cash flow can be viewed as the cash flow after tax if the firm 
was funded solely by equity and held no non-core operating assets. In this step, the statement 
of shareholders' equity is needed to assemble a restructured financial statement appropriate to 
calculate free cash flow. 
5.1.2 Defining the scope of the financial statement analysis 
Before undertaking a financial statement analysis, the critical action is to define the scope of 
the analysis, particularly in terms of the time frame of historical financial information included 
in the analysis and whether financials will be analyzed on a consolidated group level or 
individual business unit level. 
Consolidated financial statements vs. individual business unit 
A core aspect of the historical financial statement analysis is whether a company's historical 
financial data is analyzed on a consolidated basis or as the sum of all individual business units. 
Generally, this decision is formed dependent on whether the company is split into different 
business units with structural differences in operational characteristics or not. A company with 
integrated business units should be analyzed on a consolidated basis, and vice versa. In Aker 
BioMarine, its divisions are near integrated and therefore considered best suited for a 
consolidated historical financial statement analysis. 
Length of the financial statement examination period 
Concerning the length of the financial statement examination period, we define one period of 
analysis as a single financial year. The primary objective of historical financial statement 
analysis is to produce valuable quantitative information about historical financials to support 
financial valuation forecasts. Thus, selecting a historical period of analysis that coincides with 
today's operational characteristics is vital. In essence, if a company has experienced significant 
changes to its operational performance in recent years, analyzing over a lengthier period may 
not provide the optimal insight into future financial performance. Conversely, a firm with 
long-term steady operational performance in a stable business environment will find a more 
extensive examination period suitable as it may strengthen the reliability of historical financial 
information. 
As for Aker BioMarine, the company experienced relatively modest growth after de-listing 
from Oslo Børs in 2012 until 2016. From 2017 and onward Aker BioMarine has seen 
substantial operational growth. It has had a near doubling of revenues from 2017 to 2019. This 
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is also reflected in the company's prospects changing drastically from 2015 compared to 
today's outlook.  
Moreover, since 2015 Aker BioMarine has seen significant changes in its operational 
characteristics, and we consider 2015 and 2016 as less relevant for our analysis as we believe 
it would create more distortion than benefits in our analysis. Therefore, a period of three fiscal 
years (2017-2019) will be examined in our historical financial statement analysis. 
Comparable firms 
One key issue in a historical peer analysis is to establish comparability. That is comparability 
across the company being valued, and the selected peer company in terms of characteristics 
such as earnings growth prospects, profit margins from operations, access to critical resources, 
risk, and more.  In the case of Aker BioMarine, there are no other publicly listed companies 
in the krill fishing industry. In this way, the comparable companies used in our analysis will 
not fulfill the general condition that a peer company should have industry affiliation, and 
establishing such a direct link between Aker BioMarine and other public companies could 
prove to be a challenging process. This implies that the krill fishing companies described in 
section 2.3 are not applicable in the peer analysis. 
Establishing comparability 
In our selection of peer companies, we believe that the traditional fishing companies listed in 
the public marketplace today have a low degree of comparability to Aker BioMarine and 
companies in the krill fishing industry. This is mostly since peers in well-developed traditional 
fisheries have a far lower potential for growth in comparison to the considerable amount of 
allowed biomass that is yet to be captured by the krill fisheries. In this sense, krill fishing 
companies are in a unique growth position compared to that of traditional fisheries. More so, 
profit margins also differ notably, and Aker BioMarine can extract relatively high margins 
from its production of high-end krill oil products, whereas traditional fisheries in the 
marketplace today are operating with much more conservative margins. Examples of such 
public listings in the traditional fisheries segment include Clearwater Seafoods, Oceana 
Group, and Sanford Limited. 
This comparability issue also applies to salmon farming companies, with prospects of volume 
growth being somewhat limited in this industry due to high regulation and overproduction 
challenges. While Norwegian salmon farming companies can achieve high-end pricing of their 
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salmon, utilization of products and end-markets varies greatly, and we deem publicly listed 
companies in this category less relevant for a peer analysis of Aker BioMarine. 
Finally, we see a high degree of relevance and comparability in several publicly listed 
companies within the Brands and Ingredients segment. As we presented in the introduction, 
these two segments are the two segments in which Aker BioMarine splits their operational 
revenue, with 68% of 2019 revenue within Ingredients and the remaining 32% in Brands (Aker 
BioMarine, 2020b). Moreover, with Aker BioMarine’s ambitions to remain heavily invested 
in the krill oil segment we except the company to continue to hold operational characteristics 
in the future that is similar to that of companies in the Ingredients segment. This also applies 
to the Brand segment, in which the company’s efforts through the Epion and Lang brands give 
reason to a comparison to companies in this category. To add further leverage to our 
arguments, these are also the two segments that Aker BioMarine uses in various company 
presentations and investor material when comparing their performance with peer companies. 
We have confidence that our selected peer companies are reasonably motivated and that they, 
to the best of our knowledge, deliver some of the highest degrees of comparability to Aker 
BioMarine in the public market today. 
We have selected two peers from both Ingredients and Brand to capture both segments Aker 
BioMarine operates in for our historical financial analysis. The selected companies from 
Brands are Midsona and Glanbia, while Ingredients' peers are Probi and Koninklijke DSM. 
The following sub-chapter will briefly present the selected peers. 
Midsona AB (Brands) 
Midsona AB is a publicly listed Swedish company that develops, manufactures, and markets 
products in health, herbal medicines, and hygiene. The company is a leader in the Nordic 
region in natural and organic products and has the vision to become a European leader in 
health and well-being. The nutrition company had a market capitalization of SEK 4.45bn on 
November 22, 2020 (Yahoo Finance, 2020b), with a 2019 revenue of SEK 3.08bn (Midsona, 
2020). 
Glanbia Plc (Brands) 
Glanbia Plc is a global nutrition group with operations in 32 countries, with an Irish heritage. 
The group has a leading market position in sports nutrition, dairy ingredients, non-dairy 
ingredients, vitamins, and mineral premixes. The group is a worldwide supplier of dietary 
 89 
supplements, but have their largest markets in Europe and North America. The company is 
listed on London Stock Exchange and had a market capitalization of EUR 2.89bn on 
November 22, 2020 (Yahoo Finance, 2020c), with a 2019 revenue of EUR 3.9bn (Glanbia, 
2020).  
Probi AB (Ingredients) 
Probi AB is an international company focused on developing, producing, and delivering 
proven probiotics. The company has a long history of exploring and refining solutions that 
make the health-enhancing benefits of probiotics available for people globally. The global 
supplier of supplements and probiotics is listed on Nasdaq Stockholm and had a market 
capitalization of SEK 4.40bn on November 22, 2020 (Yahoo Finance, 2020d), and 2019 
revenues were SEK 626.19mn (Probi, 2020). 
DSM Koninklijke (Ingredients) 
DSM is a Dutch-based multinational company which is specialized in health nutrition and 
materials. The company's global end markets include food- and dietary supplements, personal 
care, feed, and pharmaceuticals. The company is publicly traded at the Amsterdam Stock 
Exchange with a market capitalization of EUR 24.75bn on November 22, 2020 (Yahoo 
Finance, 2020e), with 2019 revenues of EUR 8.63bn (DSM, 2020).  
Other considerations 
In this section, we outline various other considerations we have taken in connection with the 
historical financial analysis of Aker BioMarine. Firstly, we recognize that including the most 
up-to-date financial information of the company is pivotal in creating a company's financial 
valuation as of October 30, 2020. Since we are well into 2020, this means that the financial 
information of the 2019 annual report, in practice, does not reflect the latest information. 
Knivsflå (2020g) proposes one way to combat this by creating ”trailing” financial statements 
based on the latest available quarterly financial information. Since Aker BioMarine is a new 
publicly listed company, several factors limit the publicly available financial information we 
have on the firm. Most prominently, firms listed on Merkur Market are not obliged to report 
quarterly financials, and the various interim financial reports released so far this year by the 
company are heavily condensed and not suited for a historical financial statement analysis. 
For this reason, we will only include information from the latest annual reports in our historical 
financial analysis. The latest financial information is included in our financial forecasting. 
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For clarity, in preparing this thesis, we contacted the company about the possibility of 
obtaining the latest full and detailed quarterly financials for the company. Our request was not 
possible to fulfill because these are not made publicly available as of today. We were also 
offered to come by their office to look at older, physically printed historical financials, but 
could not do so due to the ongoing COVID-19 pandemic as their office is located outside of 
Bergen. 
5.2 Presentation of Aker BioMarine's financial statements 
5.2.1 Aker BioMarine’s balance sheet and income statement 
Exhibit 8: Aker BioMarine’s balance sheet as reported (2017-2019) 
In USD thousands ($)   2017 2018 2019 
     
ASSETS     
Property, plant, and equipment  206 804 232 383 318 921 
Intangible assets  95 421 114 158 190 297 
Non-current interest-bearing receivables                -                -                -  
Other non-interest-bearing non-current receivables  2 099 2 026 145 
Investments in equity-accounted investee  205 240 260 
Total non-current assets   304 529 348 806 509 624 
     
Inventories  36 198 43 704 94 725 
Trade receivables and prepaid expenses  33 970 35 223 74 264 
Current interest-bearing receivables                -                -                -  
Cash and cash equivalents  2 715 2 515 13 610 
Total current assets   72 883 81 442 182 599 
     
Total assets   377 412 430 248 692 223 
     
LIABILITIES AND SHAREHOLDERS' EQUITY     
Share capital  63 684 68 003 68 003 
Other paid-in equity  156 486 277 227 277 227 
Translation differences and other reserves  154 154 154 
Retained earnings  (161 028) (166 570) (190 838) 
Total equity   59 296 178 814 154 547 
     
Interest-bearing debt  258 322 179 424 372 473 
Other non-interest-bearing non-current liabilities  11 871 17 657 65 618 
Total non-current liabilities   270 193 197 081 438 091 
     
Interest-bearing current liabilities  16 812 25 944 47 591 
Derivative liabilities                -  1 472               -  
Accounts payable and other payables  31 110 26 937 51 994 
Total current liabilities   47 922 54 353 99 585 
     
Total liabilities   318 115 251 435 537 676 
     
Total liabilities and shareholders' equity   377 412 430 248 692 223 
Source: Aker BioMarine’s annual reports (2017-2019) 
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Exhibit 9: Aker BioMarine’s income statement as reported (2017-2019) 
In USD thousands ($)   2017 2018 2019 
     
Net sales  124 154 154 182 246 170 
Cost of goods sold  (81 768) (88 829) (145 901) 
Gross profit   42 386 65 352 100 269 
     
SG&A  (37 001) (44 686) (76 464) 
Depreciation, amortization, and impairment  (2 528) (5 539) (17 822) 
Other operating income/(cost), net  (4 538) (4 869) (3 221) 
Operating profit   (1 681) 10 258 2 762 
     
Net financial items  (15 072) (11 540) (26 097) 
Tax expense  (1 011) 259 (415) 
Net profit (loss)   (17 764) (1 022) (23 751) 
Source: Aker BioMarine’s annual reports (2017-2019) 
5.3 Reorganization of financial statements 
In this subchapter, we will carry out the restructuring of Aker BioMarine's financial 
statements. As mentioned in the chapter introduction, the rearrangement of financial 
information makes conventional financial statements more insightful, investor-oriented and 
highlights items that are particularly valuable to the upcoming valuation analysis. This 
reorganization is done by calculating invested capital, NOPAT, and free cash flow. 
5.3.1 Reorganizing to calculate invested capital 
To carry out a calculation of invested capital, the conventional balance sheet needs to be 
reorganized. Invested capital is not presented directly in traditional financial reports and needs 
to be derived by restructuring its financial statements. This is done by breaking down operating 
and non-operating items so that operating assets and operating liabilities can be grouped 
separately following the theoretical framework described earlier. As the methodology of 
Koller et al. (2020) requires, the reorganized balance sheet is produced by thoroughly 
examining the notes in each annual report of Aker BioMarine to provide more detail to balance 
sheet items to calculate invested capital. 
Detailed balance sheet and account descriptions 
Before calculating invested capital, we transform the "as-presented" balance sheet into a 
detailed balance sheet that separates operating and non-operating items. While company 
management would know what items are related to the company's operations and which are 
 92
not, we, as external analysts, have examined the notes in each annual report to gain the insight 
needed to separate these accounts. This is necessary because companies are not obliged to 
separate operating and non-operating items in the balance sheet presented in the annual 
reports. The detailed balance sheet is presented in exhibit 10. 
Exhibit 10: Aker BioMarine's detailed balance sheet (2017-2019) 
In USD thousands ($)   2017 2018 2019 
     
ASSETS     
Property, plant, and equipment  206 804 232 383 318 921 
Goodwill  65 153 66 401 94 557 
Other intangibles  30 268 47 757 95 740 
Other non-interest-bearing non-current receivables  2 099 2 026 145 
Investments in equity-accounted investee  205 240 260 
Total non-current assets   304 529 348 806 509 624 
     
Inventories  36 198 43 704 94 725 
Accounts receivable  19 301 20 438 37 393 
Prepaid expenses and other receivables  11 516 14 785 36 871 
Derivative assets  3 153                -                   -  
Operating cash  2 715 2 515 7 385 
Excess cash  0 0 6 225 
Total current assets   72 883 81 442 182 600 
     
Total assets   377 412 430 248 692 223 
     
LIABILITIES AND SHAREHOLDERS' EQUITY     
Share capital  63 684 68 003 68 003 
Other paid-in equity  156 486 277 227 277 227 
Translation differences and other reserves  154 154 154 
Retained earnings  (161 028) (166 570) (190 838) 
Total equity   59 297 178 814 154 547 
     
Interest-bearing debt  258 322 179 424 372 473 
Other non-interest-bearing non-current liabilities  11 871 17 657 65 618 
Total non-current liabilities   270 193 197 081 438 091 
     
Interest-bearing current liabilities  16 812 25 944 47 591 
Derivative liabilities                    -  1 472                  -  
Accounts payable  11 432 11 469 23 340 
Accrued expenses  13 141 11 332 26 311 
Other current liabilities  6 537 4 136 2 342 
Total current liabilities   47 922 54 353 99 585 
     
Total liabilities   318 115 251 435 537 676 
     
Total liabilities and shareholders' equity   377 412 430 248 692 223 
Source: Aker BioMarine's annual reports (2017-2019) 
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Intangible assets encompass a wide range of assets that are non-physical, such as patents, 
trademarks, copyright, goodwill, and software. For Aker BioMarine, this account includes 
goodwill, which is tested for impairment on an annual basis or if events may indicate that 
impairment loss occurs. Further, this account also includes other intangibles such as license 
agreements, fishing licenses, development, customer relations, and trademarks. We highlight 
these operating assets to calculate invested capital both with and without the goodwill and 
other intangibles. We do this because we factor in the price paid for acquisitions when 
including goodwill and other intangible assets. More so, these are assets that relate to 
acquisitions; we also need to calculate invested capital excluding goodwill and other 
intangibles to examine the company's underlying operating performance, as per the framework 
of Koller et al. (2020). A more comprehensive description of this account will follow later in 
this subchapter. 
Cash and cash equivalents are described in the annual reports as Aker BioMarine's cash at 
banks and cash on hand. While most firms need a certain amount of cash available to operate 
their business, it may not be that all the cash in the cash and cash equivalents account is 
necessary to operate the business. This precedes to a split between "operating cash" and 
"excess cash" in a company's cash account. However, Aker BioMarine does not disclose the 
amount of cash needed to operate on a day-to-day basis in their annual reports. An analyst will 
usually have to separate the two accounts by assumptions based on either industry averages or 
"rules of thumb." A detailed look into how we have distinguished excess cash from operating 
cash is provided in the second part of the invested capital calculation. 
Trade receivables is an account composed of current assets such as accounts receivable, 
prepaid expenses, other receivables, and derivative assets. While items in the trade receivables 
account is normally considered operating, the derivative assets account is a non-operating 
item. In Aker BioMarine's case, the derivative assets account is linked to forward currency 
contracts with the Norwegian bank DNB for currency risk hedging of future payments in 
constructing its new vessel Antarctic Endurance. Therefore, this account is classified as non-
operating as this account does not relate directly to the operational side of Aker BioMarine's 
business. 
Further, Aker BioMarine's accounts payable and other payables contain accounts payable, 
accrued expenses, derivative liabilities, and other current liabilities. On the flip side of 
derivative assets, the derivative liabilities account within current liabilities related to forward 
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exchange contracts, which is also tied to the currency hedging contract with DNB. This 
account is characterized as non-operating for the same reasons as the derivate assets account. 
Aker BioMarine does not describe what the other current liabilities account encompasses, but 
we classify the remaining items in the accounts payable and other payables account as 
operating items. 
Typically, deferred tax assets and liabilities are included on a company's balance sheet. This 
would be tax loss carryforwards that allow the business to carry a tax loss over to another year 
to offset profits. Aker BioMarine has chosen not to recognize deferred tax assets on its balance 
sheet based on its historical losses. Further, Aker BioMarine also has an ongoing dispute with 
the Norwegian Tax Authorities regarding the deductibility of losses. Aker BioMarine has 
appealed to the authorities' decision that NOK 296mn losses are not deductible and are now 
awaiting a decision from the authorities on this matter. Aker BioMarine's unrecognized 
deferred tax assets are described in exhibit 11: 
Exhibit 11: Aker BioMarine's overview of unrecognized deferred tax assets (2017-2019) 
In USD thousands ($)   2017 2018 2019 
     
Deferred tax assets     
PP&E and intangible assets  (1 728) (2 204) 5 280 
Inventory  (792) (512) 1 091 
Other  836 15 23 
Tax losses carried forward  69 845 49 964 52 868 
Interest rate deductibility carry-forward  4 475 6 141 7 958 
Deferred tax assets   72 636 53 404 67 220 
     
Unrecognized deferred tax assets   (72 636) (53 404) (67 220) 
     
Recognized deferred tax assets   0 0 0 
Source: Aker BioMarine's annual reports (2017-2019) 
Reorganization and calculation of invested capital 
Before we showcase our reorganized balance sheet, a description of critical considerations we 
have had to make regarding Aker BioMarine's balance sheet's reorganization will follow. This 
relates to issues and assumptions of operating cash, goodwill, and other intangibles capitalized 
operating leases and finally, the calculation of invested capital and total funds invested. As we 
established in Eq.11 in the theoretical introduction to this chapter, the total funds invested can 
be calculated using two approaches. Hence, a reconciliation of total funds invested is also 
included to test the reliability of our calculations. 
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Operating cash 
Traditionally, companies do not disclose in their annual reports how much cash they need to 
hold to fund their core operations, that is, the level of "operating cash" required. For this 
reason, an external analyst will have to make use of other practices to derive an estimate of 
operating cash. As discussed in Koller et al. (2020), past empirical analysis has shown that 
companies have held cash levels, representing ~2% of revenue. 
While this is a number based on aggregate cash holdings, required cash holdings may vary 
significantly across different industries. Notably, several studies, such as Bates, Kahle, & Stulz 
(2009) has shown that firms with higher growth opportunities hold larger cash balances. Since 
Aker BioMarine is considered a company with high growth opportunities, we have assumed a 
cash-to-revenue ratio of 3% to reflect its growth characteristics better. 
Exhibit 12: Aker BioMarine's overview of operating vs. excess cash (2017-2019) 
In USD thousands ($)   2017 2018 2019 
     
Revenue   124 154 154 182 246 170 
     
Cash and cash equivalents   2 715 2 515 13 610 
Operating cash (3% of revenue)  2 715 2 515 7 385 
Excess cash  - - 6 225 
     
Total operating cash and excess cash   2 715 2 515 13 610 
 Source: Aker BioMarine's annual reports (2017-2019) 
Goodwill and other intangible assets 
In our historical financial performance analysis, the return on invested capital will be 
examined by including (excluding) goodwill and other intangible assets. This is done to enable 
us as financial analysts to measure Aker BioMarine's ability to create value both with and 
without factoring in acquisitions' price. A detailed overview of the account is presented in 
exhibit 13.  
Koller et al. (2020) suggests adjusting goodwill and other intangibles by deferred tax liabilities 
related to the amortization of other intangibles to evaluate the effect of this account properly. 
We have decided not to do so as we have limited access to historical financials and since 
deferred tax items have not been recognized on Aker BioMarine's balance sheet. 
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Exhibit 13: Detailed overview of the goodwill and other intangibles account (2017-2019) 
In USD thousands ($)   2017 2018 2019 
     
Goodwill and other intangibles     
Goodwill  65 153 66 401 94 557 
Development  239 156 73 
License agreements  734 2 045 1 818 
Fishing licenses  - - 10 500 
Customer relation  25 401 39 881 77 674 
Trademark  3 894 5 675 5 675 
     
Total goodwill and other intangibles   95 421 114 158 190 297 
Source: Aker BioMarine's annual reports (2017-2019) 
Capitalized operating leases 
Effective from January 2019, the IFRS 16 Lease standard was implemented by Aker 
BioMarine. This standard requires companies reporting under International Financial 
Reporting Standards ("IFRS") to recognize lease payments' present value in their financial 
statements. Aker BioMarine's past financial statements have not been re-done to comply with 
this new standard. For this reason, we will re-state the operating leases from 2017 and 2018 
so that the new IFRS lease standard is more aptly accounted for in these financial years. 
We conduct this estimation of capitalized operating leases by first examining Aker 
BioMarine's annual report's notes to find commitments to future operating lease payments. 
Aker BioMarine only reports primarily aggregate numbers, so we decide to use an annuity on 
the total scheduled operating lease payments to value the future commitments in the financial 
years of 2017 and 2018. In their 2019 annual report, Aker BioMarine discloses that the 
incremental borrowing rate is used as their discount rate and that it varies between 5.7% and 
7.6%. Hence, we set an incremental borrowing rate of 6.7% (the average of the two) for this 
analysis. Moreover, from the 2018 annual report, operating lease payments of USD 6.45mn 
are translated into lease liability of USD 5.43mn. By reverse-engineering, the 6.7% interest 
rate, an average of 2.7 years of discounting is applied to value the scheduled operating lease 





Exhibit 14: Calculation of capitalized operating leases (2017-2019) 
In USD thousands ($)   2017 2018 2019 
     
Capitalized operating leases 2019 (IFRS implementation)  - - 16 557 
     
Operating leases (Minimum lease payments)     
Within one year  1 521 1 354 6 679 
In 1-5 years  4 647 4 465 11 929 
Five years or more  1 557 626 1 049 
Total scheduled operating lease payments   7 725 6 445 19 657 
     
Incremental borrowing rate  6,7% 6,7% - 
Average years (for discounting)  2,7 2,7 - 
     
Capitalized operating leases   6 510 5 431 16 557 
Source: Aker BioMarine's annual reports (2017-2019) and own calculations 
Calculation of invested capital and total funds invested 
In the final step of Aker BioMarine's balance sheet's reorganization, we calculate invested 
capital and total funds invested, as showcased in exhibit 15. To provide some further context 
to our methodology and calculations, we first calculate operating working capital by 
subtracting current operating assets from operating current liabilities. To this, we add the non-
current operating assets and subtract non-current operating liabilities to the operating working 
capital. This includes Aker BioMarine's estimated capitalized operating leases that we have 
re-stated following IFRS 16 Lease standards. In addition, other non-interest-bearing non-
current receivables are classified as operating assets as no other information is given in the 
publicly available financial statements from Aker BioMarine regarding these non-current 
assets. Further, as per Eq.11, we subtract operating liabilities from operating assets to arrive 
at invested capital, both with and without the goodwill and other intangibles. 
Moreover, following Eq.11, we also calculate total funds invested by adding back non-
operating assets to invested capital. The total funds invested are vital for checking the 
reliability of our calculations. As Eq.11 also reveals, another approach to calculating total 
funds invested is to sum the cumulative sources of financing. As a result, a reconciliation of 
total funds invested can be done by summing up debt and equity, along with their equivalents, 
allowing us to check if the two approaches reconcile and provide consistent calculations. The 
reconciliation to total funds invested is showcased in exhibit 16. 
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Exhibit 15: Reorganized balance sheet and total funds invested  
In USD thousands ($)   2017 2018 2019 
     
Operating cash  2 715 2 515 7 385 
Inventories  36 198 43 704 94 725 
Receivables  19 301 20 438 37 393 
Other current assets  11 516 14 785 36 871 
Operating current assets   69 730 81 442 176 375 
     
Accounts payable  (11 432) (11 469) (23 340) 
Accrued expenses  (13 141) (11 332) (26 311) 
Other current liabilities  (6 537) (4 136) (2 342) 
Operating current liabilities   (31 110) (26 937) (51 994) 
     
Operating working capital  38 620 54 505 124 381 
Property, plant, and equipment, excl. leases  206 804 232 383 302 364 
Capitalized operating leases  6 510 5 431 16 557 
Other non-interest-bearing non-current receivables  2 099 2 026 145 
Invested capital, excl. goodwill and other intangibles   254 033 294 345 443 448 
     
Goodwill and other intangibles  95 421 114 158 190 297 
Invested capital, incl. goodwill and other intangibles   349 454 408 503 633 745 
     
     
Investments in equity-accounted investee  205 240 260 
Other financial assets  3 153 - - 
Excess cash  - - 6 225 
Total funds invested   352 812 408 742 640 230 
Source: Aker BioMarine's annual reports (2017-2019) and own calculations 
Exhibit 16: Reconciliation of total funds invested  
In USD thousands ($)   2017 2018 2019 
     
Reconciliation of total funds invested         
     
Non-current interest-bearing debt  258 322 179 424 372 473 
Current interest-bearing debt  16 812 25 944 47 591 
Debt equivalents  11 871 17 657 65 618 
Derivative liabilities  - 1 472 - 
Capitalized operating leases  6 510 5 431 - 
Debt and its equivalents   293 515 229 928 485 682 
     
Paid-in equity  220 170 345 230 345 230 
Translation differences and other reserves  154 154 154 
Retained earnings  (161 028) (166 570) (190 838) 
Equity and its equivalents   59 297 178 814 154 547 
     
Total funds invested   352 812 408 742 640 230 
Source: Aker BioMarine's annual reports (2017-2019) and own calculations 
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5.3.2 Reorganizing to calculate net operating profit after tax 
In this subchapter, we perform a reorganization of the income statement to calculate net 
operating profit after taxes. The firm's core operations generate this measure, and as with the 
reorganization of the balance sheet, this will require us to uncover operating and non-operating 
items included in Aker BioMarine's income statement. 
Calculation of operational lease depreciation and interest 
When it comes to the IFRS 16 Lease practices' impact on operating lease interest, Aker 
BioMarine states in their annual reports that comparative financial figures before 2019 will 
not be re-stated to account for the changes. Though, we deem it relevant to classify Aker 
BioMarine's operating lease interest as it will affect our EBITA-figures. This effect occurs 
because lease costs are now charged through finance costs. Below is Aker BioMarine's 
operating lease interest calculation by applying the firm's incremental borrowing rate to the 
corresponding beginning of year operating lease liability. 
Exhibit 17: Calculation of operating lease depreciation and interest (2017-2019) 
In USD thousands ($)   2017 2018 2019 
     
Capitalized operating leases  6 510 5 431 16 557 
Operating lease interest  (544) (433) (729) 
Lease depreciation (Reported)  - - (2 833) 
Lease expenses  (2 900) (4 100) (3 562) 
     
Lease depreciation   (2 356) (3 667) (2 833) 
Operating lease interest   (544) (433) (729) 
Source: Aker BioMarine's annual reports (2017-2019) and own calculations 
Non-recurring special operating items 
According to Koller et al. (2020), one-time costs related to non-recurring events are better off 
assessed independently as non-operating items. On that account, we will need to adjust the 
company's EBITA. In 2019 and 2018, Aker BioMarine embedded non-recurring special 
operating items in its operating income and expenses. According to the notes in the company's 
annual reports, these are special items, including losses or gains on asset sales, expenses 
incurred due to restructuring, and various other material transactions that are considered either 
special or that are perceived as non-recurring (Aker BioMarine, 2020a). This includes 
acquisition costs related to the Lang Pharma and Enzymotec acquisitions, legal costs related 
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to the legal dispute with Rimfrost, and various other material and non-recurring costs. The 
company had no special items in 2017. A detailed overview of special non-occurring operating 
items extracted from Aker BioMarine's annual report is summarized in exhibit 18. 
Exhibit 18: Overview of special items included in the income statement (2017-2019) 
In USD thousands ($)   2017 2018 2019 
     
Juvel operating cost - other operating income(cost), net  - (4 204) (1 784) 
Legal costs  - (291) (836) 
Transaction related costs  - (1 406) (1 298) 
Kori launch  - - (3 428) 
Total special non-recurring operating items   - (5 901) (7 346) 
Source: Aker BioMarine's annual reports (2017-2019) 
Calculation of operating taxes 
One of the main objectives in reorganizing the historical income statements is determining the 
firm's operating taxes. This is essential because not all income statement taxes are related 
strictly to the firm's operations. Companies seldom disclose detailed information on operating 
versus non-operating taxes, so instead, Koller et al. (2020) propose a three-step methodology 
in order to derive an estimate of operating taxes: First, (i) find and convert the tax 
reconciliation table; then (ii) use the tax reconciliation table in order to determine the marginal 
tax rate and apply this tax rate to the adjusted EBITA to find all-equity taxes, and finally (iii) 
adjust the all-equity taxes for operating tax credits. We adopt this methodology in order to 
derive our estimate of operating taxes. The tax reconciliation table based on Aker BioMarine's 
reported components of income tax expense is given as follows:  
Exhibit 19: Tax reconciliation table (2017-2019) 
In USD thousands ($)   2017 2018 2019 
     
Profit (loss) before taxes   (16 754) (1 281) (23 335) 
     
Calculated income tax at a statutory rate of 23% (2017: 24%)  4 021 295 5 134 
Tax difference: Norway and abroad  (442) (34) (441) 
Unrecognized change in deferred tax assets  (1 284) 2 158 (3 934) 
Permanent differences  168 51 (1 175) 
Currency translation and other  (3 474) (2 211) 1 
Total tax expense   (1 011) 259 (415) 
     
Effective tax rate   - 6% 20% - 2% 
Source: Aker BioMarine's annual reports (2017-2019) 
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Adjustment to Aker BioMarine's statutory tax rate is given in the tax reconciliation table. The 
statutory tax rate is the tax rate that is imposed by the Norwegian Tax Administration. The tax 
reconciliation table is then used as the basis to carry out the remaining two steps of calculating 
the firm's operating taxes. Using the statutory tax rate given in the reports, we multiply it with 
the EBITA in its corresponding year as presented in exhibit 20. In essence, this gives us the 
company's all-equity taxes without regard to its interest tax shield. 
The final step is to adjust the statutory taxes on EBITA by searching the tax reconciliation 
table for other taxes relating to its core operations. While Aker BioMarine has reported limited 
information on the nature of its taxes historically, we classify “tax differential Norway and 
abroad” as ongoing and consider this an operating tax item. The remaining tax items given in 
the tax reconciliation table are remarked as non-operating. In sum, this adjustment then gives 
us our computation of Aker BioMarine's historical operating taxes as given in exhibit 20. 
We should note that for companies that disclose sufficient information on deferred taxes, 
operating cash taxes can be computed to give a more proper representation of actual cash taxes 
paid by the company, according to Koller et al. (2020). For companies that do not provide 
sufficient information on operating from non-operating deferred taxes, the authors recommend 
using operating taxes excluding any cash adjustment. The latter is the case for Aker 
BioMarine, and we decide to use operating taxes as such. 
Exhibit 20: Calculation of operating taxes (2017-2019) 
In USD thousands ($)   2017 2018 2019 
     
EBITA  2 800 23 014 24 962 
Statutory tax rate (*Reported by the company)  24% 23% 23% 
Statutory taxes on EBITA   (672) (5 293) (5 741) 
     
Tax differential Norway and abroad  (442) (34) (441) 
Operating taxes   (1 114) (5 327) (6 182) 
Source: Aker BioMarine's annual reports (2017-2019) and own calculation 
Calculation of NOPAT and reconciliation to net income 
Finally, our reorganized income statement is presented through a calculation of NOPAT. 
Building on the theoretical framework presented in chapter 3, we compute the adjusted 
operating profit and add back amortization of intangibles to determine EBITA. Although 
EBITDA or EBIT may be viewed as more common measures in practice, there are several 
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reasons we choose EBITA over the two. Firstly, since an asset is capitalized on the balance 
sheet and is consequently depreciated over its useful life, this is a reduction in value that must 
be accounted for when assessing Aker BioMarine's profits and returns. Hence, we use EBITA 
instead of EBITDA to account for this in our calculation of NOPAT. 
Consequently, when we use EBITA, this implies that amortization is still left untouched. 
While amortization in practice makes a similar effort to capture a reduction in value just as 
depreciation does, intangibles' accounting treatment does not equal those of physical assets. 
More so, when intangible assets originate within the firm, such items are expensed rather than 
capitalized. For this reason, EBITA is chosen over EBIT, in line with prevailing accounting 
principles (Koller et al., 2020). 
Exhibit 21: Calculation of NOPAT (2017-2019) 
In USD thousands ($)   2017 2018 2019 
     
Total revenue  125 540 155 334 247 070 
Other income adjustments  (1 387) (1 152) (900) 
Net sales   124 154 154 182 246 170 
     
Cost of goods sold, adjusted  (65 400) (71 508) (120 792) 
Gross profit, adjusted   58 754 82 674 125 378 
     
SG&A  (37 001) (44 686) (76 464) 
Depreciation  (14 959) (16 439) (28 077) 
Other operating income/(cost), net  (4 538) (4 869) (3 221) 
EBITA, unadjusted   2 256 16 680 17 616 
     
Juvel operating cost - other operating income(cost), net  - 4 204 1 784 
Legal costs  - 291 836 
Transaction related costs  - 1 406 1 298 
Kori launch  - - 3 428 
Operating lease interest  544 433 - 
EBITA, adjusted   2 800 23 014 24 962 
     
Operating taxes  (1 114) (5 327) (6 182) 
NOPAT   1 686 17 687 18 780 





Exhibit 22: Reconciliation to net income through NOPAT (2017-2019) 
In USD thousands ($)   2017 2018 2019 
     
NOPAT  1 686 17 687 18 780 
     
Amortization  (3 937) (6 421) (14 854) 
     
Operating lease interest  (544) (433) - 
Financial income  1 179 7 829 6 669 
Financial expenses   (16 251) (19 369) (32 766) 
Financial items, net  (15 616) (11 973) (26 097) 
     
Juvel operating cost - other operating income(cost), net  - (4 204) (1 784) 
Legal costs  - (291) (836) 
Transaction related costs  - (1 406) (1 298) 
Kori launch   - - (3 428) 
Special operating items  - (5 901) (7 346) 
     
Non-operating taxes  103 5 586 5 767 
     
Net income   (17 764) (1 022) (23 751) 
Source: Aker BioMarine's annual reports (2017-2019) and own calculations 
5.3.3 Reorganizing to calculate free cash flow 
As the final remaining part of Aker BioMarine's financial statements' reorganization, we 
compute the free cash flow. As outlined in Eq. 13, free cash flow is computed by adding back 
any non-cash operating expenses to NOPAT and subtracting potential investments in invested 
capital. 
In the first step of calculating the FCF, we add back depreciation of capitalized assets. We do 
not add back other non-cash expenses such as the amortization of other intangibles, as they 
were not subtracted from revenue in our NOPAT calculation. Further, increases in the 
operating working capital as calculated in our reorganized balance sheet in exhibit 15 are 
deducted. The capital expenditures line refers to investments in property, plant, and equipment 
and is treated as cash outflows. Consistent with previous definitions and the Koller et al. (2020) 
framework, we also subtract increases in capitalized operating leases. Finally, after adjusting 
for changes in net other assets and investments in goodwill and other intangibles, we arrive at 
the free cash flow for Aker BioMarine in the financial years of 2017-2019. 
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Exhibit 23: Aker BioMarine's free cash flow (2017-2019) 
In USD thousands ($)   2017 2018 2019 
     
NOPAT  1 686 17 687 18 780 
Depreciation  14 959 16 439 28 077 
Gross cash flow   16 645 34 126 46 857 
     
Decrease (increase) in operating working capital  3 855 (15 885) (69 876) 
Less: Capital expenditures  (111 296) (42 018) (98 058) 
Decrease (increase) in capitalized operating leases  1 671 1 079 (11 126) 
Decrease (increase) in other assets, net of liabilities  (14) 73 1 880 
Investment in goodwill and other intangibles  (27 726) (18 737) (76 139) 
     
Free cash flow (FCF)   (116 865) (41 362) (206 462) 
Source: Aker BioMarine's annual reports (2017-2019) and own calculations 
5.4 Historical financial analysis 
Once the invested capital, NOPAT, and free cash flow are derived, we can start assessing Aker 
BioMarine's historical financial performance through our historical financial analysis. As 
presented in the overview of our historical financial statement analysis framework in exhibit 
7, the third and final part of this analysis evolves around examining historical financial 
performance through two principal components of value creation: return on invested capital 
and revenue growth. This includes extracting the financial information that we gathered in our 
reorganization of the financial statements and analyzing this information both in a historical 
context for the firm itself and connection to the performance of the comparable firms outlined 
in subchapter 5.1. 
We acknowledge that for a growth case such as Aker BioMarine, an analysis of historical 
financials may not paint the most precise picture of how the firm's future financial performance 
will be. However, we conduct this analysis to extract valuable information that can help 
prepare the firm's financial prospects. More so, by looking at comparable companies with a 
similar operational nature, we hope to see trends or patterns that may tell us why Aker 
BioMarine's financial attributes look as they do today or how they may look in the coming 
years. 
In previous chapters, we have briefly described ROIC as a restorative measure of profitability. 
ROIC is the ratio of a firm's after-tax profit, excluding any interest expense (or income) 
divided by the company's amount of invested capital. While the average starting and ending 
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invested capital is preferred by some analysts, we decide to use ending invested capital in our 
ROIC analysis. Besides being regarded as an accurate measure of the firm's profitability, the 
ROIC can also be used as a benchmark for comparison to the weighted average cost of capital 
to measure the quality of a firm's investment (Damodaran, 2012). 
As such, the return on invested capital can be computed by the metrics that we computed in 
the reorganization of financial statements and is given as follows: 




Furthermore, by analyzing historical revenue growth, we can gain insight into how Aker 
BioMarine's top line will develop in the future. For a relatively young and fast-growing firm 
like Aker BioMarine, there is more emphasis on how revenue growth will come about in the 
future rather than in the past, but assessing historical information is valuable, nonetheless. We 
want to uncover where Aker BioMarine has previously come from, whether this has come 
through organic growth, from effects of developments in foreign exchange (“FX”) rates, or if 
growth has come as an effect of M&A activity. 
5.4.1 Analysis of return on invested capital 
Analyzing ROIC means analyzing how the firm is profiting from the capital invested in its 
core operations. This section will look at ROIC from a holistic perspective. To do this, we will 
have to break down ROIC into its smaller components to see which factors are driving changes 
in this metric. More specifically, this will allow a more detailed view of how Aker BioMarine's 
performance differs from its peers and which underlying components in ROIC are responsible 
for these differences. To do this, we begin by separating Eq.14 into smaller parts, as stated in 
Koller et al. (2020), through the following equation: 







Eq.15 allows us to see ROIC as a product of three firm profitability elements: capital turnover, 
profitability margin, and operating taxes. The EBITA-to-Revenue ratio resembles the firm's 
profit margin and tells us the portion of revenue that is translated into earnings after subtracting 
expenses related to operations. Capital turnover, expressed as the revenue-to-invested capital 
ratio, indicates the percentage of revenue that the firms generate on its invested capital. These 
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two products are then multiplied by the operating tax rate, which finally leads to ROIC. All 
else equal, either an increase in operating profitability, a rise in capital turnover, or a reduction 
in taxes will push the ROIC upwards. 
De-composition of operating ratios 
Exhibit 24: Operating ratios relating to Aker BioMarine's profitability (2017-2019) 
Percentages (%)   2017 2018 2019 
     
Profitability margin - operating ratios (% of revenue)     
Profit margin (EBITA-to-Revenue)  2.3% 14.9% 10.1% 
Cost of goods sold, adjusted  52.7% 46.4% 49.1% 
Selling, general, and administration  29.8% 29.0% 31.1% 
Other operating costs  3.7% 3.2% 1.3% 
Depreciation  12.0% 10.7% 11.4% 
Special operating items, adjustment   -0.4% -4.1% -3.0% 
To fully understand the underlying's of ROIC, we start by examining the operating ratios from 
our reorganized income statement. Although our examination period is relatively short, Aker 
BioMarine's operating profit margin (EBITA-to-Revenue) has been rather volatile within the 
period, reflected in an increase from a 2.3% margin in 2017 to 10.1% in 2019. This is 
predominantly due to a decrease in the relative cost of goods sold, mainly attributable to higher 
krill oil production volumes. Reading into Aker BioMarine's marketing material, they also 
point out that margins on Qrill Aqua, responsible for 27% of the firm's revenue, have been 
improving noticeably in this same period due to the company's decoupling strategy. The 
decoupling strategy involves fixed pricing on a majority of longer-term customer contracts in 
which Aker BioMarine's commodity prices are decoupled from that of the spot-market (Aker 
BioMarine, 2020c). 
Selling, general, and administration also had a slight upturn relative to revenue during the 
period, from 29.8% to 31.1% in 2017 and 2019, respectively. This is driven by increased 
marketing spend by the company, such as new brand launches. Further, other operating costs 
have fallen from 3.7% to 1.3% in the examination period. While we see no noticeable trends 
in these overall costs, this decrease relates to the IFRS 16 standard's impact and would 
otherwise have stayed at the general historical level without this impact. Depreciation as a 
percentage of revenue stayed relatively stable throughout the period. 
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De-composition of capital turnover 
Exhibit 25: Capital turnover (2017-2019) 
Percentages (%)   2017 2018 2019 
     
Return on invested capital (% of revenue)     
Operating working capital  31,1% 35,4% 50,5% 
PP&E  166,6% 150,7% 122,8% 
Capitalized operating leases  5,2% 3,5% 6,7% 
Other non-interest-bearing receivables  1,7% 1,3% 0,1% 
Invested capital/Revenue   204,6% 190,9% 180,1% 
     
Capital turnover   0,49 0,52 0,56 
The capital turnover is computed by dividing revenue with invested capital. In exhibit 25, we 
present a breakdown of the components affecting capital turnover. Over the past three years, 
the operating working capital has increased significantly but steadily relative to revenues, from 
31.1% in 2017 to 50.5% in 2019. This push comes from increases in inventory balances due 
to the build-up of inventory. The latest year's development is also attributable to an expanded 
operational fleet from 2 to 3 operative vessels in 2019, which ties up a substantial amount of 
working capital in fuel and various production assets. In terms of property, plant, and 
equipment, this account has increased in absolute terms throughout our examination period 
but decreased relative to revenues. This is reflected in Aker BioMarine's significant 
investments in fixed assets in recent years, generating an increased amount of revenue as more 
of its potential is utilized. 
Calculation of return on invested capital 
Exhibit 26: Calculation of return on invested capital (2017-2019) 
Percentages (%)   2017 2018 2019 
     
Return on invested capital     
Profitability margin (EBITA-to-Revenue)  2.3% 14.9% 10.1% 
Capital turnover, excl. goodwill  0.49 0.52 0.56 
Capital turnover, incl. goodwill  0.36 0.38 0.39 
     
Pre-tax ROIC (excl. goodwill)  1.1% 7.8% 5.6% 
Operating taxes on EBITA  39.8% 23.1% 24.8% 
Goodwill as a % of invested capital  27.3% 27.9% 30.0% 
     
ROIC excl. goodwill   0.7% 6.0% 4.2% 
ROIC incl. goodwill   0.5% 4.3% 3.0% 
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Following our analysis of Aker BioMarine's line items, we calculate the company's historical 
return on invested capital as a product of these components. The pre-tax ROIC is first 
calculated for each year due to the operating profit margin and the corresponding capital 
turnover. From this, we subtract the operating taxes as in Eq.15 and arrive at ROIC, both 
excluding and including goodwill. The rationale behind this is presented in the reorganization 
of the balance sheet in sub-chapter 5.3. We see that goodwill was a relatively modest part of 
invested capital in the period, but the two numbers do leave some room for interpretation, 
nonetheless. 
In 2017, Aker BioMarine's ROIC was 0.7% net of goodwill and 0.5% when goodwill is 
included. ROIC grew notably in our historical examination period and reached a historical 
high in 2018, when Aker BioMarine experienced a considerable uptick and ended at an ROIC 
of 6.0% excluding goodwill and 4.3% when goodwill is included. This is mainly due to the 
significant increase in Aker BioMarine's operating margin, primarily driven by strong krill oil 
sales characterized by high margins. Nevertheless, Aker BioMarine sustained overall revenue 
growth in 2019 but fell slightly in margins and delivered a slightly lower ROIC in the latest 
financial year. Aker BioMarine's return on invested capital with and without goodwill 
presented in figure 22, along with the corresponding Ingredients segment is operating margin 
across the same period for visualization purposes. 
Figure 22: Return on invested capital and Ingredients operating margin (2017-2019)  
 
5.4.2 Peer historical analysis of return on invested capital 
In order to fully understand Aker BioMarine's return on invested capital, we turn the spotlight 
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firms listed in the public marketplace today are fully comparable to Aker BioMarine and its 
industry-specific operational characteristics. We have selected four peers viewed as 
competitors in the firm's two segments, Ingredients, and Brands, we believe that analyzing 
their historical ROIC will allow us to get a greater understanding of what drives value creation 
in its competing segments. Following Koller et al. (2020), we will analyze ROIC excluding 
goodwill to avoid including the effect of price premiums paid in acquisitions and allow for 
more consistent analysis across the comparable group. We structure this analysis in the same 
way as our firm analysis, starting with an analysis of operating margin, before proceeding to 
look at capital turnover, and finally examining the ROIC. Details of the financials of the firms 
included in our analysis are attached in the appendix. For visual purposes, we note that the 
comparable company's in the Ingredients segment is visualized in blue colors and Brands in 
green in our analysis. 
Operating margin 
Our comparable firms' operating margin, or EBITA-to-Revenue ratio, is given in figure 23: 
Figure 23: Operating margin: Aker BioMarine vs. comparable firms 
 
From figure 23, we see that Aker BioMarine's operating margin in 2017 was well below that 
of its peers in the same year. Consequently, following a significant boost in margin 
predominantly driven by increased krill oil sales in 2018 and 2019, Aker BioMarine delivered 
operating margins above its Brands peers in the last two years of our analysis. Our analysis is 
notable because peers in the ingredient segment are consistently delivering higher operating 
margins, ranging from an average of 18.6% to 21.1% within our period of analysis. In 
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The best performer of the peers, Probi, has a premium position in the Ingredients market which 
allows them to extract significant margins on their goods sold. This is a trend for companies 
in this segment, and Ingredients company DSM also posted higher margins than Brands peers 
in all of the years included in our analysis. While Aker BioMarine's margins have been 
somewhat more modest due to a significant focus on growth over margins in recent years, it 
targets these premium markets through their increased offering in the high-margin Ingredients 
segment. The Brands segment is characterized by more intense price competition, putting great 
pressure on operating margins for peers in this segment. 
Capital turnover 
Our comparable firms' Revenue-to-Invested capital ratio, expressed capital turnover, is given 
in figure 24: 
Figure 24: Capital turnover: Aker BioMarine vs. comparable firms 
 
Since we compare the ROIC of the peer group, excluding goodwill, the graph above shows 
revenue divided by invested capital net of goodwill. In the capital turnover analysis, we see a 
very dominant trend in which Brands companies post capital turnover numbers vastly above 
Aker BioMarine and other peers. There are several components to this difference, but the 
Brand companies are more mature and more effective in generating a return on their invested 
capital. On the other hand, Ingredients companies are less mature and have more capital tied 
up to fuel higher growth expectations. This is also very much the case for Aker BioMarine, 
who posted the lowest capital turnover in all years included in our analysis. As argued 
previously in our thesis, and which we will further stress in our forecasting, Aker BioMarine 
has made substantial investments in recent years to facilitate its extensive growth ambitions, 
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Return on invested capital 
Following our argument that an analysis of ROIC excluding goodwill is favored when 
comparing across different firms, the results of our analysis of ROIC net of goodwill is 
visualized in figure 25 below: 
Figure 25: ROIC, excl. goodwill: Aker BioMarine vs. comparable firms 
 
Overall, our entire peer group outperforms Aker BioMarine on ROIC between 2017 and 2019. 
Although the Brands' peers have delivered lower operating margins than Aker BioMarine in 
the last two financial years, their efficient operational characteristics reflected in healthy 
capital turnover push their ROIC well above all three years. On the flip side, the Ingredients 
peers had notably lower capital turnover than their more mature peers, but due to their healthy 
operating margins, they posted the highest average ROIC of the two peer groups ranging from 
13.2% to 13.9% during the period. 
As we have argued, relevant peers in the Ingredients segments are entitled to premium pricing 
in their end-markets, which pushes their ROIC significantly upwards despite growth 
anticipation leading to a more capital-intensive operation. Aker BioMarine performs lower in 
both components of ROIC, which ultimately results in a lower ROIC than its peers. This also 
highlights the shortcomings of this historical financial analysis, in which an Aker BioMarine 
set-up for future growth is performing artificially low on these metrics. Thus, we claim that 
the historical numbers' importance as indicators for future performance is somewhat limited. 
However, as we have seen a clear improvement trend during this period, we believe our 
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5.4.3 Analysis of historical revenue growth 
In this subchapter, we conduct a strategic earnings analysis of Aker BioMarine's previously 
reported results. The scope of the analysis will be limited to the past three years, which are the 
years that have been disclosed to the public. With only three years of detailed financial 
information, we can only assess the growth of two years. Hence, the scope of this past 
performance analysis will be of limited interest in the valuation, but we deem it critical to 
understand the company's operations. The second part of the chapter will assess their 
performance with relevant peers. We chose two peers from the Brand segment and two in the 
Ingredients segment. This is to illustrate the broad scope of the operations of Aker BioMarine. 
Finally, it should also be noted that the historical analysis only has a minimal impact on the 
forecasting, as we consider Aker BioMarine to be a high-growth case. The weight put on the 
historical performance analyses depends on the life cycle of the firm. Historical analyses of 
mature firms in the steady state will be helpful in forecasting. This is not the case with growth-
companies as these enjoy a sizable growth. Consequently, the past performance of Aker 
BioMarine will not reflect future results.  
Revenue growth of Aker BioMarine 
The revenue growth for Aker BioMarine has been substantial in the past two years, from 2017 
to 2019. The growth between 2017 to 2018 was at ~24%, which partly can attribute to the 
increased demand for omega-3 supplements (Euromonitor, 2020c). 
Figure 26: Aker BioMarine: historical revenues vs. YoY growth rate 
Source: Aker BioMarine annual reports 2018 – 2020 
There were no acquisitions or inorganic growth in this period, so the real growth is allocated 
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However, the acquisition of Lang contributed heavily to the increased revenues in 2019 and 
must be separated from growth to analyze its development further. 
On March 1, 2019, Aker BioMarine acquired the full-service market dietary supplement 
company Lang Pharma. The acquisition was performed for strategic reasons to ensure that 
Lang remained deeply invested in the krill oil segment and further explore and utilize the 
pharma company's synergies and competencies. Lang will continue to operate as a separate 
unit, but as a subsidiary of Aker BioMarine. Lang's annual results have been included in its 
consolidated income statement and balance sheet as of March 1, 2019. It is essential to correct 
this to gain a better understanding of the underlying operation growth. In 2019, the Lang 
business unit contributed revenues of USD 82.2mn and a net profit of USD 5.7mn to the 
consolidated statement (Aker BioMarine, 2020a). If the acquisition had occurred on January 
1, 2019, the additional contribution to Aker BioMarine would have been USD 11.1mn and 
USD 0.4mn in revenues and net profit, respectively. These amounts were calculated using 
Lang's results and adjusting them for discrepancies in the accounting policies between Aker 
BioMarine and Lang Pharma (Aker BioMarine, 2020a).  
Figure 27: Aker BioMarine: Adjusted revenue growth vs. YoY adjusted growth 
Source: Aker BioMarine annual reports 2018 – 2020 
Illustrated by figure 27, the adjusted growth plummeted to ~6% between 2018 and 2019. These 
numbers are adjusted for the revenues which were directly acquired from Lang Pharma; it may 
be hidden synergy revenues from the increased scope of operations, new partners, or 
complementary sales, which is problematic to estimate. When analyzing companies' past 
performances, it is important to strip out the effects of acquisitions (divestitures) to avoid 
overestimating (underestimating) the real growth rates of the operations. As illustrated above, 
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which will introduce a significant overestimation if not accounted for in the historical analysis, 
if implemented for future estimates. 
The fiscal year of 2019 is also the first year of operations with the new krill vessel Antarctic 
Endurance. It should be noted that the vessel did operate at low capacity as guided by the 
company, catching ~44 000MT. Exhibit 27 showcases estimated vessel economics, which may 
further help to understand the development of the revenues in Aker BioMarine in the past 
years. 
Exhibit 27: Summary of vessel economics  
 
2017 2018 2019 17' - 19' average 
Metric tons (MT) 
 
    
Operative vessels 
 
2 2 3*  
Total catch 
 
171 554 207 259 232 368  
Total offshore production 
 
29 123 36 561 40 872  
Production output offshore 
 
16.98 % 17.64 % 17.59 % 17.40 % 
Growth in offshore production - 25.54 % 11.79 % 18.67 % 
 
 
    
USD thousands 
 
    
Total salaries 
 
14 923 18 249 21 866 34.41 % 
Fuel costs 
 
11 470 18 980 19 042 30.95 % 
Direct production costs 
 
3 311 5 243 3 321 7.43 % 
Other opex 
 
11 227 13 656 18 637 27.21 % 
Total offshore opex 
 
40 931 56 128 62 866 100.00 % 
 
 
    
Per vessel opex 
 
    
Salaries 
 
7 462 9 125 7 289 34.36 % 
Fuel 
 
5 735 9 490 6 347 31.04 % 
Direct production costs 
 
1 656 2 622 1 107 7.75 % 
Other opex 
 
5 614 6 828 6 212 26.85 % 
Total 
 
20 467 28 065 20 955 100.00 % 
Source: Aker BioMarine annual reports and investor presentation 
*Antarctic Endurance did not operate on full capacity 
The adjusted growth between 2017 and 2018 was ~26%, which is equal to the offshore 
production growth, which makes it remarkable that the adjusted growth the following year 
was only half of the offshore production growth. Due to the few years of data, it is problematic 
to derive which of the offshore production growth to revenue growth is “abnormal.” Koller et 
al. (2020) also reason that the currency effects should be stripped out, in addition to 
acquisitions and divestitures, to gain a robust understanding of the growth. Aker BioMarine 
operates globally and is exposed to currency fluctuations, primarily through the USD, EUR, 
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and NOK exchange rates. Further, Aker BioMarine has operations in countries with local 
currencies in Uruguay, India, Australia, Thailand, New Zealand, Canada, and China, but these 
fluctuations are minimal (Aker BioMarine, 2020b). The predominant currency effect is USD, 
which Aker BioMarine has as its presentation and functional currency. Aker BioMarine has 
NOK denominated financial instruments. Therefore, the balance sheet is exposed to changes 
in the NOK/USD exchange rate, which should be adjusted.  
Aker BioMarine seeks to ensure that both revenues and expenses are in the same currency, 
such that the future cash flows are estimated and offset. The management periodically assesses 
the need for currency hedging derivatives to hedge the overall risk. Such a derivative was in 
place in investment in the new vessel. In May 2017, Aker BioMarine entered a currency 
contract with DNB for the hedging of currency risk from future installments related to the 
vessel under construction, Antarctic Endurance (Aker BioMarine, 2020b). The currency effect 
for the different years is insignificant for 2019, with a net USD 1 000 gain (Aker BioMarine, 
2020a), while 2018 and 2017 introduced a loss of USD 2.21mn and USD 3.47mn (Aker 
BioMarine, 2019), which should be adjusted before presenting the final organic growth 
estimates.  
Adjusting the revenues for acquisitions, divestitures, and currency effects the past three years 
provides us with the final organic growth estimates at ~25% from 2017-2018 and ~8% 
between 2018-2019. To better understand the drivers of Aker BioMarine, we presented the 
vessel economics in exhibit 27, which illustrates that the revenues are closely correlated to 
offshore production. It should be noted again that the data points are few, and the correlation 
between revenues and offshore production is not statistically significant. 
Figure 28: Aker BioMarine: Organic revenue growth 
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Aker BioMarine revenue growth compared with peers  
As outlined above, the FX- and mergers, divestitures, and acquisitions (“MD&A”) effects 
should be stripped from the revenues to find the organic growth of the core operations of the 
company analyzed. Aker BioMarine only had one acquisition in the final year of the historical 
analysis where they reported the revenue which it contributed, making it easy to correct for 
the acquisition. This is not the case with the peers we have selected. The effect of acquisitions 
affects the current year of the acquisition and the following year of the deal. This is due to 
accounting standards that lead to an artificial increase the following year if not accounted for, 
as only parts of the revenue are consolidated in the year of the deal, but the following year, the 
target's whole annual revenues are incorporated. This should be corrected for if not, the growth 
will not reflect the company's “true” growth rate. This is also true for divestitures. It does have 
the opposite effect on the statements than the acquisitions. If one fails to correct all the 
elements, the comparison with the peers and Aker BioMarine will be incorrect.  
The peers selected for Aker BioMarine consist of two peers from the Ingredients segment and 
two from the Brands segment. As discussed earlier, Aker BioMarine has few true peers and 
zero public peers. This makes the selection of peers somewhat different than Aker BioMarine, 
but the peers as based on what Aker BioMarine believes to be their closest peers. It should be 
noted that none of these companies are the same size or industry as Aker BioMarine, but they 
are the closest peers we can find, which is publicly traded. The majority of companies 
operating in the krill industry are private companies, making it problematic to quantitatively 
analyze the industry and find critical operating and financial metrics. 
Figure 29: Organic growth revenues 
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As figure 29 illustrates, Aker BioMarine has outperformed its organic revenue growth peers 
in the past two years. These growth rates have been stripped of currency- and MD&A effects 
to find the growth in the core operations revenue. The illustrates that Aker BioMarine has 
performed well even if the industry has not been peaking. As the krill industry is expected to 
experience significant growth going forward, the growth rates seen in figure 29 may be the 
beginning of a high-growth period for Aker BioMarine. It is challenging to compare 1-to-1 
with these companies as they are different in size, location, and products they offer, such that 
we cannot credit or discredit any of the peers based on common factors that have affected them 
all. The organic revenue growth development versus non-adjusted revenue growth (figure 30) 
reveals the same pattern; Aker BioMarine grows its operations superior. It is essential to be 
aware of the companies' different sizes, as it is easier for smaller companies to have higher 
growth in their revenues than billion-dollar companies. 
Figure 30: Non-adjusted revenue growth 
Source: Annual report of the companies 
5.4.4 Historical analysis of credit health and risk 
To conclude our historical financial statements analysis, we turn the spotlight to Aker 
BioMarine's credit health and capital structure to examine how Aker BioMarine's operations 
are financed. Building on Damodaran's (2012) frameworks and Koller et al. (2020), our 
analysis will include measuring and assessing liquidity, credit health, and leverage 
computation of coverage ratios and debt multiples. Since an analysis of financing also 
encompasses how the firm returns its cash to shareholders, examining its historical payout 
ratio would make sense. As discussed before, Aker BioMarine has not been paying out 
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(Aker BioMarine, 2020a, p. 91). Therefore, this is not included in our historical analysis and 
is discussed in greater detail in our chapter on forecasting. 
Analysis of Aker BioMarine's liquidity 
To analyze Aker BioMarine's liquidity, and therein the company's ability to meet its 
obligations in the near-term future, we will examine its interest coverage ratio. The interest 
coverage ratio, computed by dividing EBITA or EBITDA by interest expenses, is a metric 
showcasing its capacity to cover interest payments. This number can function as a tool to 
assess how well equipped the company is to pay down its short-term debt obligations. 
However, as with any simple financial ratio, it has its limitations, and interpretation of this 
number should be made with caution. In our assessment of Aker BioMarine's liquidity, we 
will compute the interest coverage ratio using both EBITA and EBITDA as proposed by Koller 
et al. (2020). Aker BioMarine's interest coverage ratios are summarized in exhibit 28: 
Exhibit 28: Breakdown of Aker BioMarine's interest coverage ratios 
In USD thousands ($)   2017 2018 2019 
     
EBITA  2 800 23 014 24 962 
EBITDA  17 215 39 019 53 039 
Interest expense  10 745 12 263 22 785 
     
EBITA-to-Interest   0.26 1.88 1.10 
EBITDA-to-Interest   1.60 3.18 2.33 
 
From our calculations, we can see that Aker BioMarine does have sufficient EBITA and 
EBITDA to meet its interest expenses, expect in 2017. Notwithstanding, a lower ratio may 
indicate that its ability to meet interest obligations is problematic. Relative to 2017, its interest 
coverage ratio has been far better in the last two years. More so, in 2019, Aker ASA converted 
NOK 1 bn of debt 2019, reducing interest expense, which may have been a contributing factor. 
Since the company has advocated the last years that they have been in a growth and 
development phase to build up a fully functioning and market-leading krill company, we argue 
that this analysis is less meaningful given its higher volatility in earnings in this period. To 
better understand the firm's credit health, this measure should be accompanied by other 
financial metrics and an analysis of comparable firms' credit situation. 
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Comparable firm liquidity analysis 
Figure 31: EBITDA-to-Interest expense: Aker BioMarine vs. comparable firms 
 
In our analysis of interest coverage ratio for comparable firms, we select EBITDA as the 
numerator. The numbers highlight one of the critical issues with our peer group, which is 
rooted in having more mature business models than krill companies, although they serve the 
same end markets. Hence, our peers operate under relatively stable business environments, 
leading to a far higher output on liquidity multiples than Aker BioMarine. This effect is most 
prominent in our peer group for Glanbia and Probi, delivering an interest coverage ratio of 
>12.5 in all years of our examination period. This is mainly due to Probi's low debt levels in 
recent years, while Glanbia had deficient debt levels in 2017 and 2018. On average, the 
EBITDA-to-Interest ratio in the peer group ranged from 16.5 to 20.3 in the period. As 
discussed previously, we expect Aker BioMarine to drastically better its interest coverage 
ratios as it transitions from growth and expansion to enhance its profitability. 
Historical synthetic credit rating 
External credit rating agencies, such as Standard & Poor's, Moody's, and Fitch, conduct third-
party credit ratings for businesses. These rating agencies place a firm in a range of different 
rating categories from "best to worst" based on the firm's probability of defaulting on its debt. 
Since the public information on Aker BioMarine's credit rating is minimal, we can instead 
approximate a synthetic rating for the company based on Damodaran's framework (2012). This 
is an alternative rating of a firm's default risk based on the EBIT interest coverage ratio. By 
collecting credit rating data on all small-cap US firms, a link is established between its 
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A historical synthetic credit rating can be attached to any company based on their interest 
coverage ratio from this data. To perform this assessment, we extract data on credit ratings 
and interest coverage ratios for all firms with >USD 5 bn market capitalization from 
Damodaran's online databases (Damodaran, 2020): 
Exhibit 29: Interest coverage ratio and credit ratings of >USD 5 bn firms 
Interest coverage ratio Rating Spread 
   
Above 12.5 Aaa/AAA 0,63% 
9.5 - 12.5 Aa2/AA 0,78% 
7.5 - 9.5 A1/A+ 0,98% 
6.0 - 7.5 A2/A 1,08% 
4.5 - 6.0 A3/A- 1,22% 
4.0 - 4.5 Baa2/BBB 1,56% 
3.5 - 4.0 Ba1/BB+ 2,00% 
3.0 - 3.5 Ba2/BB 2,40% 
2.5 - 3.0 B1/B+ 3,51% 
2.0 - 2.5 B2/B 4,21% 
1.5 - 2.0 B3/B- 5,15% 
1.25 - 1.5 Caa/CCC 8,20% 
0.8 - 1.25 Ca2/CC 8,64% 
0.5 - 0.8 C2/C 11,34% 
Below 0.5 D2/D 15,12% 
      
                    Source: Damodaran (2020) 
From this table, we see that based on Aker BioMarine's EBIT interest coverage ratio, the 
company would be assigned a synthetic rating at the bottom of this bracket, ranging from D2/D 
to B3/B- between 2017 and 2019. Despite its simplicity, we would still argue that such a rating 
is flawed and believe that it does not fully capture the complexity of a firm's financial situation 
in a growth and development phase such as Aker BioMarine. We will discuss the implications 
of credit ratings in greater detail in our chapter on capital cost. 
Analysis of Aker BioMarine's leverage 
While interest coverage ratios are utilized to analyze a firm's capacity to meet its interest 
obligations, it does not assess its ability to pay back the principal on its outstanding debt. Debt 
ratios attempt to do so (Damodaran, 2012). Accordingly, we will evaluate Aker BioMarine's 
leverage employing the debt multiples Debt-to-EBITA and Debt-to-EBITDA. These multiples 
will tell us the degree of debt loaded on its earnings before deduction of interest, tax, 
depreciation, and amortization in a given year. A visualization of Aker BioMarine's debt 
multiples is presented in exhibit 30: 
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Exhibit 30: Breakdown of Aker BioMarine's debt multiples  
In USD thousands   2017 2018 2019 
     
Debt multiples     
Debt  275 134 205 368 420 064 
EBITA  2 800 23 014 24 962 
EBITDA  17 215 39 019 53 039 
     
Debt-to-EBITA   98,26 8,92 16,83 
Debt-to-EBITDA   15,98 5,26 7,92 
 
Aker BioMarine's Debt-to-EBITDA is less volatile than the liquidity multiple based on EBITA 
and is seemingly more suitable for comparison across the period. Although both multiples 
generally show the same trend, Debt-to-Earnings levels have gone down significantly from 
2017 due to a more significant percent-wise increase in EBITA and EBITDA compared to the 
corresponding increase in debt. Notably, debt increased sharply in 2019 due to investments in 
vessels and the acquisition of Lang. Aker BioMarine's growth characteristics have resulted in 
inflated debt multiples, which are likely to not follow the same trend in the future. 
Figure 32: Debt-to-EBITDA: Aker BioMarine vs. comparable firms 
 
Comparing Aker BioMarine's Debt-to-EBITDA to that of the peer group, it is evident that the 
company has operated on significantly higher debt multiples during the last three years. Due 
to low debt holdings, the comparable companies in the Ingredients segment are on average 
hovering around 1 in all three years. Brands company, and in particular Midsona, hold larger 
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It should be noted that there are significant differences in capital structure between various 
industries. Hence, and as expected, due to the nature of our selected peer group, our historical 
analysis does not give us detailed results when comparing debt multiples. 
5.5 Summary of historical financial analysis 
Exhibit 31: Breakdown of Aker BioMarine's debt multiples  
In percentages (%)   2017 2018 2019 
     
Profit margin (EBITA-to-Revenue)     
Probi  24.0% 23.7% 27.7% 
DSM  13.3% 16.6% 14.5% 
Midsona  8.5% 7.9% 8.4% 
Glanbia  11.9% 9.1% 6.8% 
Aker BioMarine  2.3% 14.9% 10.1% 
     
Capital turnover     
Probi  0.79 0.71 0.69 
DSM  1.10 1.06 1.07 
Midsona  1.87 1.74 1.34 
Glanbia  1.41 1.53 1.72 
Aker BioMarine  0.49 0.52 0.56 
     
ROIC, excl. goodwill     
Probi  14.2% 13.1% 15.0% 
DSM  12.3% 14.5% 12.9% 
Midsona  11.9% 10.9% 9.4% 
Glanbia  14.0% 12.2% 10.5% 
Aker BioMarine  0.7% 6.0% 4.2% 
     
Organic revenue growth rate     
Probi  - 0.2% 3.4% 
DSM  - 7.5% -2.8% 
Midsona  - 3.0% -6.0% 
Glanbia  - 4.1% 6.6% 
Aker BioMarine  - 25.4% 7.8% 
     
Interest coverage ratio (EBITDA)     
Probi  27.43 25.66 61.82 
DSM  11.02 17.17 16.10 
Midsona  10.72 9.50 8.17 
Glanbia  45.00 27.11 12.92 
Aker BioMarine  1.60 3.18 2.33 
     
Debt-to-EBITDA     
Probi  1.11 0.76 0.33 
DSM  1.79 1.43 1.55 
Midsona  3.66 4.93 5.19 
Glanbia  1.59 2.42 2.85 














Based on the qualitative strategic analysis and the quantitative financial statement assessment, 
the chapter will attempt to quantify Aker BioMarine's future earnings. The purpose of these 
forecasts is to develop and present projections for the company’s income statement, balance 
sheet, and cash flow statement. This, together with the costs of capital presented in chapter 7, 
makes the foundation of the fundamental valuation of Aker BioMarine. 
6.1 Framework for performance forecasting 
Before preparing the performance forecasting, it must be clarified how long the forecasting 
period will be, in what detail it will be presented, and what techniques and methods will be 
utilized in the forecasts. 
Choice of timeframe 
The timeframe in this paper will be from 2020 until a predetermined time t. Time t, called the 
continuing value (“CV”), represents when the forecast will change from a detailed forecast to 
a simple forecast with constant growth (Knivsflå, 2020a). As a result, the forecasting period 
will cover the time until Aker BioMarine will enter the “steady state”. Which is when a 
company does not acquire abnormal returns on their future investments in the expansion 






























cost of capital 
Chapter 9: 
Relative valuation 
Step: 1 Step: 2 Step: 3 Step: 4 Step: 5 
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Before a company reaches a steady state, the timeframe is individual and dependent on several 
factors such as the industry and internal aspects (Kaldestad et al., 2016). If a company operates 
in a mature industry and (or) expansion for the company is complicated, the forecasting period 
can be short as the company will reach constant growth faster. However, if the company 
operates in a high-growth environment and (or) the possibilities for expansion are vast, the 
forecasting period should be extended. 
Kaldestad et al. (2016) assert that companies in cyclical industries, industries that may expect 
significant growth, or industries with sizeable super profits should have a forecasting period 
longer than five years. The krill industry should be categorized as an industry that may 
experience significant growth going forward. This entails that the industry is not mature, and 
the companies within can experience sizable fluctuations in their statements such that it is not 
appropriate with a constant growth rate in the immediate future. As a more extended 
forecasting period will incorporate both bust and booms, it will be a well-founded choice to 
adopt for Aker BioMarine, as they are affected by the economic cycle with the sales of omega-
3 supplements.  
Since the industry players are investing a lot right now in new vessels and facilities, it is 
difficult to determine how the future industry dynamics will play out. The uncertainty in our 
forecasts will be reduced with an extended forecasting period, compared with a diminished 
period. The growth of both the sales of omega-3 supplements, krill harvesting, and new 
products also pulls toward a more extended forecasting period. It is expected that some of the 
growth will lessen when approaching 2025. Even though a more extended timeframe is 
required for Aker BioMarine, the timeframe must not exceed a length such that the projected 
cash flows will be so uncertain it reduces the full informational value of the paper itself. 
Knivsflå (2020a) also argues that the choice of timeframe should be affected by the quality of 
the company's accounting standard. A shorter period may be appropriate if the company 
prioritizes a value-based accounting standard. This is because value-based accounting captures 
the changes in value quickly, which increases the informational value of the financial 
statements of the company. Aker BioMarine reports, according to IFRS 16, which implies that 
the reporting is value-based. This is an argument that pulls in the direction of a short 
timeframe. 
 125 
Even though Aker BioMarine has a high reporting standard, it is optimal to choose a more 
extended timeframe for the company than most others. Therefore, we have determined a 
forecasting period of ten years, going from 2020 – 2029, where 2030 represents the continuing 
period.  
Choice of detail levels 
After the decision of timeframe, an adequate level of detail should be decided for the 
forecasted statements. The two most common distinctions in forecasting are between a focused 
level and a detailed level, where the focused level only includes a few value drivers, and the 
detailed level includes several. The choice between these two methods is highly dependent on 
the length of the forecasting period. 
A short timeframe advocates for a detailed level as the precision in the forecasts will be better. 
The longer timeframe, the more problematic it is to forecast the exact numbers in each line 
item; it is not appropriate to deploy a detailed level when using a longer timeframe. The 
uncertainty in the forecasts will perhaps be reduced if one chooses to use a focused method 
instead of a detailed one (Knivsflå, 2020a). Since this paper's time horizon is long, we have 
decided it will be most beneficial to focus on the critical value drivers. 
As touched upon in previous chapters leading up to the performance forecasting, our forecasts 
for the financial year of 2020 will incorporate the latest financial information that is publicly 
available up until October 30, 2020. The requirements on interim financial reporting on 
Merkur Market are relatively liberal compared to that of Oslo Børs’ main list. Consequently, 
the financial information released so far this year, apart from the 2019 annual report, is heavily 
condensed. We focus on reflecting the critical features of the Q3 2020 financials in our 
estimates, along with our assumptions to forecast 2020 on a detailed level.  
Choice of forecasting technique 
When the timeframe and level of detail has been determined, the remaining element is the 
forecasting technique. In this paper, the forecasted statements will have dynamic value drivers 
at predetermined years, which changes during the periods. The first years are more 
straightforward to forecast with better precision than the years far ahead. Since it takes time 
to reap the sown investments for the other industry players, it will be simpler to predict how 
large the market share Aker BioMarine will maintain in the coming years.  
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Once the competitors receive the ordered vessels and equipment, it is more problematic to 
project the industry dynamics. Looking at the long run, it will be natural to assume that the 
growth will converge to the long-term economic growth.  
Knivsflå (2020a) claims that the likelihood that a company may go bankrupt is often 
underestimated in the forecasts of the expected value. Thus, it is recommended to forecast the 
expected value under the assumption of normal operations, and at the same time, calculate the 
bankruptcy risk separately. We will present the future synthetic credit ratings of Aker 
BioMarine in chapter 7, which analyzes the bankruptcy risk. In light of this, we deem it optimal 
to only forecast one scenario for Aker BioMarine with sensitivity analyses. The forecast 
reflects the company's expected development and is built on the qualitative strategic analysis 
from chapter 4. The uncertainty in the value drivers will be accounted for in the fundamental 
valuation in chapter 8 with sensitivity analyses.  
Since the assumption in fundamental valuations is that all cash flows are realized at the end of 
the year, the company may be unfairly penalized as cash flow normally is generated steadily 
throughout the year. To avoid this, we mid-year adjust the cash flows such that it assumed to 
realize mid-year. Lastly, the value drivers will be computed from the statements at the 
beginning of the period. This is to minimize the uncertainty related to the forecasted 
statements' calculations, which will increase the informational value needed for the valuation.  
6.1.2 Framework for revenue forecasting 
Different approaches exist to estimate companies' future revenues, but the two most common 
are a top-down and bottom-up approach (Koller et al., 2020). The top-down approach begins 
with the macroenvironment and looks at the entire market in which the company operates. 
Going forward, the company's market share will be estimated, and the revenues will be a result 
of the industry sales and the company's market share. This approach is best implemented when 
the company and industry are mature and reaching a steady state. The second approach often 
used is bottom-up, where one begins with the microenvironment. The first step is to project 
the customers' demand for the products and then add up all the product revenues to accumulate 
future revenue. Besides, the company must try to forecast demand from new customers and 
lost demand from existing companies.  
This method is better applicable to companies with strong growth. Regardless of the method 
chosen, over more extended periods, there will be discrepancies between actual and projected 
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income due to disruptive technologies, change in customer demands and new corporate 
strategies. Consequently, an ongoing assessment of whether the current forecasts are 
consistent with the macro-and microenvironment should be periodically carried out (Koller et 
al., 2020). 
We have decided to adopt a combination of the bottom-up and top-down approach as this is 
better suited for the growth case of Aker BioMarine. As Koller et al. (2020) proclaim in their 
chapter on financial performance forecasting, using a combination of market information and 
forecasts and the firm's financial forecasts is ideal for creating explicit bounds for our revenue 
growth forecasts. Neither the industry nor the company itself is mature, and it is expected to 
undergo radical changes and considerable growth in the coming years. We assume this 
approach to be the most suitable for our case. 
6.1.3 Framework for financial statement forecasting 
As explained above, the company's financial statements will be projected in-depth in the short-
term portion of the defined forecasted period. This activity aims to help provide accurate 
insights into how the company's financial statements may look in the foreseeable future, which 
then, in turn, will be used as a basis for better forecasting its performance in the long-term and 
the forecasting period. Typically, the company's income- and cash flow statements are the 
most relevant statements that should be projected. We install a three-step procedure to project 
each object in the company's income statement.  
The first step includes defining the economic relationship that drives the forecasted object in 
a metric. While most objects are economically related to sales and revenues, particular objects 
have economic relationships with some assets or liabilities. I.e., while account receivables are 
closely related to revenues and the income, it is more fitting to relate depreciation and 
amortization (“D&A”) to PPE and intangible assets. If we manage to establish a ratio in this 
economic relationship, the next step includes the forecasting of this ratio in the coming years. 
Eventually, in the final step, the forecasted ratio is introduced in the projections in the object's 
driver to determine the object's final projection. E.g., the projection of the company's D&A 
for a given year can be obtained by multiplying the projected D&A ratio of the company's 
forecasted capex for that year.  
We analyze and present specific common economic relationship ratios. The ratios will be 
utilized for various objects in both income- and cash flow statements in our forecasts.  
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Framework for forecasting the income statement 
Objects in the financial statements such as the cost of goods sold (“COGS”), impairment, 
transport, sales, general and administration (“SG&A”), marketing, R&D, and payroll expenses 
are variable costs and tend to follow the same trend as the company revenue. As a result, it is 
appropriate to deploy revenue as their forecast driver (Koller et al., 2020). However, costs 
such as D&A are based on the prior PPE. When estimating the D&A costs, the gross PPE 
should be employed as D&A are just the practice of allocating the purchase cost of PPE (Koller 
et al., 2020). Nevertheless, employing the gross PPE may lead to an overestimation of the 
depreciation as fully depreciated assets still may show up in the PPE due to complex 
accounting rules. 
Further, non-operating objects must also be forecasted. They serve the purpose as it helps to 
grasp several angles of the company's performance and may help develop future strategies. 
Moreover, with the cash flow projections they work as a checkbook for flaws and mistakes 
that may have been made during the modeling. The most frequent non-operating objects are 
non-operating revenue and interest income (expense). Non-operating revenue may spawn 
from non-operating assets such as subsidiaries, customer financing, or equity investments 
(Koller et al., 2020). Hence, the appropriate drivers for these are their respective non-operating 
assets. Income and expenses related to interest can be more easily assigned as these are more 
clearly linked to the assets (liabilities). 
Exhibit 32: Forecasting drivers for income statement items 
Type Line Object Typical Driver Typical Ratio 
Operating 
COGS Revenue COGS/Revenue 
SG&A Revenue SG&A/Revenue 










operating asset or growth in 
non-operating income 
Interest income Prior-year excess cash 
Interest income(t)/Excess 
cash(t-1) 
Interest Expense Prior-year total debt 
Interest expense(t)/Total 
debt(t-1) 
Source: Koller et al. (2020) 
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Framework for forecasting the balance sheet 
Similar to elements in the financial statements, various balance sheet items also trend with the 
revenue. This is especially true in the working capital objects account receivable and accrued 
expenses. The two exceptions in the working capital are accounts payable and inventories 
connected to the company's procurement, and their driver should therefore be assigned to 
COGS. The one exemption from this “rule of thumb” is when the input prices do not deviate 
significantly from the company's marginal cost, it may be viable to adopt the revenues as the 
driver, like the other working capital objects (Koller et al., 2020). 
When a company aims for a consistent expansion, capital and resource investments in the PPE 
are required to develop the operations. Therefore, similarly to the account receivable and 
accrued expenses, the driver for net PPE should be revenues (Koller et al., 2020). It is further 
reasoned that, over time, the ratio of net PPE for a given year to revenue in that year is 
relatively stable. When we use the revenue as the driver, net capex should also be computed 
based on the forecast to control the forecasts' flaws. 
Exhibit 33: Forecasting drivers for balance sheet items 







Inventories COGS Inventories/COGS 
Accounts 
payable 
COGS Accounts payable/COGS 
Accrued 
expenses 
Revenue Accrued expenses/Revenue 






Growth in non-operating 
assets 
Pension assets or 
liabilities 
None Trend toward zero 
Deferred taxes 
Operating taxes or 
corresponding balance 
sheet item 
Change in operating deferred 
taxes/Operating taxes, or 
deferred taxes/corresponding 
balance sheet item 
Source: Koller et al. (2020) 
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As with the forecasting of the income statements, non-operating assets- and liabilities should 
also be included in the projected balance sheets. It should be noted that the non-operational 
assets- and liabilities do not affect the free cash flows and will not impact the intrinsic value 
of the company derived from the cash flows. The values of these assets and liabilities are 
computed separately and added to the operations' intrinsic value to obtain the company's 
reasonable value. These objects are also necessary to project as it: (i) help managers to better 
understand and plan the company's strategic operations and (ii) assists analysts and 
management in the financial forecasting to control for flaws and mistakes that may have 
occurred. Many non-operating assets- and liabilities do not have a driver, and their growth 
rates are estimated based on historical growth rates and adjusted if needed. Large adjustments 
in these growth rates may be appropriate in high-growth firms such as Aker BioMarine. 








6.2 Revenue forecasting 
As the first step towards building a complete financial forecast for our valuation of Aker 
BioMarine, we start at the top line by forecasting revenue. As mentioned in the introduction 
to this chapter, we deploy a mixed approach to develop our revenue forecast, in which both 
the company's forecasts and revenue guidance and macroeconomic data are used as the 
building blocks leading to our final estimates. In this approach, we also will combine revenue 
from pre-existing customers with that of new customers. Concerning Aker BioMarine's listing 






















analyst material. This, along with Q3 2020 year-to-date reported revenues, will function as the 
basis for our 2020-2030 forecasts.  
Moreover, our projections will be split between Aker BioMarine's two operating segments, 
Ingredients and Brands, to provide as much detail to our calculation as possible. While we 
deem the company's plans and forecasts as the most critical components to our forecasts of 
expected revenue growth, we will also take a closer look at the systems in place for Aker 
BioMarine to reach its projected growth. More so, we will examine the market mechanisms 
and provide our assessment to verify and correct projections where it is needed. Consequently, 
we adopt a combination of the bottom-up and top-down approach to derive our revenue growth 
forecast. Aker BioMarine's own summary of forecasted organic growth is presented in figure 
33. 
Figure 33: Vocal organic growth ambitions 
Source: Aker BioMarine (2020b) 
6.2.1 Structural drivers of revenue growth 
Before presenting our final forecasts of each division's revenue growth, we start by presenting 
information and forecasts on structural drivers of revenue growth in both the Ingredients and 
Brands segment. By doing so, we hope to construct an insightful view on the market that Aker 
BioMarine competes in and the potential growth and revenues to be captured in the end-
markets that it sells its products in. For a relatively young and fast-growing firm like Aker 
BioMarine, Damodaran (2012) advocates three aspects that need to be addressed before 
estimating future revenue growth: (i) The historical revenue growth rate for the firm in 
question, and (ii) the potential and historical growth rate in the overall market that the firm 
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operates in, and finally (iii) competitive advantages and barriers to entry possessed by the 
company itself.  
Global reach 
We deem Aker BioMarine's global sales reach and distribution channels vital in driving 
revenue growth in the Brands segment. In figure 34, we have identified and visualized the 
regions in which the company sells its products. Overall, North America ("NA") is the largest 
market in revenue by a sizeable margin, with around 42% of revenues in 2019. The Europe, 
Middle East and Africa (“EMEA”) region is responsible for more than 2/3 of Aqua sales, 
mostly due to its position as the world leading region in aquaculture and salmon farming. For 
the group, the APAC has also been an essential contributor to overall sales historically, with 
23% of sales in 2019. Although, we believe that the sales split for 2019 does not fully capture 
the effect of Aker BioMarine's emerging Brands' efforts. The division is headquartered in the 
US, with connections to the largest retailers in North America, and we believe that the majority 
of its revenue growth will be realized in the US region. Therefore, a critical aspect of 
estimating future revenue growth is to analyze how revenue will develop in all global markets. 
Figure 34: Group current regional sales split, and Aqua sales split 2019 
Source: Aker BioMarine (2020b) and own creation 
Forecasted growth for dietary supplements and omega-3 
To grow within the dietary supplement category, Aker BioMarine is dependent on growth 
from capturing current consumers in the market and growth in the overall market. Therefore, 
accompanied by Euromonitor's forecasts for future dietary supplement growth, we have 
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attempted to forecast overall growth in the global retail value of dietary supplements until 
2030. The global dietary supplement market's global retail value grew by a compound average 
growth rate (“CAGR”) of 4% from 2017 to 2019. According to Euromonitor, this growth is 
expected to escalate between today and 2024, mainly due to structural trends such as an 
increasingly aging population and increased health focus partly fueled by the COVID-19 
pandemic (Euromonitor, 2020c). Our forecast for the development in the dietary supplement 
market is showcased in exhibit 35. 
Exhibit 35: Forecast of growth in the global dietary supplement market 
 Historical  Forecast 
In USD thousands 2017 2018 2019  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E 2030E 
                
Market value 60.3 62.7 65.0  68.0 71.0 75.0 78.0 82.0 86.1 90.4 94.9 98.7 102.7 106.8 
Annual growth - 4.1% 3.7%   4.6% 4.4% 5.6% 4.0% 5.1% 5.0% 5.0% 5.0% 4.0% 4.0% 4.0% 
                
CAGR 3.9%   4.6% 
Source: Aker BioMarine (2020b), Euromonitor (2020c) and own forecasts 
Aker BioMarine’s historical performance in the dietary supplement market 
Historically, Aker BioMarine has outperformed the market growth with Superba Krill posting 
a CAGR of 12% between 2017 and 2019, compared to the dietary supplement market with 
~3.9%. For this reason, in line with Aker BioMarine's growth ambitions, we believe that 
growth in the company's krill-based dietary supplement sales will be comfortably above the 
growth of the general market. Further, in line with the company's forecasts, we see no adverse 
effect on demand from the COVID-19 outbreak. On the contrary, since omega-3 and krill-
based dietary supplements are considered immune-boosting and health-promoting, we predict 
growth to strengthen in the coming decade. On the back of this, the Omega-3 market is 
estimated to see a CAGR of as much as 13% from the year 2019 until 2025, according to 
Research and Markets (Research and Markets, 2019). Since krill is considered a small omega-
3 ingredient in market share compared to omega-3 coming from other sources, we believe the 
room for revenue growth in the case of Aker BioMarine and krill-based products is higher 
than that of the traditional market, which will be reflected when we later forecast the final 
revenue growth for the segment. 
Forecasted growth in aquaculture 
Another driver for revenue growth in Aker BioMarine's product sales is the increase in 
aquaculture production, contributing to near 27% of Aker BioMarine's revenue in 2019. The 
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company sells krill-based products for use as a component in aquaculture feed, a substantial 
market in Europe and APAC. Today, the salmon market is one of Aker BioMarine's largest 
customers within the aquaculture industry, reflected in 74% of Aqua sales stemming from the 
EMEA region, as showcased in figure 34. In this near EUR 15bn market, feed cost is 
responsible for more than 50% of production costs, according to Mowi (2020). 
Aker BioMarine produces sustainable and premium marine feed components, answering to a 
demand for sustainable quality feed from the aquaculture industry. Accordingly, growth in 
this segment is attributable to growth in the overall aquaculture industry and the potential for 
increased demand for high-quality, sustainable feed ingredients. In exhibit 36, we present 
OECD-FAO (2020) forecasts of growth in aquaculture production until 2029 along with an 
estimate for 2030 in order to provide further backing to Aker BioMarine's forecasts of revenue 
projections and our potential tweaks and adjustments. 
Exhibit 36: Forecast of growth in the global aquaculture industry 
 Historical  Forecast 
Million MT 2017 2018 2019  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E 2030E 
                
Production 79.5 82.1 84.1  86.0 87.7 90.0 92.3 94.7 96.9 99.0 101.0 103.1 105.2 107.4 
Annual growth - 3.2% 2.4%   2.2% 2.0% 2.6% 2.7% 2.5% 2.3% 2.2% 2.0% 2.1% 2.1% 2.1% 
                
CAGR 2.8%   2.3% 
Source: OECD-FAO (2020) 
Historically, the CAGR of the global aquaculture industry production has hovered around 3%. 
Coming out of some decades characterized by significant growth, the aquaculture industry's 
development is expected to weaken in the coming decade. OECD/FAO (2020) rationalizes 
this with expected decreases in productivity gains, scarcity of suitable locations for production, 
and strict environmental regulation. One highly relevant factor that may boost growth in 
aquaculture is the emergence of land-based aquaculture. If planned volumes in this sector are 
realized, we might see a substantial upside to production estimates. Further, as environmental 
standards in the sector toughen, we believe Aker BioMarine may see additional demand for 
their aquaculture products as they are produced in a sustainable manner relative to its peers in 
the seafood and aquaculture industry. 
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Competitive position and barriers to entry 
To conclude our presentation of essential drivers of future revenue growth, we want to 
highlight the competitive position of Aker BioMarine and what this may imply for future 
growth in revenues. Damodaran (2012) highlights competitive advantages and barriers to entry 
are two of the most vital factors to be in place for a firm to achieve and maintain growth. 
As we discussed thoroughly in the strategical analysis in chapter 4, Aker BioMarine holds a 
strong competitive position in the industry with close to 62% of all annual harvest volumes, 
more than 80% of annual krill oil production volumes as well as operating on of the most 
technically advanced and modern fishing fleets among its peers (Aker BioMarine, 2020b). 
More so, it is the only krill fishery that controls the full value chain from harvest to sales and 
branding. To add to that, the krill fishing industry today embodies several features that create 
barriers to entry. Krill harvest vessels are expensive and require custom fitting and advanced 
technology, and additional support vessels are needed to harvest at the same levels of 
productivity as Aker BioMarine.  
Although competition is expected to increase slightly as new Chinese players enter the market, 
we believe that the company holds several strategical advantages to capture revenue growth 
in the near term and sustain this growth even in the longer term. 
6.2.2 Projection of Ingredients growth 
The Ingredients segment was Aker BioMarine's only segment until the Brands segment was 
introduced in 2019 after the acquisition of Lang. This segment remains at the core of the 
business today, with 68% of revenue coming from Ingredients in 2019. It is expected to 
maintain an important role in the firm's business model in the foreseeable future, as this 
division encompasses krill harvesting and the production of krill meal and krill oil. With the 
introduction of state-of-the-art krill harvesting vessel Antarctic Endurance to its operations 
during 2019, the segment has already seen an increase in its revenue contribution in 2020, with 
the full effect expected to be seen in 2021. With this addressable market in place for Aker 
BioMarine to manifest its presence, we expect future revenue growth in the Ingredients 
segment to be driven by three factors: vessel harvesting capacity, offshore production of 
products, and product price development. 
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Vessel harvesting capacity 
In 2019, Aker BioMarine received their new krill fishing vessel Antarctic Endurance, which 
ramped up their harvesting vessel fleet from two to three operative vessels. More than 1/3 of 
the annual total available harvesting quota for all krill fisheries in "Area 48" in the arctic was 
not harvested in the same year. 
Therefore, in an "Olympic Quota" fishing environment, introducing new vessels to the fleet 
will increase the maximum harvest for an individual operator. Although the players operating 
in the krill fishing industry today cannot fully exploit the currently allowed quota, Aker 
BioMarine is superior to its peers in krill harvesting. More precisely, and as showcased in 
figure 35, Aker BioMarine today captures ~62% of the total harvest in the Antarctic krill 
fishing region Area 48. On top of this, Aker BioMarine has also seen higher growth than its 
peers in the last four years, with a CAGR of ~15.4% relative to an overall market CAGR of 
9.6%. With recent investments in both technology for re-fits and advanced newbuilds, we 
believe this trend is likely to continue for Aker BioMarine in the coming years. 
Figure 35: Krill harvest development in Antarctic krill fishing regions 
Source: Aker BioMarine (2020b) 
All three of the company's vessels are custom-built to enable good krill harvest and onboard 
production and packaging. Central to the firm's highly effective harvesting approach is the use 
of support vessels that transport krill from the fishing grounds to the shore, so that harvesting 
vessels can remain on location to continuously fish and produce. The company has one support 
vessel in operation with another newbuild to be brought into operations in 2021. We anticipate 
a bounce in the harvest in 2021 once this vessel is introduced to the rotation and as Antarctic 
Endurance closes in on its full production run-rate. 






892 892 892 892
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Aker BioMarine Other Remaning quota Area 48 Precautionary quota Area 58
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Moreover, there are also entry barriers for competing firms to take a share of the remaining 
quota. In particular, it requires considerable investments in harvesting vessels, support vessels, 
and production factories to increase harvest capacity. Aker BioMarine has already carried out 
these investments, and it is likely to take years for competitors to make the necessary 
investments to follow suit. 
Based on the firm's projections of vessel harvesting capacity from mid-2020, we have 
developed a forecast for Aker BioMarine's production per vessel, presented in exhibit 37. Our 
forecasts are predominantly based on the company's projections from mid-2020 until 2024. 
Since the release of these forecasts, Aker BioMarine has announced that 2020 harvest numbers 
are likely to end up below their initial targets due to challenging ice conditions and various 
technical issues, reducing the utilized capacity of Antarctic Endurance to as low as 62% this 
year. This was also reflected in Q3 financials reported below initial guidance, which we will 
discuss later. For this reason, we have adjusted volumes in 2020 to reflect the issues mentioned 
earlier. According to the firm's projections, production rates are expected to reach their full 
capacity of ~74 000MT in 2022 before staying at maximum capacity until 2024. From 2024 
and onwards, we project that production will continue to increase moderately by ~2% annually 
due to technical advances and vessel upgrades. 
Exhibit 37: Historical and forecasted production on vessel level 
 Historical  Forecast 
In MT thousands 2017 2018 2019  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E 2030E 
                
Antarctic Sea 19.1 23.2 18.0  15.0 20.0 23.2 23.2 23.2 23.7 24.1 24.6 25.1 25.6 26.1 
Saga Sea 10.1 13.4 15.8  15.0 17.0 18.8 18.8 18.8 19.2 19.6 20.0 20.3 20.8 21.2 
Antarctic Endurance - - 7.1  19.2 30.4 32.0 32.0 32.0 32.6 33.3 34.0 34.6 35.3 36.0 
                
Vessel capacity 29.2 36.6 40.9   49.2 67.4 74.0 74.0 74.0 75.5 77.0 78.5 80.1 81.7 83.3 
Source: Aker BioMarine (2020b) and own forecasts 
Product production and shifts in pricing 
The offshore production aboard the company's three purpose-built vessels turns into three 
products: Pet meal, Aqua meal, and Nutra meal. Historically, the Aqua meal has been the most 
produced product aboard the vessels by a significant margin. Aker BioMarine has stated that 
this trend will continue as the capacity increase stemming from Antarctic Endurance will be 
mostly realized as Aqua meal. Hence, with this vessel at full capacity in 2021 along with the 
new support vessel, we expect to see a steep increase in production next year in line with Aker 
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BioMarine's forecasts of producing around 74 000MT between 2021 and 2024. The historical 
production split and related production forecasts are showcased in exhibit 38. 
Exhibit 38: Historical and forecasted production by product group 
 Historical  Forecast 
In MT thousands 2017 2018 2019  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E 2030E 
                
Aqua meal 23.8 31.6 33.2  40.8 55.8 60.5 60.5 60.5 61.7 62.9 64.2 65.5 66.8 68.1 
Nutra 4.6 4.3 6.4  7.0 10.1 11.9 11.9 11.9 12.1 12.4 12.6 12.9 13.1 13.4 
Pet meal 0.8 0.7 1.3  1.4 1.5 1.6 1.6 1.6 1.6 1.7 1.7 1.7 1.8 1.8 
                
Total production 29.2 36.6 40.9   49.2 67.4 74.0 74.0 74.0 75.5 77.0 78.5 80.1 81.7 83.3 
Source: Aker BioMarine (2020b) and own forecasts 
These products are predominantly sold through fixed contracts, with only 9% of Ingredients 
revenue coming from the spot market. Of the remaining revenue, 57% stems from long-term 
contracts, with the last 33% attributable to 1-year contracts and (or) predictable pricing (Aker 
BioMarine, 2020b).  
In 2019, 54% of the segment's revenue came from sales of the Superba Krill products. Since 
Superba Krill production is responsible for the highest margins among products in the 
Ingredients segment, Aker BioMarine is targeting to increase the portion of raw material 
sourced into the production of Superba Krill to lift margins and reach its 2024 EBITDA target 
of USD 200mn. The company has reported that a large part of costs is fixed, and scaling its 
business model is likely to cause higher revenue and higher percent-wise margins. The latter 
will be addressed later in this chapter. 
Since we have only access to limited information on each krill product's pricing, we have 
decided to analyze product pricing on an aggregate level. Aker BioMarine has reported 
historical prices per product since 2017 to be stable as they have maintained a steady portion 
of revenues from higher-margin and lower-margin product categories. In line with the firm's 
guidance, we believe that prices per product will increase in the coming years as more raw 
material is shifted towards high-margin krill oil production. From 2024 and onwards, we 
forecast price growth to flatten out. 
Total ingredients revenue 
As we have argued, 2020 has proved more challenging than expected for the company due to 
difficult weather conditions and technical issues preventing the new harvesting vessel from 
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reaching production levels in the upper range of its capacity. Although management has stated 
that COVID-19 has had limited to no impact on Aker BioMarine's activity in 2020, the 
pandemic has had a troubling effect on its outbound logistics and crew changes. Company 
officials expect these issues faced in 2020 to be short-lived. Nonetheless, growth is expected 
to be driven significantly in 2021 as the updated operative fleet will produce at near full run-
rate levels, which we consider is the primary driver of growth in this segment. 
Historically, Aker BioMarine's revenue growth has been nearly 1:1 with the growth in 
production output from its harvesting vessels. From 2022 and onwards, we expect revenue 
growth levels to stabilize as the expanded operational fleet settles into full run-rate production. 
The Ingredients segment is the firm's most mature segment, and our growth rate of ~2% 
starting in 2025 reflects our perception that the firm is likely to focus on finding growth in 
other segments once the krill harvest has reached its intended scale from the recent additions 
to the operative fleet. 
We find it hard to predict any future development in the total available quota for krill fisheries, 
and we determine that a steady 2% increase in revenue is suitable to account for potential 
future increases in the total allowable quota for krill harvesting. Finally, to derive our ultimate 
forecast of revenue stemming from the Ingredients segment, we combine Aker BioMarine's 
forecasts for increased production and per unit pricing along with our tweaks to estimates and 
various corrections to reflect our interpretation of projected growth. Our forecasts follow in 
exhibit 39. 
Exhibit 39: Forecast of Revenue from the Ingredients segment 
 Historical  Forecast 
In USD 2017 2018 2019  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E 2030E 
                
Production 29.2 36.6 40.9  49.2 67.4 74.0 74.0 74.0 75.5 77.0 78.5 80.1 81.7 83.3 
Annual growth - 25.3% 11.7%   20.3% 37.0% 9.8% 0.0% 0.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 
                
Pricing 1.2 1.2 1.2  1.3 1.3 1.3 1.3 1.3 1.4 1.4 1.4 1.4 1.4 1.4 
Revenue per unit 4.25 4.21 4.33  3.92 4.01 4.14 4.27 4.36 4.40 4.44 4.44 4.44 4.44 4.44 
                
Revenue (USDm) 124.2 154.2 177.2   192.7 270.3 306.4 316.0 322.3 332.0 342.1 348.9 355.9 363.0 370.3 
                
Nominal growth - 24.2% 14.9%   8.8% 40.2% 13.4% 3.1% 2.0% 3.0% 3.0% 2.0% 2.0% 2.0% 2.0% 
Source: Aker BioMarine (2020b) and own forecasts 
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6.2.3 Projection of Brands growth 
Brands are the newest of Aker BioMarine's segments and were incorporated in 2019 after 
acquiring mass-market private label and manufacturing company Lang Pharma. Since then, 
the firm has also launched its own brand development business, Epion, to operate under the 
Brands segment. In 2019, the Brands segment was only responsible for 32% of Aker 
BioMarine's revenue. The division is a central part of the company's strategic ambition to bring 
krill products to the masses by gaining direct access to large US retailers. By 2024, the firm 
expects to have 50% of its total group revenue from its Brands segment. Hence, this implies 
that aggregate growth in the Brands segment is anticipated to be higher than in the Ingredients 
segment in the coming five years. 
Furthermore, this segment completes Aker BioMarine as a krill harvesting company with a 
fully integrated value chain from krill harvesting to distribution and sales. This also includes 
sales channels in more than 65 countries, entering a global market to capitalize on. Through 
the self-developed brand Epion, Aker BioMarine aims to educate consumers and source 
marketing efforts to open new revenue opportunities for krill-based brands. Aker BioMarine 
is trying to break into a large and established dietary supplements market dominated by 
supplements coming from more conventional sources such as plants, meats, fish, fruits, and 
herbs. Hence, one of the company's most critical challenges in achieving revenue growth is to 
shift current end-consumers of dietary supplements towards krill-based products and capitalize 
on the overall growth in the Brands segment going forward. 
Lang revenue growth forecasting 
The acquisition of the US-based manufacturer and private label Lang Pharma has positioned 
the US brand segment through access to some of the largest North American retailers such as 
Target, CVS, Walmart, and Costco. This acquisition is the first step towards opening 
opportunities for revenue growth for krill-based products in these markets, and through Lang, 
the company will have access to the distribution channels of retailers in the US, accounting 
for ~85% of retail sales in this market. Historically, Lang Pharma's revenues grew 14% in 
2018 and only 1% in 2019. Given that Aker BioMarine targets a 50/50 ratio between 
Ingredients and Brands revenue in 2024, along with USD 100m to come from the Epion 
division, we estimate that the Lang division is set to deliver close to USD 200mn in revenues 
in 2024. 
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Based on the company's projections of growth in the coming years, along with our adjustments 
and critical considerations, we have developed a forecast of the Lang subdivisions revenue 
growth from 2020 to 2030. As of YTD Q3, Aker BioMarine has reported USD 77mn in 
revenues for the Lang division before eliminations. This is in line with Aker BioMarine's 
projected growth in 2020. We set our forecast for full-year 2020 to USD 107mn and a 19% 
nominal revenue growth to reflect this. Moreover, backed by our assessment of projected 
revenue growth in aquaculture and the dietary supplements market, we forecast two-digit 
growth until 2025 to reflect the firm's ambitions to generate 50% of total group revenue in the 
Brands segment. After this, we foresee growth to slow but stay at relatively high levels as Aker 
BioMarine becomes an established market participant in a fast-growing market. 
Exhibit 40: Forecast of revenues from Lang 
 Historical  Forecast 
In USD millions 2019 Q1-Q3 '20  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E 2030E 
               
Revenue 90.1 75.0  107.0 125.0 142.0 165.0 193.1 212.4 223.0 231.9 241.2 250.8 260.8 
Growth rate - -   18.8% 16.8% 13.6% 16.2% 17.0% 10.0% 5.0% 4.0% 4.0% 4.0% 4.0% 
               
Split               
Organic 1.2% -  19% 17% 14% 16% 17% 10% 5% 4% 4% 4% 4% 
Currency - -  - - - - - - - - - - - 
M&A - -  - - - - - - - - - - - 
Nominal growth 1.2% -   19% 17% 14% 16% 17% 10% 5% 4% 4% 4% 4% 
 
Reading into Aker BioMarine's takes on their future revenue growth, they anticipate that all 
of the Brands segment's revenue development will be exclusively organic. As we have 
discussed previously, the company has undertaken several investments to position itself for 
accelerated growth in the years to come. To add to this, Aker BioMarine has not communicated 
any intention to make further acquisitions in the foreseeable future. Consequently, we forecast 
that all of the future growth is attributable to organic revenue growth. 
Epion revenue growth forecasting 
The second component to revenue growth in the Brands segment is Aker BioMarine's self-
made consumer-based krill brand company Epion. Now, this sub-division has one brand in its 
portfolio, Kori, which is a krill oil supplement made for human consumption introduced to the 
market in 2020. Through Lang's retail infrastructure, the brand is currently in sale in several 
of the largest US retailers, including Target, CVS, and Walmart. Aker BioMarine has stated 
that one of the primary purposes of Epion is to educate consumers on the benefits of krill-
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based supplements and facilitate rapid growth in the US retail landscape. As a manifest to this, 
the company has pledged that all the EBITDA generated from this company is to be invested 
right back into the firm to grow and reach USD 100mn in sales by 2025. 
Exhibit 41: Forecast of revenues from Epion 
 Historical   Forecast 
In USD millions 2019 Q1-Q3 '20  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E 2030E 
               
Revenue - 9.3  14.0 36.0 56.5 74.0 88.1 99.1 105.0 110.3 115.8 120.4 125.2 
Growth rate - -   - 157.1% 56.9% 31.0% 19.0% 12.5% 6.0% 5.0% 5.0% 4.0% 4.0% 
               
Split               
Organic - -  - 157% 57% 31% 19% 13% 6% 5% 5% 4% 4% 
Currency - -  - - - - - - - - - - - 
M&A - -  - - - - - - - - - - - 
Nominal growth - -   - 157% 57% 31% 19% 13% 6% 5% 5% 4% 4% 
 
According to Aker BioMarine's preliminary reports on revenue for 2020, Epion has 
contributed around USD 9mn of the total USD 75mn generated from the Brands segment year-
to-date Q3 2020. This leaves our projections for the full financial year of 2020 at USD 14mn. 
Since the segment has no financial history, we rely on Aker BioMarine's growth estimates and 
the overall market's fundamental growth characteristics. As we have discussed, the company 
forecasts Epion to deliver revenues of around USD 100mn within the next five years. To 
achieve this, an estimated CAGR of 48% is required from projected 2020 revenues. 
We believe this effect will be most prominent in the near-term future, with ~157% sales growth 
forecasted in 2021. However, this growth is not substantial in absolute terms, and we foresee 
double-digit growth in revenue until 2025, which coincides with the firm's ambition of USD 
100mn in 2025. From this, we anticipate growth to flatten out at around 6-5%. 
Brands total revenue growth forecasting 
To obtain our ultimate forecast of Brands revenue growth, we sum up the projected revenue 
growth in the Lang and Epion sub-divisions. As outlined earlier, our final estimate reflects our 
assessment and adjustments of Aker BioMarine's rough revenue growth projections supported 
by several forecasts of growth in relevant markets and an analysis of the firm's future strategic 
development.  
The company's growth ambitions for the Brands segments are intensive, and at the core of 
these aspirations is the underlying aim of reaching a 50/50 Brands and Ingredients revenue 
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split by 2024. Ingredients revenue makes up ~63% of current YTD Q3 2020 revenues, and 
hence, Brands will have to deliver a higher revenue CAGR until 2024. 
Exhibit 42: Forecast of total Revenue from the Brands segment 
 Historical   Forecast             
In USD millions 2019 Q1-Q3 '20  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E 2030E 
               
Lang revenues              
Revenue 90.1 75.0  107.0 125.0 142.0 165.0 193.1 212.4 223.0 231.9 241.2 250.8 260.8 
Growth rate 1% -   18.8% 16.8% 13.6% 16.2% 17.0% 10.0% 5.0% 4.0% 4.0% 4.0% 4.0% 
               
Epion revenues              
Revenue - 9.3  14.0 36.0 56.5 74.0 88.1 99.1 105.0 110.3 115.8 120.4 125.2 
Growth rate - -   - 157.1% 56.9% 31.0% 19.0% 12.5% 6.0% 5.0% 5.0% 4.0% 4.0% 
               
Split               
Organic 1.2% -  34.3% 33.1% 23.3% 20.4% 17.6% 10.8% 5.3% 4.3% 4.3% 4.0% 4.0% 
Currency - -  - - - - - - - - - - - 
M&A - -  - - - - - - - - - - - 
Nominal growth 1.2% -   34.3% 33.1% 23.3% 20.4% 17.6% 10.8% 5.3% 4.3% 4.3% 4.0% 4.0% 
 
When consolidating the Brands sub-divisions' revenue growth, we see that our forecasts imply 
a 21% CAGR from current revenues to the revenue target in 2025. Thus, our estimates put us 
close to Aker BioMarine's ambition to generate USD 100mn in sales from Epion within five 
years and to produce around 50% of group revenue in the segment. As with any forecast of 
revenue far into the future, we have made some assumptions to the forecast based on our 
assessments of how the market will develop and what slice of the future market growth that 
Aker BioMarine itself will capture. For revenue growth beyond near-term targets, we expect 
the Brands segment to remain stable and settle at a revenue growth rate in line with the overall 
dietary supplements market. 
6.2.4 Forecasting of total revenue growth 
Finally, the forecast for total revenue growth is determined as a revenue growth product in 
Aker BioMarine's two business segments, Ingredients and Brands. As per our presented 
forecasting guidelines, we determined a time frame for our forecast from 2020 to 2030, where 
2030 is our continuing value year.  
Ultimately, our final forecast of total revenue growth has been derived through a combination 
of the bottom-up and the top-down approach in which we have paired growth estimates 
coming directly from the company with several external sources of relevant market 
 144
information and projections. We recognize that forecasting for more extended periods for a 
firm with limited historical information and operating in a young industry is related to several 
issues regarding uncertainty in the projections. Consequently, by combining the bottom-up 
and the top-down approach, we have attempted to establish bounds in our forecast as 
advocated by Koller et al. (2020). 
We are confident that the estimates represent our best assessment and interpretation of how 
the future development in the firm's revenue growth will look like, despite the noisiness that 
such estimates may carry. More so, all of the information presented in the introduction, our 
strategical analysis, and the historical financial analysis has been thoroughly examined and 
filtered into our equation before forecasting the revenue growth of Aker BioMarine. Finalizing 
this sub-chapter, we present our forecasts for revenue growth exhibit 43 as follows: 
Exhibit 43: Forecast of total revenue growth 
 Historical   Forecast 
In USD millions 2019 Q1-Q3 '20  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E 2030E 
               
Ingredients revenue             
Revenue 177.2 142.7  192.7 270.3 306.4 316.0 322.3 332.0 342.1 348.9 355.9 363.0 370.3 
Growth rate 15.0% -   8.8% 40.2% 13.4% 3.1% 2.0% 3.0% 3.0% 2.0% 2.0% 2.0% 2.0% 
               
Brands revenue              
Revenue 90.1 84.3  121.0 161.0 198.5 239.0 281.1 311.4 328.0 342.2 357.0 371.2 386.1 
Growth rate 1.0% -   34.3% 33.1% 23.3% 20.4% 17.6% 10.8% 5.3% 4.3% 4.3% 4.0% 4.0% 
               
Eliminations              
Eliminations (13.4) (13.9)  (15.4) (17.3) (20.2) (21.6) (23.5) (24.5) (24.8) (25.6) (27.1) (26.4) (26.5) 
Total revenue 246.2 213.1   298.4 414.0 484.7 533.4 579.9 619.0 645.3 665.5 685.8 707.8 729.9 
               
Split               
Organic 14.9% -  21.2% 38.8% 17.1% 10.0% 8.7% 6.7% 4.2% 3.1% 3.0% 3.2% 3.1% 
Currency - -  - - - - - - - - - - - 
M&A 53.4% -  - - - - - - - - - - - 
Nominal growth 68.3% -   21.2% 38.8% 17.1% 10.0% 8.7% 6.7% 4.2% 3.1% 3.0% 3.2% 3.1% 
 
Eliminations 
For clarity, according to Aker BioMarine's financial reports, the two operating segments, 
Brands and Ingredients, are managed separately, and financial results are measured on a stand-
alone basis. Therefore, the “eliminations” column is used to eliminate transactions between 
them. We have forecasted eliminations to make up 3-5% of total revenue annually, in line with 
historical eliminations. 
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6.3 Forecasting the financial statement 
This subchapter will focus on the financial statements forecasting, and more specifically, the 
income statements and the balance sheets over the next ten years. We forecast until Aker 
BioMarine to enter steady state in 2029. The short-term projections are presented in detail with 
changes each year before we generalize the medium- and long-term growth. The 
generalization is due to the large uncertainties in the coming years, making it more rational to 
assume an average ratio in those years, as justified previously in the chapter. The following 
subchapter aims to clarify and justify the selected ratios and forecasted metrics in our 
projections. The subchapter will commence with the ratio assumptions in our statements, 
followed by a justification of our assumptions. Lastly, the chapter will present the projections 
based on our assumptions. 
6.3.1 Income statement forecasting 
Exhibit 44: Summary of income statement ratios and assumptions 
 Historical  Forecast  CV 
In percentages (%) 2019  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E  2030E 
               
Revenue growth 68.3%  21.2% 38.8% 17.1% 10.0% 8.7% 6.7% 4.2% 3.1% 3.0% 3.2%  3.1% 
               
Operating expenses           
 
Cost of goods sold 
(% of revenue)  
49.1%  47.6% 46.6% 45.7% 44.8% 43.5% 42.6% 41.8% 40.9% 40.1% 39.3%  39.3% 
 
SG&A 
(% of revenue)  
31.1%  30.0% 30.5% 30.3% 30.3% 30.1% 29.4% 29.0% 28.7% 28.6% 28.3%  28.3% 
 
Other costs, net 
(% of revenue)  
1.3%  1.1% 1.1% 1.1% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0%  1.0% 
 
Depreciation 
(% of t-1 Net PP&E) 
11.7%  11.7% 11.7% 11.7% 11.7% 11.7% 11.7% 11.7% 11.7% 11.7% 11.7%  11.7% 
               
Non-operating items         
 
Amortization 
(% of t-1 intangible assets)  
13.0%  16.7% 16.7% 16.7% 16.7% 16.7% 16.7% 16.7% 16.7% 16.7% 16.7%  16.7% 
 
Interest expenses 
(% of t-1 total debt)  
11.1%  6.7% 6.7% 6.7% 6.7% 6.7% 6.7% 6.7% 6.7% 6.7% 6.7%  6.7% 
 
Interest income 
(% of t-1 marketable sec.)  
120%  2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0%  2.0% 
 
Other financial expenses 
(% of t-1 net debt equivalents) 
20.4%  2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0%  2.0% 
               
Taxes               
Statutory tax rate 23.0%  23.0% 23.0% 23.0% 23.0% 23.0% 23.0% 23.0% 23.0% 23.0% 23.0%  23.0% 
Operating tax rate 24.8%  24.0% 24.0% 24.0% 24.0% 24.0% 24.0% 24.0% 24.0% 24.0% 24.0%  24.0% 
* For visual purposes, we only include one historical year. 
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Gross margin (COGS/Revenue ratio) 
The historical ratio has been averaging 58.44% the past two years, which we consider high-
end. The rationale behind this is that Aker BioMarine depreciates their producing assets 
(vessels and Houston facility) in the reported COGS (~20% of the reported COGS is historical 
depreciation), and the reported COGS is derived from historical weighted average production 
costs. In accordance with IFRS, actual production expenses are capitalized in the inventory 
each quarter and new weighted average cost is calculated at quarter-end. Thus, weighted 
average costs at quarter-end are used as COGS in the following quarter. The lead times are 
typically six to nine months, depending on the product. The implication of this is that the 
reported COGS is different than the true COGS. For this reason, we have decided to split 
COGS and depreciation to paint a clearer picture of how Aker BioMarine's COGS will develop 
in our forecasts. 
Going forward, we expect the unit economic gross margin of the Ingredients segment to 
increase from ~59% to ~65% in 2022 due to a more favorable product mix with higher 
margins. I.e., shifting from Qrill Aqua (~30% margin) to krill oil products (between ~50-70% 
margin) will boost the overall margins. In the Brands segment, we expect a margin increase 
from ~47% in 2019 to ~52% in 2022, driven by the contribution from Epion and its high-
margin brand Kori, while the gross margin of Lang is assumed to be constant. The growth 
beyond 2020 will steadily increase as the high-margin products drive much of the projected 
growth. Based on the elements mentioned above, we expect the gross margin to be ~54% in 
2022, and following the company guidance, we presume this to be the medium-term margins. 
The long-term margins are expected to increase further as we judge the high margin products 
to be the primary driver of growth, projecting a long-term gross margin of ~61%. 
SG&A/Revenue 
In the past two years, the SG&A/Revenue ratio has been stable, averaging 30.02%, and we 
regard this to be the average ratio going forward. A ratio of 30% is consistent with the past 
performance of Aker BioMarine, and in line with the near-term company guidance (Aker 
BioMarine, 2020b). In the long-term estimates, the revenues to grow exponentially such that 
the SG&A/Revenue ratio will shrink as we move closer to steady state, to ~28%. However, 
the exception will be 2020 with the US launch of Kori, in which we have incorporated USD 




Aker BioMarine expects to use ~35 000MT of fuel annually with the delivery of the new 
vessel. The company has purchased call options for 100% of its expected fuel consumption 
for 2021 – 2024, making the line item fully fixed in this period. The fuel consumption is baked 
in the “other operating expenses” item and will not be forecasted separately. The hedging of 
the fuel is as follows (Aker BioMarine, 2020b): 
Figure 36: Aker BioMarine fuel hedging 
Source: Aker BioMarine (2020b) 
Aker BioMarine's 2019 cost of fuel was on average ~USD 750 per MT (Aker BioMarine, 
2020). The company is still exposed to the spread between the Rotterdam index and the local 
price in Montevideo, Uruguay, which historically has been USD 200-300 per MT. The total 
cost of the call options purchased are USD 9mn and will be settled in 2021. The company has 
not hedged the 2020 consumption, but the majority of volumes have already been purchased.  
Looking beyond the period of fuel hedging, it will be challenging to forecast both the fuel 
consumption due to potential acquisitions (divestitures) of vessels and companies, in addition 
to the fluctuation of the fuel prices. The fuel cost follows the brent oil price closely, and the 
forecasting of commodities is highly unreliable. Averaging a full cycle is a better proxy for 
future prices than forecasts (Petersen, Plenborg, & Kinserdal, 2017). Hence, we will not utilize 
commodity forecasts but rather look at historical averages to estimate long-term fuel prices. 
General operating costs 
A significant part of the “other operating costs” item consists of fuel expenses, while the rest 
consists of general operating costs such as IT, insurance, licensing fees, travel expenses, and 
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utilities. We expect these costs to continue to be a small percentage of the revenues going 
forward. These costs are expected to increase slightly with the integration and expansion of 
Lang before normalizing in 2022. 
Taxes, depreciation, and amortization  
In certain jurisdictions, Aker BioMarine pays taxes, and in the US, it pays state tax based on 
nexus (employee and inventory), whereas the tax-loss carryforwards offset federal tax. 
Further, the firm has significant historical net operating losses in Norway and expects to limit 
the annual tax expenses in 2020 and medium-term. The statutory taxes are not expected to 
change in the coming years. We assume the operating tax will be equal to the average between 
2018 and 2019 long-term. The discrepancies and uncertainties regarding the tax elements 
discussed and the ongoing lawsuit against Norway make it problematic to forecast the 
carryforwards' outcome. Thus, we do not adjust the projections for the potential upside in the 
court case or carryforwards. 
Further, over the past ten years, Aker BioMarine has invested ~USD 600mn in fixed assets, of 
which the majority is vessels with ~USD 314mn since 2015. We expect the maintenance of 
around ~USD 10mn quarterly from 2020 in depreciation in the vessels and the plant, with 
some increases in the future with the expected investment in a new protein plant, following 
Aker BioMarine (2020b). Further, the total depreciation is expected to be increased after 
accounting for the new Antarctic Provider, which is already included in the depreciation in 
COGS, which is adjusted. Lastly, the company has guided the quarterly amortization of ~USD 
4mn related to customer portfolios and the Flexitech production technologies. 
Other non-operating items and financial expenses 
The projections of non-operating items do not affect the fundamental valuation of Aker 
BioMarine's core operations as they do not run through the free cash flows. Still, they 
contribute to the forecasting as a checking account for whether there are any mistakes in 
forecasting the operating items. This being outlined, we do not expect any radical changes in 
the non-operating items going forward. 
The net financial items include interest payments to external lenders and Aker ASA, in 
addition to the FX effects. We decided to strip out the FX effects in our projections in the 
financial items as it is unfeasible to forecast long-term. Consequently, our forecast of "other 
financial expenses" is set to a rate of 2% of other non-current liabilities, including expenses 
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concerning a guarantee fee payable to the firm's parent company Aker ASA and does not take 
into account any future potential FX effects. In 2019, Aker ASA also converted NOK 1bn of 
debt to equity, which reduces the interest rate expenses going forward. The 2019 interest 
expense ratio is artificially high as the interest expense is based on last year's borrowing, not 
considering the debt conversion made by Aker ASA. 
Exhibit 45: Income statement forecast and net income reconciliation 
 Historical  Forecast   CV 
In USD thousands 2019  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E  2030E 
               
Revenue 246 170  298 367 414 023 484 666 533 350 579 894 619 024 645 274 665 508 685 758 707 809  729 879 
Cost of goods 
sold 
(120 792)  (142 012) (193 119) (221 549) (238 927) (252 254) (263 890) (269 579) (272 471) (275 147) (278 315)  (286 993) 
Gross margin 125 378  156 355 220 904 263 117 294 423 327 640 355 134 375 695 393 037 410 611 429 495  442 887 
               
SG&A (76 464)  (89 576) (126 450) (146 766) (161 509) (174 548) (182 219) (187 129) (191 001) (195 867) (200 144)  (206 385) 
Depreciation (28 077)  (32 000) (29 938) (40 255) (45 662) (48 691) (51 299) (53 063) (55 313) (57 048) (58 784)  (60 674) 
Other costs (3 221)  (3 198) (4 394) (5 092) (5 547) (5 971) (6 310) (6 512) (6 649) (6 783) (6 931)  (7 147) 
Special op. items 7 346  - - - - - - - - - -  - 
EBITA 24 962  31 581 60 123 71 005 81 705 98 430 115 306 128 990 140 073 150 913 163 636  168 681 
               
Operating taxes (6 182)  (7 566) (14 404) (17 011) (19 574) (23 581) (27 624) (30 903) (33 558) (36 155) (39 203)  (40 411) 
NOPAT 18 780   24 015 45 719 53 994 62 131 74 849 87 682 98 088 106 516 114 758 124 433   128 270 
               
Reconciliation                           
               
NOPAT 18 780  24 015 45 719 53 994 62 131 74 849 87 682 98 088 106 516 114 758 124 433  128 270 
               
Amortization (14 854)  (16 000) (13 326) (11 099) (9 244) (7 699) (6 413) (5 341) (4 448) (3 705) (3 086)  (2 570) 
               
Interest expense (22 785)  (28 144) (16 419) (20 979) (21 351) (20 620) (19 717) (18 576) (17 625) (16 589) (15 615)  (14 732) 
Interest income 288  130 185 594 633 822 1 185 1 220 1 245 1 342 1 422  1 490 
Other fin. 
expenses 
(3 599)  (1 312) (1 036) (2 567) (3 422) (3 885) (4 118) (3 695) (3 049) (2 479) (1 652)  (747) 
Net finance 
items 
(26 097)  (29 327) (17 271) (22 952) (24 140) (23 683) (22 650) (21 052) (19 429) (17 726) (15 845)  (13 989) 
               
Special op. items (7 346)  - - - - - - - - - -  - 
               
Non-op. taxes 5 767  6 745 3 972 5 279 5 552 5 447 5 210 4 842 4 469 4 077 3 644  3 218 
Net income (23 751)   (14 567) 19 095 25 222 34 299 48 913 63 828 76 537 87 107 97 404 109 147   114 928 
 
6.3.2 Balance sheet forecasting 
The following subchapter will present and justify the assumptions in our projections of the 
balance sheet. The balance sheet will be presented at the end of the subchapter after the 
rationale and explanations. The following balance sheet ratios and assumptions will function 
as the quantitative basis of our balance sheet forecasts and is summarized in exhibit 46 as 
follows: 
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Exhibit 46: Summary of balance sheet ratios and assumptions 
 Historical  Forecast   CV  
In percentages (%) 2019  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E  2030E Driver 
                
Operating working capital             
Operating cash 3.0%  6.0% 4.0% 4.0% 4.0% 3.0% 3.0% 3.0% 3.0% 3.0% 3.0%  3.0% % of revenues 
Inventories 286.2  310.5 300.0 286.2 280.0 280.0 280.0 280.0 280.0 280.0 280.0  280.0 COGS days 
Receivables 55.4  55.4 55.4 55.4 54.3 53.2 52.2 52.2 52.2 52.2 52.2  52.2 Revenue days 
Other current assets 54.7  54.7 54.7 54.7 53.6 52.5 51.5 51.5 51.5 51.5 51.5  51.5 Revenue days 
Accounts payable 70.5  58.5 58.5 58.5 58.5 58.5 58.5 55.6 50.0 50.0 50.0  50.0 COGS days 
Accrued expenses 39.0  26.8 26.8 26.8 26.8 26.8 26.8 26.8 25.0 25.0 25.0  25.0 Revenue days 
Other current 
liabilities 
3.5  3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5  3.5 Revenue days 
                
Fixed assets               
PP&E incl. leases 130%  100% 96.9% 93.9% 91.0% 88.2% 85.4% 85.4% 85.4% 85.4% 85.4%  85.4% % of revenues 
Other non-current 
receivables 
0.1%  0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1%  0.1% % of revenues 
                
Non-operating assets             
Investments in equity 0.1%  0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1%  0.1% % of revenues 
Other financial assets -  3.0% 2.2% 1.9% 1.7% 1.6% - - - - -  - % of revenues 
Excess cash 2.5%  - 4.9% 4.6% 6.0% 8.6% 9.8% 9.6% 10.0% 10.3% 10.5%  10.5% % of revenues 
                
Goodwill and other intangibles             
Goodwill 38.4%  31.7% 22.8% 19.5% 17.7% 16.3% 15.3% 14.7% 14.2% 13.8% 13.4%  13.0% % of revenues 
Other intangibles 38.9%  26.7% 16.0% 11.4% 8.6% 6.6% 5.2% 4.1% 3.3% 2.7% 2.2%  1.8% % of revenues 
 
Net working capital (“NWC”) 
The operating NWC has steadily increased the past three years, driven by higher balances in 
accounts receivable and accounts payable that follows the development in revenues and costs. 
The inventory balance has increased due to inventory build-up. Aker BioMarine has also 
increased the number of operational vessels from Q1 2019 with Antarctic Endurance, which 
resulted in further inventory build-up. The inventory build-up concerns production 
consumables and fuel, contributing to an increasing amount of working capital being tied up. 
In Q2 2020, the company stated that the total krill inventory was close to 35 200MT, up from 
27 500MT in the same period last year, implying a YoY inventory growth of ~28%, supporting 
its growth strategy going forward (Aker BioMarine, 2020b). 
A substantial part of the inventory's increase comes from the feed segment, as Aker BioMarine 
has strategically increased the inventory to hold and maintain a safety stock. Accordingly, our 
forecast for 2020 attempts to reflect the inventory build-up as signaled by the company this 
year to include the most up-to-date information available of the company's financials. 
Projecting the NWC as a percentage of revenues medium-term, we expect it to rise to ~50% 
as Antarctic Endurance operating on maximum capacity and continuing growth will affect all 
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the working capital aspects. Having the large-scale vessel, Antarctic Endurance, operating on 
maximum capacity will increase the inventories. Further, the acquisition of Lang is also 
expected to increase the inventories. On average, pharmaceutical companies underperform on 
working capital management, as the average pharma company holds 180 days of finished 
goods in inventory compared to consumer goods that only hold 60 days (Keeling et al., 2010). 
One implication of the acquisition is that we expect the inventory to increase in the coming 
years, tying up capital. We do not expect any substantial changes in the ratio between account 
payables and COGS in the years going forward, but we see some improvement in account 
payable COGS days as the firm nears its steady state. 
Projecting NWC long-term, we consider the ratios to normalize in a steady state. We believe 
the growth investments require much capital tied in operations predominantly in the near term. 
When Aker BioMarine reaches a steady state, the company does not need the same amount of 
capital tied in the operations as a growth company does. Consequently, from 2026, the ratio 
will converge towards normalization at 48-49%. 
Fixed operating assets 
The fixed operating assets consist of PPE and other intangible assets such as advances to 
customers and software.  Over the past ten years, Aker BioMarine has undergone substantial 
investments in their fixed assets, mostly in vessels. In the past two years, the Net PPE to 
revenues has been ~150%, reflecting the new vessel's investment. Medium-term, we expect 
this ratio to decrease as Antarctic Endurance nears the finalization of payments is due in 2021. 
The last large expansion that is planned is the investment in the protein plant of ~USD 13.5mn. 
We do not expect any large investments for expansion beyond this, but instead, purchase to 
replace parts and maintain existing assets suffering from wear and tear. Hence, we deem the 
asset categories to follow the revenues as a fixed percentage. The item “other intangible assets” 
surged ~65% from 2018 to 2019 due to the acquisition of Lang (Aker BioMarine, 2020a).  
We do not believe this line item will experience any substantial changes in the coming years. 
Consistent with our pre-assumption that Aker BioMarine is not expected to engage in any 
acquisition activity in the foreseeable future, other intangibles will remain unchanged net any 
reduction in value from amortization. 
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Non-operating assets and liabilities 
The projections of these objects do not affect the valuation of the company’s core business 
operations as they do not affect the free cash flows. They still need to be accounted for when 
we are determining the value of the whole company. We will try to estimate these assets' fair 
values (liabilities) and add them back to the total valuation. The projections of these objects 
also serve to mitigate potential flaws and mistakes in the forecasting. We do not assume any 
significant changes in these objects, except for the non-current derivatives, where derivatives 
from fuel hedging will be capitalized. 
Exhibit 47: Forecasted balance sheet statement and reconciliation to total funds invested 
 Historical  Forecast  CV 
In USD thousands 2019  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E  2030E 
               
Operating working capital              
Operating cash 7 385  17 902 16 561 19 387 21 334 17 397 18 571 19 358 19 965 20 573 21 234  21 896 
Inventories 94 725  120 808 158 728 173 738 183 287 193 510 202 436 206 800 209 019 211 071 213 502  220 159 
Receivables 37 393  45 322 62 890 73 621 79 396 84 598 88 500 92 253 95 146 98 041 101 194  104 349 
Other current assets 36 871  44 689 62 012 72 593 78 288 83 417 87 265 90 965 93 818 96 673 99 781  102 893 
Accounts payable 23 340  22 777 30 974 35 534 38 321 40 458 42 325 41 075 37 325 37 691 38 125  39 314 
Accrued expenses 26 311  21 929 30 430 35 622 39 200 42 621 45 497 47 426 45 583 46 970 48 480  49 992 
Other current liabilities 2 342  2 839 3 940 4 612 5 075 5 518 5 890 6 140 6 333 6 525 6 735  6 945 
Operating working capital 124 381  181 176 234 849 263 572 279 708 290 325 303 060 314 736 328 708 335 172 342 371  353 046 
               
Fixed assets               
PP&E, incl. leases 318 921  298 367 401 188 455 082 485 270 511 262 528 842 551 268 568 555 585 854 604 693  623 548 
Other non-current receivables 145  176 245 286 315 343 366 381 393 405 418  431 
Invested capital, ex. 
goodwill 
443 448   479 719 636 282 718 940 765 294 801 929 832 268 866 385 897 656 921 431 947 482   977 025 
               
Goodwill and other 
intangibles 
190 297  174 297 160 971 149 872 140 628 132 928 126 516 121 175 116 726 113 022 109 936  107 366 
Invested capital, incl. 
goodwill 
633 745   654 016 797 252 868 812 905 921 934 858 958 784 987 560 1 014 382 1 034 452 1 057 418   1 084 391 
               
Non-operating assets              
Investments in equity 260  260 260 260 260 260 260 260 260 260 260  260 
Other financial assets -  9 000 9 000 9 000 9 000 9 000 - - - - -  - 
Excess cash 6 225  - 20 436 22 396 31 824 49 984 60 728 61 979 66 821 70 859 74 227  159 465 
Total funds invested 640 230   663 276 826 948 900 469 947 006 994 102 1 019 773 1 049 799 1 081 464 1 105 571 1 131 905   1 244 116 
               
Reconciliation                             
               
Non-current interest-bearing 
debt 
372 473  197 473 265 530 271 085 260 167 246 696 229 666 215 465 199 999 185 476 172 296  159 902 
Current interest-bearing debt 47 591  47 591 47 591 47 591 47 591 47 591 47 591 47 591 47 591 47 591 47 591  47 591 
Debt equivalents 65 618  51 823 128 343 171 087 194 244 205 897 184 770 152 460 123 964 82 611 37 329  79 751 
Derivative liabilities -  - - - - - - - - - -  - 
Capitalized operating leases -  - - - - - - - - - -  - 
Total debt and its 
equivalents 
485 682  296 887 441 464 489 763 502 002 500 184 462 027 415 516 371 554 315 678 257 217  287 244 
               
Paid-in equity 345 230  569 401 569 401 569 401 569 401 569 401 569 401 569 401 569 401 569 401 569 401  569 401 
Translation differences 154  154 154 154 154 154 154 154 154 154 154  154 
Retained earnings (190 838)  (203 166) (184 071) (158 850) (124 551) (75 638) (11 809) 53 247 122 933 195 986 272 389  347 092 
Dividend payable -  - - - - - - 11 481 17 421 24 351 32 744  40 225 
Equity and its equivalents 154 547   366 389 385 484 410 706 445 004 493 918 557 746 634 283 709 910 789 893 874 688   956 872 
               
Total funds invested 640 230   663 276 826 948 900 469 947 006 994 102 1 019 773 1 049 799 1 081 464 1 105 571 1 131 905   1 244 116 
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Following Koller et al. (2020), we utilize the “excess cash” and “debt equivalents” line items 
in our reconciliation to total funds invested in making the balance sheet balance. The tweaks 
made are consistent with our assumptions concerning Aker BioMarine's future capital 
structure. As the firm transitions towards a steady state and increased profits instead of 
intensive growth, we project that the increased funds will be put to use to increase the equity 
portion. More so, we anticipate that the firm will deploy a capital structure matching its mature 
peers in the pharmaceutical and biotech industry. This will also include paying a dividend 
from the year 2026. 
6.4 Forecasts of FCF and ROIC 
In the final step of our Aker BioMarine performance forecasting, we use our completed 
financial statement forecasts to calculate future free cash flow and return on invested capital. 
These measures will serve as the basis for the up-coming fundamental valuation analysis in 
chapter 8. As we discussed in the introduction to our thesis, we will also need a forecast of 
economic profit to produce a valuation estimate from this methodology. However, as this 
requires estimating the firm's weighted average cost of capital, this forecast will be presented 
once our WACC is derived in the subsequent chapter on WACC estimation. 
6.4.1 Forecast of free cash flow 
Exhibit 48: Aker BioMarine's forecasted free cashflow 
 Historical  Forecast  CV 
In USD thousands 2019  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E  CV 
               
NOPAT 18 780  24 015 45 719 53 994 62 131 74 849 87 682 98 088 106 516 114 758 124 433  128 270 
Depreciation 28 077  32 000 29 938 40 255 45 662 48 691 51 299 53 063 55 313 57 048 58 784  60 674 
Gross cash flow 46 857   56 015 75 657 94 248 107 793 123 540 138 981 151 151 161 829 171 806 183 217   188 944 
               
Decrease (increase) in WC  (69 876) 
 (56 795) (53 673) (28 723) (16 136) (10 616) (12 736) (11 675) (13 973) (6 463) (7 199)  (10 675) 
Less: Changes in net PP&E  (109 184) 
 (11 446) (132 759) (94 148) (75 850) (74 683) (68 879) (75 489) (72 600) (74 347) (77 623)  (79 529) 
Decrease (increase) in other 
assets, net of liabilities  
1 880  (31) (68) (42) (29) (27) (23) (16) (12) (12) (13)  (13) 
Investment in goodwill and 
other intangibles 
(76 139)  - - - - - - - - - -  - 
               
Free cash flow (FCF) (206 462)   (12 257) (110 844) (28 665) 15 778 38 213 57 343 63 971 75 245 90 983 98 382   98 726 
 
Consistent with the new support vessel's anticipated introduction in 2021 and a consequent 
spike in revenues, we anticipate that 2020, 2021 and 2022 will result in negative free cash 
flows. From 2023 we expect a robust and gradual increase in FCF due to improved margins 
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and capitalization on scale benefits. Our forecasts lead to an FCF of USD 98.4mn as the 
company reaches its steady state in 2029. 
6.4.2 Forecast of return on invested capital 







Percentages (%) 2019 
 
2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E 
 
2030E                
Operating ratios (% of revenue) 
             
EBITA-to-Revenue 10.1%  10.6% 14.5% 14.7% 15.3% 17.0% 18.6% 20.0% 21.0% 22.0% 23.1%  23.1% 
COGS, adjusted 49.1%  47.6% 46.6% 45.7% 44.8% 43.5% 42.6% 41.8% 40.9% 40.1% 39.3%  39.3% 
SG&A 31.1%  30.0% 30.5% 30.3% 30.3% 30.1% 29.4% 29.0% 28.7% 28.6% 28.3%  28.3% 
Other operating costs 1.3%  1.1% 1.1% 1.1% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0%  1.0% 
Depreciation 11.4%  10.7% 7.2% 8.3% 8.6% 8.4% 8.3% 8.2% 8.3% 8.3% 8.3%  8.3% 




          
 
 
ROIC (% of revenue)  
 
          
 
 
Operating working capital 50.5%  60.7% 56.7% 54.4% 52.4% 50.1% 49.0% 48.8% 49.4% 48.9% 48.4%  48.4% 
PP&E, incl. Leases 129.6%  100.0% 96.9% 93.9% 91.0% 88.2% 85.4% 85.4% 85.4% 85.4% 85.4%  85.4% 
Other receivables 0.1%  0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1%  0.1% 




          
 
 
Capital turnover (ex. goodwill) 0.56  0.62 0.65 0.67 0.70 0.72 0.74 0.74 0.74 0.74 0.75  0.75 
Pre-tax ROIC (ex. goodwill) 5.6%  6.6% 9.4% 9.9% 10.7% 12.3% 13.9% 14.9% 15.6% 16.4% 17.3%  17.3% 




          
 
 
After-tax ROIC, ex. goodwill 4.2%   5.0% 7.2% 7.5% 8.1% 9.3% 10.5% 11.3% 11.9% 12.5% 13.1%   13.1% 
After-tax ROIC, incl. goodwill 3.0%   3.7% 5.7% 6.2% 6.9% 8.0% 9.1% 9.9% 10.5% 11.1% 11.8%   11.8% 
 
Since Aker BioMarine has not created value historically, our forecasted ROIC differs 
significantly from that of the historical ROIC that we presented in chapter 5. Consequently, 
the future ROIC will proliferate in line with our projections of the effect on future financial 
coming from the shift from intensive growth to the production of higher-margin products and 
overall increased profit margins. In the longer term, we believe that the firm, in its steady state, 
will trend toward the industry ROIC. This is consistent with the argumentation that we 
provided in the strategic analysis and our assessment of its future financial growth potential. 
The improvement of ROIC in 2020 is limited to reflect the latest information and guidance 
that Aker BioMarine has released so far for 2020 financials. 
To be clear, while one may claim that high growth projections such as the ones forecasted are 
not correlated with growth in profit margins, we argue that this is not entirely the case for Aker 
BioMarine. This is predominantly linked to one structural part of Aker BioMarine's business 
model, that is, that a vast portion of costs is fixed. According to the company itself, fixed costs 
make up ~65% of costs. Therefore, once scale is achieved on investments, the firm is expected 
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to deliver significantly improved returns. Furthermore, the company has stated that it is near 
fully invested and that the firm is now in an ideal strategic position to extract the full financial 
benefits of these investments in the coming years. 
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This chapter will present the frameworks used in the analysis of Aker BioMarine’s cost of 
capital. The chapter introduces fundamental theories for capital cost before discussing key 
elements that affect Aker BioMarine's cost of capital, such as the risk-free rate, market risk 
premium, equity beta, and liquidity premium. Finally, we will calculate the different beta 
values and capital costs to compute the weighted cost of capital for Aker BioMarine. The costs 
of capital estimated in this chapter will serve as the discount rate for the valuation analysis in 
the subsequent chapters. 
The capital cost should reflect the returns an investor should expect to achieve with a similar 
investment with equal risk (Dahl et al., 1997). The return should compensate for inflation, the 
time value of money, and the risk associated with the investment itself (Kaldestad et al., 2016). 
The cost of capital may be utilized in two different ways, either as a measure of profitability 
or as the discount rate in a valuation. If employed as a measure of profitability, a company's 
profitability will be measured based on the return of equity being more significant than the 































cost of capital 
Chapter 9: 
Relative valuation 
Step: 1 Step: 2 Step: 3 Step: 4 Step: 5 
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7.1 Framework for cost of capital 
7.1.1 Theories for costs of equity 
There are several models one can utilize to estimate a company's cost of equity. The most 
common forms are factor models and the single-index model. We will briefly present the 
different factor models, but the focus will be on the single-factor model.  
7.1.2 Factor models 
The factor models are characterized such that investors only are compensated for systematic 
risk. Therefore, investors should only expect to be compensated for carrying the non-
diversifiable risk, not firm-specific risk. The factor models incorporate macroeconomic, 
fundamental, and statistical factors to determine the market equilibrium and calculate the 
required return rate. There are primarily two types of factor models: single factor and multiple-
factor models. 
Single-factor model 
In perfect capital markets, a particular factor model is called the capital asset pricing model 
(“CAPM”). Perfect capital markets meaning the investors have diversified all firm-specific 
risk, and only being compensated for the systematic risk (Knivsflå, 2020c). CAPM is one of 
the most implemented models for estimating equity return, and it assumes that all investors 
are well-diversified and utility-maximizing.  
 𝑟𝐸 = 𝑟𝑓 + 𝛽[𝐸(𝑟𝑚) − 𝑟𝑓] Eq.16 
Where,  𝑟𝑓 = Risk-free rate at time t 
  𝑟𝑚 = Return on the market portfolio at time t 
  𝛽 = Beta (systematic risk) 
The estimated return of equity is the return rate an investor would acquire with a risk-free 
investment plus a premium for the systematic risk. The company's beta, which is the market 
sensitivity, represents what systematic risk premium the investor should require in addition to 
the risk-free rate. Thus, the beta value may be interpreted as a relative measure of the 
systematic risk by investing in the company's equity.  
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The beta is expressed as the covariation between the company's return and the market portfolio 
multiplied by its relative volatility compared with the market portfolio. The beta of the market 
portfolio is 1, while the beta value of a risk-free investment is 0 (Knivsflå, 2020c). 




Where,  𝑉𝑎𝑟(𝑟𝑚) = Variance of the market portfolio 
𝐶𝑜𝑣(𝑟𝑖 , 𝑟𝑚) = Covariance between the market portfolio and the selected 
company 
Multiple factor models  
The multiple-factor models come in many forms and variants, but we will present the two 
most renowned and employed models in asset pricing. 
Fama and French's three-factor model 
One of the most adopted multiple factor models is Fama and French's three-factor model. The 
asset pricing model from 1992 expands the CAPM by adding both size risk and value risk 
factors to the systematic market risk. The model incorporates the fact that both value- and 
small-cap stocks often outperform the market. When these two factors are integrated, the 
model adjusts for these outperforming tendencies, which is better to evaluate asset managers' 
performance further. 
 𝑟𝑖 − 𝑟𝑓 = 𝛼𝑖𝑡 + 𝛽1(𝑟𝑚 − 𝑟𝑓) + 𝛽2𝑆𝑀𝐵 + 𝛽3𝐻𝑀𝐿 + 𝜖𝑖𝑡 Eq.18 
Where, ri = Total return of stock i at time t 
rf = Risk-free rate at time t 
rm = Return on the market portfolio at time t 
ri – rf= Excess return 
rm  − rf = Excess return on the market portfolio 
SMB = Size premium (small minus big) 
HML = Value premium (high minus low) 
β1,2,3 = Factor coefficients 
The model suggests that companies with returns correlated with small stocks or high book-to-
market value stocks will be given a risk premium. Even though the model may have better 
explanatory power than the CAPM, it has its shortcomings.  
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The three-factor model is based on US empirical evidence but does not have a better theoretical 
grounding than the CAPM. Secondly, as the model uses factor coefficients to calculate the 
different risk premiums in the model, finding this beta for three different factors is quite 
complicated as one runs into circular calculation problems (Koller et al., 2020). When different 
calculations are conditional on each other, it makes the estimates challenging to compute 
accurately.  
Arbitrage pricing theory (“APT”) 
The APT model the second multi-factor model we are presenting. The idea behind it is based 
on the concept that an asset’s returns can be predicted using the linear relationship between 
the asset's expected return and several macroeconomic variables that adequately capture the 
market's systematic risk (Bodie, Kane, & Marcus, 2018): 
 𝐸(𝑟𝑖) = 𝐸(𝑟𝑓) + (𝐸(𝑖) − 𝐸(𝑟𝑓) × 𝛽𝑛 Eq.19 
Where, E(r)i = Expected return on the stock 
𝑟𝑓 = Risk-free rate at time t 
𝛽𝑛 = Sensitivity of the stock price to macroeconomic factor n  
E(i) = Risk premium associated with factor i 
As the model opens for multiple factors, it is difficult to determine the appropriate number of 
factors and the model's factors. The model itself appears quite sophisticated and reliable, but 
the above-mentioned “flaws” make the implementation of the model challenging. 
7.1.3 Choice of the model when estimating the cost of equity 
To approximate a reasonable estimation of the cost of equity for Aker BioMarine, we will 
employ an extended version of the CAPM that includes a liquidity premium. The liquidity 
premium is added to the cost of equity, and the size of the premium depends on three 
conditions: the degree of market failure, degree of illiquidity, and firm-specific risk. The 
premium intends to compensate the investors for illiquidity risk, which is not compensated in 
the traditional CAPM. As there is no simple theory or framework to compute the correct 
liquidity premium, the premium will be estimated with a discretionary approach (Knivsflå, 
2020c). Aker BioMarine is now publicly traded on Merkur Market, which makes the stocks 
easily tradeable.  
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On the other hand, it is less liquid than the stocks on Oslo Børs main list. Merkur Market only 
requires 30 different shareholders, while Oslo Børs requires 100, and the free float is also 
lower than what is required on Oslo Børs.  
Lastly, the firm-specific risk with Aker BioMarine is slightly higher than what we expect from 
the public companies at Oslo Børs. All these elements are pulling in the direction of a liquidity 
premium. The ownership structure is concentrated as Aker Capital AS owns 77.8% and is the 
only owner with above 1.5% ownership, with the remaining 22.2% free float (Aker BioMarine, 
2020a). The remaining shareowners hold an insignificant stake in the company and will have 
little influence regarding dividend policy, investments, and critical strategic decisions. We, 
therefore, deem the stock to be slightly less liquid than other companies with dispersed 
ownership. The significant degree of ownership concentration will increase the risk that the 
minority will be locked with illiquid stocks (Rubin, 2007). 
We also consider the firm-specific risk related to Aker BioMarine to be above-average, and 
investors should be compensated for that. Aker BioMarine just became public recently and 
has disclosed limited previous financial information. Consequently, we believe a liquidity 
premium are required. 
 𝑟𝐸 = 𝑟𝑓 + 𝛽[𝐸(𝑟𝑚) − 𝑟𝑓] + 𝝀 Eq.20 
Where, λ = Liquidity premium  
Risk-free rate (“Rf”) 
The risk-free interest rate is the hypothetical return an investor can expect without taking on 
risk. If an investment does not give a higher expected return than the risk-free interest rate, it 
will make more sense to allocate capital to a risk-free return. Government bonds or NIBOR 
rates are often used as measurements of risk-free interest rates in the Norwegian market, and 
international companies often utilize US government bonds as the risk-free rate. In theory, 
risk-free interest rates should be free of both bankruptcy and default risk, but this is rarely met 
in practice. Further, the risk-free rate should be in the same currency as the company's cash 
flows are estimated.  
Not all government bonds can be labeled as risk-free, and some even have high default risk. 
Koller et al. (2020) claim that 10-year government bonds are more liquid than 30-year 
government bonds and contain a lower reinvestment risk.  
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Reinvestment risk will arise if the investor's actual return deviates from the expected return. 
The factors mentioned above indicate that neither Norwegian government bonds nor the 
Norwegian interbank overnight rate (“NIBOR”) alone may be suitable as proxies for the risk-
free rate.  
When using the Norwegian government bonds, we must deduct the risk premium 
corresponding to an AAA rating, the Norwegian bonds rating (World Government Bonds, 
2020). If one uses the NIBOR rate, a deduction must be made by the risk premium based on 
the average credit rating of the banks operating in Norway, which is AA. (Knivsflå, 2020d). 
Both advantages and disadvantages with the deployment of both governments' yields and 
NIBOR rates should be discussed before deciding what interest rate we use in the analysis.  
Knivsflå (2020d) argues that the three-month (“3M”) NIBOR rate may be utilized to measure 
the risk-free rate. The 3M NIBOR is short-term fixed-income security that is virtually risk-
free instead of investing in long-term government securities, where an investor or company 
risks impairment. The 3M NIBOR is profoundly affected by current monetary policy and will 
be exposed to more fluctuations than the long-term interest rate. As a result, the required rate 
of return will be more volatile. This implies that the government bonds may be more suitable 
as the long interest rates vary less than short-term rates and provide a more stable return rate. 
However, the downside is that it can be embedded both a liquidity premium and a premium 
for inflation risk, which indicates that the long interest rate is not risk-free (Kaldestad et al., 
2016). We decided to utilize the US government bond in combination with the Norwegian to 
proxy the normalized long-term risk-free rate. The method is further discussed later in the 
chapter.  
Market risk premium (“MRP”) 
Berk & DeMarzo (2020) define MRP as the excess return of the risk-free rate an investor can 
get by investing in the market portfolio. Mathematically, MRP can be derived as the difference 
between the expected returns in the market portfolio minus the risk-free rate. There are two 
standard alternatives for calculating the MRP, where Berk & DeMarzo (2020) advocate using 
the average MRP's historical data. Different methods for calculating the MRP have given rise 
to different answers to the historical MRP, but the common denominator is that the US stock 
market has been used as a basis for the surveys.  
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Koller et al. (2020) contend that the US stock market may be characterized by survivorship 
bias as it historically has given large excess returns compared to similar countries. For the 
same reason, many recommend deducting this premium when determining a forward-looking 
MRP, assuming the US stock market will not replicate its excess return relative to other 
countries.  
The second method for determining the MRP is based on questionnaires about the future MRP. 
This method's strength is that it provides an impression of what professional industry players 
envisage in the time ahead and that the premium reflects the expected future returns rather 
than the historical ones. It should be mentioned that the estimates that emerge in these surveys 
are very likely to be characterized by historical data. This implies that the estimations that 
emerge will, to a greater extent, indicate what practitioners use, rather than what the “true” 
MRP will be. PwC (2019) conducts an annual survey called “Risikopremien i det norske 
markedet,” and is based on professional investors' opinions in the Norwegian Association of 
Financial Analysts (“NFF”). 
Lastly, it is conceivable that companies operating in emerging markets will be exposed to 
various market risk types. It is, therefore, standard for a surcharge founded on a land-based 
risk premium. It is stated in the annual report of Aker BioMarine for 2019 that the group 
primarily has activities in the Antarctic waters and the US Collected data presented by 
Damodaran (2020b) show that the US, like Norway, is AAA-rated, which also indicates that 
you do not need a surcharge for land-based risk when operating. It is therefore considered 
reasonable not to impose a land-based risk premium in Aker BioMarine’s case. 
Systematic risk (β) 
The CAPM uses the beta to measure the systematic risk of security concerning the aggregate 
market portfolio. Systematic risk, in turn, can be described as a non-diversifiable risk. In the 
CAPM world, only this type of risk can an investor require a return on, as unsystematic risk 
can be diversified away by holding a broad portfolio. The market portfolio is defined in theory 
as all accumulated assets, i.e., both listed and non-listed assets. In practice, this is problematic 
because securities that are not listed on the stock exchange are not traded on public platforms 
available to the public. Therefore, practitioners and theorists lean towards measuring the 
covariation of a stock against a broadly diversified portfolio.  
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The main index at Oslo Børs may be an alternative, but considering how exposed the index is 
to energy, it can be argued that the index is not to be described as “broadly diversified.” 
Therefore, other alternatives can be the S&P500 or MSCI World Index, although S&P can 
also be heavily weighted towards a specific sector, such as technology. If a regression beta, 
often referred to as the equity beta, is greater than 1 it indicates that the security's share price 
has fluctuated more than the market index.  
Similarly, a stock with an equity beta <1 have historically softer fluctuations, while a beta 
value <0 will suggest that companies are countercyclical and therefore move in the opposite 
direction of the market - within the period in which the regression analysis has been carried 
out. We distinguish between two types of betas: the equity beta (levered beta) and the asset 
beta (unlevered beta). The company's equity beta measures the market risk to the company 
when the capital structure is considered, whilst the asset beta reflects the risk on the company's 
investments without considering debt. Therefore, the company's asset beta will only reflect the 
risk based on its operations, without risk-adjusting for the effect of debt.  
Many practitioners and theorists prefer an industry approach to determine the asset beta to 
overcome the high standard deviations associated with individual companies' equity beta. In 
practice, the method is based on the fact that similar companies will face much of the same 
investment risk and that their margins of error will be neutralized as long as the data sample 
is large enough. By stripping each company of its respective capital structure, one can compare 
the asset beta to similar industry companies. Based on an average or median value, one can 
then adjust the investment beta based on the capital structure, which results in an equity beta 
that can be installed in the CAPM. 
We can calculate the equity beta through the following formula when we assume that the debt 
beta of the company is 0: 




Where, β a = Asset beta 
t = Marginal tax rate 
D = Debt  
E = Equity 
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Marshall Blume (1975) presented empirical indications that the company's regression beta 
tends to converge towards the market beta of 1, from a long-term perspective. It may, 
therefore, make sense to adjust the equity beta. Adjusting the equity beta will reflect a long-
term perspective, and its validity will be more correctly compared to the expected future equity 
beta. The adjustment factor is calculated as follows: 






) × 1 Eq.22 
It may also be essential to discuss the intuition behind why companies' equity beta tends 
towards the market. Companies that mature over time, as a rule, become more diversified. If 
it is not expected that the company will achieve a more diversified product portfolio over time, 
we can reject this adjustment. 
7.1.4 Theories for costs of debt 
The cost of a company's debt tells us how much interest companies pay to finance their 
investments and assets. A company's perceived default risk is central in assessing the debt 
cost. Creditors will demand higher compensation for lending capital if the perceived default 
risk to the counterparty increases. Default risk is a combination of (i) a company's ability to 
generate operating cash flows and how highly levered the company is, and (ii) the volatility 
of the company's cash flows.  
The former is based on the premise that companies with low default risk are expected to 
generate a cash flow that exceeds their financial obligations. Volatility in the same cash flows 
also plays a role, as companies with a stable operational cash flow will have a lower default 
risk than companies with larger fluctuations, everything else being equal. For instance, 
companies operating in cyclical markets such as the oil- and tank market where cash flow 
depends on oil prices and tank rates, will have a higher default risk than companies in stable 
markets, such as real estate and the healthcare sector. 
The first method suitable to estimate the cost of debt is the long-term yield of straight bonds 
issued by a company. This method is appropriate for investment-grade corporate debt, which 
is BBB+ or higher, since only a small chance of default on these bonds (Koller et al., 2020).  
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Nevertheless, these bonds may include a premium for the reinvestment risk as earlier cited, 
but Koller et al. (2020) still argues that it is insignificant for investment-grade companies due 
to the low probability of default.   
The second method used is to look at the industry to estimate the costs when the above method 
is inappropriate. The industry standard for calculating the cost of debt for a company is by 
looking at the bonds' credit rating or yield-to-maturity (“YTM”). If this is unobservable for a 
company, Damodaran (2020a) proposes calculating a synthetic credit rating that reflects the 
company's solvency and proposes in this context to use the interest coverage ratio as a starting 
point. The formula for the interest coverage ratio (“ICR”) can be calculated as: 




With the ICR ratio, Knivsflå (2020c) suggests that the equity ratio is applicable when 
estimating the synthetic credit rating. Companies with significant leverage are riskier 
investments than underleveraged companies. Thus, it is insightful to include the equity ratio 
in the analysis as the debt cost should reflect the risk associated with the investment. The 
company's interest coverage ratio and equity ratio can be assigned a synthetic credit rating as 
a mark-up on the borrowing cost over risk-free interest. We can therefore calculate the 
company's cost of debt as: 
 𝑃𝑟𝑒 − 𝑡𝑎𝑥 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑑𝑒𝑏𝑡 = 𝑔𝑟𝑜𝑠𝑠 𝑟𝑓 + 𝐶𝑟𝑒𝑑𝑖𝑡 𝑑𝑒𝑓𝑎𝑢𝑙𝑡 𝑠𝑝𝑟𝑒𝑎𝑑 
Eq.24 
7.1.5 The weighted average cost of capital  
The capital cost tells us what the debt and equity investors should demand compensation for 
incurring associated risks. If a company is financed with both debt and equity, it would be 
instinctive to use a weighted average of both the cost of equity and debt. In short, the WACC 
consists of three different components: (i) the company's objective and market-based capital 
structure, (ii) the cost of equity, and (iii) the cost of debt, adjusted for taxes, respectively. To 
calculate WACC, we utilize the following formula: 
 
 𝑊𝐴𝐶𝐶 = [
𝐸
(𝐷 + 𝐸)
× 𝑟𝐸] + [
𝐷
(𝐷 + 𝐸)
× 𝑟𝑑 × (1 − 𝑡)] Eq.25 
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7.2 Calculations of costs of capital 
7.2.1 Estimation of the cost of equity 
The cost of equity will be calculated based on the CAPM and a liquidity risk premium. The 
CAPM elements consist of the risk-free rate, the market risk premium, and equity beta, and 
we will present the estimation of these values in the coming subchapter. 
Risk-free rate 
To estimate the future risk-free, we deploy the framework presented by Knivsflå (2020d), with 
the elements of a Norwegian 10-year bond, US 30-year bond, and 3M NIBOR. It is expected 
that the risk-free rate in the long-term will converge toward the average, and in a steady state, 
be constant (Knivsflå, 2020d). Today's interest rates are significantly below the historical 
average, making it challenging to forecast the risk-free rate. Since the historical average is 
substantially larger than today's level, it is plausible to expect that the interest will increase as 
the economy recovers from the pandemic. It is expected to increase to ~2.00% in the medium 
term, before normalizing at ~3.00% in the long-term (Knivsflå, 2020d). To estimate a 
“normal” risk-free rate, we weight the 3M NIBOR 2/3, and the average of a Norwegian 10-
year bond and US 30-year bond with 1/3. 
 𝑅𝑓 = (
2
3




(10𝑦𝑁𝑜𝑟𝑤𝑒𝑔𝑖𝑎𝑛𝑏𝑜𝑛𝑑 + 30𝑦𝑈. 𝑆𝐵𝑜𝑛𝑑)
2
 Eq.26 
The estimated average of 3M NIBOR between 1996 and 2019 is 3.5%, and the average of the 
two bonds are 1.9%, providing a normal long-term interest rate to be 3.0%. We decided to 
implement the bond yields from November 2019, as the COVID-19 caused all interest rates 
(yields) to plummet, distorting the long-term estimation. If the risk-free rate in the steady state 
is artificially low, the other costs of capital will also be affected by this, which would affect 
the final valuation of Aker BioMarine.  
Nonetheless, what exemplifies that the projected interest rate is adequate, is that the financing 
cost is fundamentally higher than long government security yields. Long government security 
yields are relied upon to give a good sign of how the interest level will develop over the long 
haul. This way, it is close to guaranteeing that a gross risk-free rate of 3.0% in a steady state 
can be safeguarded.  
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Further, to calculate the risk-free rate after tax in the forecasting, it is essential to predict its 
future tax rate and the Norwegian banks' risk premium. We have no indications that lead us to 
believe there will be changes in the statutory tax rates, therefore we project it to be fixed at 
23% during the whole period. Lastly, we assume that the banks' average credit rating of AA 
will be constant during the whole period (Knivsflå, 2020d). 
Exhibit 50: Risk-free rate forecasting 
 Forecast  CV 
  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E  2030E 
             
3M NIBOR 0.51% 0.83% 1.32% 1.86% 2.01% 2.15% 2.35% 2.57% 2.78% 2.93%  3.00% 
Credit premium (AA) 0.50% 0.50% 0.50% 0.50% 0.50% 0.50% 0.50% 0.50% 0.50% 0.50%  0.50% 
Gross risk-free rate 0.01% 0.33% 0.82% 1.36% 1.51% 1.65% 1.85% 2.07% 2.28% 2.43%  2.50% 
Tax (23%) 0.00% 0.08% 0.19% 0.31% 0.35% 0.38% 0.43% 0.48% 0.52% 0.56%  0.58% 
Net risk-free rate 0.01% 0.25% 0.63% 1.05% 1.16% 1.27% 1.42% 1.59% 1.76% 1.87%  1.93% 
Source: Knivsflå (2020d) and own projections 
Market risk premium 
It is problematic to predict how the market risk premium will develop in the coming years, 
and the best estimate for the future risk premium is based on the historical (Knivsflå, 2020d). 
Thus, we consider the current market risk premium of 5.1% to be constant in our forecasts. 
PwC's annual questionnaire (2019) suggests that the current risk premium is at ~5% and that 
there are no indications that the future risk premium will deviate significantly. Further, both 
Kaldestad et al. (2016) and Knivsflå (2020d) assert that the market's risk premium is likely to 
be constant at ~5%. Hence, we deem 5.1% to be the appropriate risk premium in all the 
forecasted years in the valuation.  
Equity beta 
To retrieve the equity beta of Aker BioMarine, we decided to use the average asset beta of the 
peers presented in the historical analysis, adjusted it for the capital structure of Aker 
BioMarine. Since the company only has been listed for a few months, there are not enough 
data to derive a reliable equity bet. Koller et al. (2020) suggest that the equity beta should be 
derived from a minimum of 60 data points with monthly returns, and Thomson Reuters’ Eikon 
requires that the stocks have minimum been traded for 30 months to derive a reliable beta. 
Appendix 5 displays the regression analysis with the returns of Aker BioMarine against Oslo 
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Børs, whereas the implied equity beta was 0.845. The beta will neither be weighted nor 
included further in the analysis of Aker BioMarine as the data sample is inadequate. 
Exhibit 51: Average industry beta calculations 
Aker BioMarine - Beta calculations  
Peers Equity beta Adjustment factor Asset beta 
DSM 0.862 -0.187 0.675 
Probi 0.971 -0.003 0.968 
Midsona 0.790 -0.281 0.509 
Glanbia 0.531 -0.166 0.365 
Average industry beta     0.629 
 
The equity betas were retrieved from Thomas Reuters' Eikon software and adjusted for their 
capital structure before arriving at the asset beta. We assume the asset beta will be constant 
throughout the valuation. 
Exhibit 52: Equity beta forecasting 
  Forecast  CV 
  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E  2030E 
Asset beta 0.629 0.629 0.629 0.629 0.629 0.629 0.629 0.629 0.629 0.629  0.629 
Adjustment factor 0.393 0.555 0.578 0.547 0.491 0.401 0.317 0.254 0.194 0.142  0.145 
Blume adjustment - - - - - -0.010 -0.018 0.039 0.059 0.076  0.075 
Equity beta 1.022 1.184 1.207 1.176 1.120 1.020 0.964 0.922 0.882 0.848  0.850 
 
The asset beta has been adjusted for the capital structure changes every year in our forecast to 
find the appropriate beta for each year. The long-term equity betas are Blume-adjusted to 
incorporate the empirical evidence implying that all betas converge towards the beta of the 
market portfolio in the long haul. Since Aker BioMarine's beta is below 1, the Blume-
adjustment increases the beta, and consequently the capital cost. 
Liquidity premium  
We deploy a liquidity premium of 4.20% in 2020, which is related to the low free float in the 
share and the lack of diversification in ownership. Aker BioMarine expects to be listed on the 
main index during 2021, so we adjust the liquidity premium to incorporate the probability. 
After 2022, we expect Aker BioMarine to be listed on the main index, but we still adjust the 
equity cost by 2.1% due to the substantial ownership concentration. 
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7.2.2 Cost of equity calculation 
Based on the calculations and previous elements discussed in this chapter, it is possible to 
estimate the future cost of capital of Aker BioMarine. Exhibit 53 illustrates the development 
in the cost of equity over the forecasting period. The small fluctuations are driven by the 
increase in the risk-free rate and changes in the equity beta. The risk-free rate is assumed to 
converge towards the historical level, while the equity beta changes because of the projected 
capital structure changes. In the coming years, the debt will rise, which increases the risk 
associated with the company's equity, which investors require compensation for in the form 
of an enhanced required rate of return on the equity. 
Exhibit 53: Cost of equity calculations 
  Forecast CV 
  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E  2030E 
Risk-free 0.01% 0.25% 0.63% 1.05% 1.16% 1.27% 1.42% 1.59% 1.76% 1.87%  1.93% 
Equity beta 1.022 1.184 1.207 1.176 1.120 1.020 0.964 0.922 0.882 0.848  0.850 
Market risk premium 5.10% 5.10% 5.10% 5.10% 5.10% 5.10% 5.10% 5.10% 5.10% 5.10%  5.10% 
Liquidity premium 4.20% 3.45% 2.10% 2.10% 2.10% 2.10% 2.10% 2.10% 2.10% 2.10%  2.10% 
Cost of equity 9.42% 9.74% 8.89% 9.14% 8.97% 8.57% 8.44% 8.40% 8.35% 8.29%  8.36% 
 
7.2.3 Estimation of the cost of debt 
Aker BioMarine's future debt costs must be rooted in the forecasted metrics and projected 
based on these numbers. The coming subchapter will calculate the synthetic rating of Aker 
BioMarine in the coming period. The synthetic rating is the foundation for the calculations of 
the future costs of debt. The projected rating consists of two important ratios: (i) interest 
coverage ratio and (ii) the equity ratio. The ratings are based on Knivsflå (2020c) and 
Damodaran's (2020c) thresholds for the various scores. 
Exhibit 54: Synthetic rating 
  Forecast CV 
  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E  2030E 
Interest coverage ratio 0.554 2.850 2.855 3.361 4.218 5.399 6.473 7.496 8.721 10.117  11.634 
Equity ratio 0.552 0.466 0.456 0.470 0.497 0.547 0.604 0.656 0.714 0.773  0.769 
Implied credit rating B BB BB BBB BBB A- A A A+ AA  AA 
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Exhibit 54 illustrates the projected synthetic rating for Aker BioMarine in the period of 2020 
– 2030. The healthy development can be attributed to a rapid expansion in the equity ratio and 
interest coverage ratio. 
Bankruptcy risk 
Bankruptcy risk (insolvency risk) is the likelihood that Aker BioMarine will be unable to meet 
its debt obligations. It is the probability of it becoming insolvent due to its inability to service 
the debt acquired. The credit agencies attempt to assess the bankruptcy risk through the bond 
rating and rating the issuers, such as we did with the synthetic credit rating. The synthetic 
credit rating implies that the company has the probability of 0.51% going bankrupt once it 
reaches the projected AA rating (Pirogova, 2019). The adjustment factor in the cost of debt 
estimation is to capture circumstances that should be reflected in the debt cost but are not fully 
considered in the synthetic rating. 
7.2.4 Cost of debt calculation 
Exhibit 55: Cost of debt calculation 
  Forecast  CV 
  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E  2030E 
Synthetic rating B BB BB BBB BBB A- A A A+ AA  AA 
Net risk-free rate 0.01% 0.25% 0.63% 1.05% 1.16% 1.27% 1.42% 1.59% 1.76% 1.87%  1.93% 
Net risk premium 4.75% 2.70% 2.70% 1.73% 1.73% 1.54% 1.39% 1.39% 1.16% 0.77%  0.77% 
Adjustment factor 3.30% 5.07% 5.00% 4.52% 3.97% 3.58% 3.18% 2.77% 2.15% 1.42%  1.20% 
Cost of debt 8.05% 8.02% 8.33% 7.30% 6.87% 6.39% 5.99% 5.75% 5.06% 4.06%  3.90% 
 
Exhibit 55 illustrates the projected cost of debt over the next ten years, and it is important to 
note that this is the net of taxes and adjusted with a premium. We consider the cost of debt to 
be artificially low if the adjustment factor is excluded.  
The factor fluctuates with the modifications in the capital structure and the expected rise in 
the risk-free rate. The main driver of the increased cost of debt is the rise in the risk-free rate, 
which we expect to normalize over the decade. The net risk premium is obtained from Knivsflå 
(2020c). 
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7.2.5 Calculation of the weighted average cost of capital 
This subchapter had the purpose of explaining and providing calculations to Aker BioMarine's 
capital cost, which is positioned as the discount rate in the coming chapter. The WACC 
changes yearly due to significant capital structure changes in the coming years before 
stabilizing at the end of the forecasting period when Aker BioMarine approach its target capital 
structure in 2029. We believe it is necessary to have a dynamic WACC that captures the capital 
structure changes, such as Knivsflå (2020c) also suggests. 
Exhibit 56: Weighted average cost of capital 
  Forecast  CV 
  2020E 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E 2029E  2030E 
Cost of equity 9.42% 9.74% 8.89% 9.14% 8.97% 8.57% 8.44% 8.40% 8.35% 8.29%  8.36% 
Net cost of debt 8.05% 8.02% 8.33% 7.30% 6.87% 6.39% 5.99% 5.75% 5.06% 4.06%  3.90% 
WACC 8.81% 8.82% 8.58% 8.17% 7.91% 7.58% 7.47% 7.49% 7.41% 7.33%  7.33% 
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The past chapters have built the foundation for the valuation of Aker BioMarine, which is 
presented in this chapter. Through the industry and Aker BioMarine's performance analysis, 
we have built projections for the cash flows that are discounted with the WACC presented in 
the subsequent chapter. These cash flows and economic profits are together with the 
WACC, the basis for this chapter, that aims to ultimately determine the fair market value of 
equity of Aker BioMarine as of October 30, 2020. We implement the two valuation approaches 
that are most suitable for this case: discounted cash flow and economic value added, both 
presented in chapter 3. The coming chapter illustrates step-by-step how we determine the fair 
market value of Aker BioMarine and finishes off with an interpretation of the results where 
we discuss the value drivers and the metrics' sensitivity. 
The frameworks presented in chapter 3 are carried out in four separate steps. The frameworks 
commence with the valuation of the core operations of Aker BioMarine. We are continuing 
with a valuation of the non-operating assets added on the core operations' valuation, arriving 
at the “gross enterprise value.” Further, the non-equity claims must be adjusted to obtain the 
equity value. Finally, we divide the equity value with the number of outstanding shares to 
arrive at the fair value of Aker BioMarine's outstanding shares in Merkur Market. The coming 






























cost of capital 
Chapter 9: 
Relative valuation 
Step: 1 Step: 2 Step: 3 Step: 4 Step: 5 
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8.1 Discounted cash flow valuation 
8.1.1 Valuation of Aker BioMarine's core operations  
The previous chapter presented the computation to obtain the different WACC rates of Aker 
BioMarine, while chapter 6 presented the projection of future cash flows. Exhibit 58 illustrates 
the projections of the cash flows generated by the core operations of Aker BioMarine, together 
with the discount factor. The forecasts are presented in chapter 6, but we now include the 
discount factors to show the present value of these future cash flows. We expect Aker 
BioMarine to reach a steady state in 2029; while 2030 will be the continuing year in the 
valuation. The three components in the continuing year make up ~90% of the total value of 
Aker BioMarine; therefore, the free cash flow and WACC must be normalized without any 
abnormal growth rates. If not, it will overestimate (underestimate) the value of Aker 
BioMarine. 
The free cash flows in CV are projected to be USD 98.73mn, without any abnormal items, and 
our WACC is estimated to be 7.33%. Knivsflå (2020d) stresses that a company's 
growth cannot exceed the global economy's expected growth. This is because if the company 
grows faster than the global economy, it will eventually become the global economy. This 
assumption is unrealistic, and the growth must therefore be realistic. The expected growth in 
the global economy consists of two elements: (i) the expected growth in the real economy and 
(ii) the expected global inflation. The latter is estimated to be 2.0%, whilst the former at 3.0%. 
The absolute maximum growth perpetuity of the company may be set to 5.0%. However, we 
do consider a perpetual growth rate of 5.0% to be overestimating the value of Aker BioMarine. 
We have estimated a perpetual growth rate of ~3.1% to be satisfactory in the continuing year. 
The combined present value of all cash flows from core operations between 2020 and 
2029, plus the continuing value is equal to USD 1 233.62mn. The estimates from 2020 are the 
reported numbers from Q1 to Q3 added on our estimates for Q4 to arrive at 2020 estimates. 
The cash flows are also mid-year adjusted, as we do not want to unfairly penalize Aker 
BioMarine as the cash flows occur steadily throughout the year. Without the adjustment, all 
cash flows would be treated in the end-year, but the adjustment assumes the cash flows occur 
in the middle of the year instead. 
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8.1.2 Valuation of non-operating assets  
The second step in the valuation framework is to estimate the value of the non-operating assets 
to obtain the gross enterprise value, consisting of both the value of core operations and non-
operating assets. Aker BioMarine is expected to have excess cash of ~USD 6.23mn in 2020, 
in addition to a minor equity post of USD 0.26mn. It is problematic to adjust the equity post 
to find the market value of the equity as it should be, but as the post is insignificant, we 
consider it not to impact the valuation of Aker BioMarine. The combined market value for all 
of Aker BioMarine's non-operating assets is approximated to be USD 6.47mn, 
implying a gross enterprise value of USD 1 240.08mn. The market value of debt is calculated 
as in Eq.27. 







Where,  C = interest expense 
Kd = Cost of debt 
t = Weighted average maturity 
BV = Book value of debt 
Exhibit 57: Aker BioMarine's market value of debt 
All values in USD thousands  
Aker BioMarine Book values 
Current debt 47 591  
Non-current debt 197 473  
Interest expense 28 144  
Cost of debt 8.05 % 
  
Total debt 245 064  
Weighted average maturity  8.25  
  
The market value of debt 294 428  
 
After the gross enterprise value has been estimated, we need to correct non-equity claims in 
Aker BioMarine before arriving at the total equity value. The determinations of the book 
values of debt and other non-equity claims were presented in the previous chapter, and so it 
only needs to be adjusted to find the book values' market values. The total borrowings of Aker 
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BioMarine are estimated to be USD 245.06mn, with other non-equity claims being at USD 
51.82mn. To estimate the debt's market value, one can think of the interest-bearing debt in the 
books as a single coupon, and the coupon should be equal to the interest expenses on all the 
debt with a maturity weighted on the debt. The current interest-bearing debt is assumed to 
have a maturity of one year, while the non-current is assumed to have ten years to maturity. 
Finally, after adjusting the book values to estimate the market values, the debt value increases 
to USD 294.43mn. 
Exhibit 58: Absolute valuation of Aker BioMarine using the Discounted Cash Flow model 
All values in USD thousands          
Forecast year Free cash flow NOPAT Discount factor PV of FCF 
2020E (12 257) 24 015 0.919 (11 264) 
2021E (110 844) 45 719 0.845 (93 614) 
2022E (28 665) 53 994 0.778 (22 296) 
2023E 15 778 62 131 0.719 11 345 
2024E 38 213 74 849 0.666 25 464 
2025E 57 343 87 682 0.619 35 518 
2026E 63 971 98 088 0.576 36 869 
2027E 75 245 106 516 0.536 40 345 
2028E 90 983 114 758 0.499 45 420 
2029E 98 382 124 433 0.465 45 760 
Continuing value 98 726 128 270 0.465 1 085 242 
PV of mid-year adjustment 
      
34 829 
          
The present value of core operations       1 233 617 
          
Excess cash       6 225 
Other financial assets       - 
Investments in equity-accounted investee     240 
Gross enterprise value       1 240 081 
          
Less: Value of debt and capital leases       (294 428) 
Less: Other non-equity claims       (51 823) 
Less: Value of non-controlling interests       - 
Equity value       893 831 
          
Shares outstanding       87 586 
Value per share (USD)       10.21 
          
NOK/USD as of October 30, 2020       9.48 
Value per share (NOK)       96.74 
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After correcting and adjusting for non-equity claims, the value of shareholder's equity and the 
fair market value is estimated to be USD 893.83mn, as illustrated in exhibit 58. We estimate 
the fair market value of a share of Aker BioMarine as of October 30, 2020, is NOK 
96.74. This valuation implies that the stock is undervalued as it traded at NOK 82.00, 
indicating a potential upside of 17.98%. 
8.2 Economic value added  
The economic value added approach is a measure of Aker BioMarine's financial performance 
based on the residual wealth derived from the deduction of the WACC from the operating 
profit, adjusted for taxes on cash. The framework attempts to capture the actual economic 
profit of Aker BioMarine to assess whether an organizational value was created or lost. The 
idea behind the framework is to investigate whether the return on capital invested exceeds the 
costs of capital, which is useful in capital intensive industries such as Aker BioMarine operates 
in. There are three common pitfalls one should be aware of when adopting the framework that 
Koller et al. (2020) describes.   
i. The importance of using the invested capital from the beginning of the year, instead of 
averages or mid-years values.   
ii. The invested capital for ROIC and economic profits must be defined by the same 
metric, either with or without goodwill. If consistent, it will lead to identical results 
with the DCF approach.   
iii. The implementation of the same WACC in all projections, which is also consistent 
with our DCF approach. 
Exhibit 59 illustrates the value of Aker BioMarine's core operations based on the EVA 
framework. The framework should provide the same results derived from the DCF approach, 
as clarified before. We project the ROIC to significantly exceed the cost of capital, providing 
Aker BioMarine a joyful growth. As with the DCF, a substantial part of the value creation is 
in the continuing year. Using the EVA frameworks, the gross enterprise value provides the 
same core operations as the DCF. As of October 30, 2020, the core operations' value is 
estimated to be USD 1 233.62mn. Similarly, as with the DCF, we must adjust for the non-
operating assets before arriving at the gross enterprise value. 
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Exhibit 59: Absolute valuation of Aker BioMarine using the Economic Profit model 
All values in USD thousands            
Forecast year ROIC* WACC Invested capital* Economic profit Discount factor PV of EP 
2020E 5.42% 8.81% 443 448 (15 053) 0.919 (13 835) 
2021E 9.53% 8.82% 479 719 3 416 0.845 2 885 
2022E 8.49% 8.58% 636 282 (599) 0.778 (466) 
2023E 8.64% 8.17% 718 940 3 395 0.719 2 441 
2024E 9.78% 7.91% 765 294 14 317 0.666 9 541 
2025E 10.93% 7.58% 801 929 26 871 0.619 16 644 
2026E 11.79% 7.47% 832 268 35 897 0.576 20 689 
2027E 12.29% 7.49% 866 385 41 646 0.536 22 330 
2028E 12.78% 7.41% 897 656 48 271 0.499 24 097 
2029E 13.50% 7.33% 921 431 56 906 0.465 26 468 
Continuing value 13.54% 7.33% 947 482 58 833 0.465 644 547 
PV of mid-year adjustment 
          
34 829 
Invested capital in 2019           443 448 
              
The present value of core operations  
      
1 233 617 
              
Excess cash           6 225 
Other financial assets           - 
Investments in equity accounted investee       240 
Gross enterprise value           1 240 081 
              
Less: Value of debt and capital leases       (294 428) 
Less: Other non-equity claims        (51 823) 
Less: Value of non-controlling interests       - 
Equity value 
          
893 831 
              
Shares outstanding           87 586 
Value per share (USD)           10.21 
              
NOK/USD as of October 30, 2020         9.48 
Value per share (NOK)      96.74 
*Excl. goodwill 
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The final step is to adjust for the debt and other non-equity claims to obtain shareholder's 
equity. Our estimates from the EVA framework provides the same results as the DCF, valuing 
Aker BioMarine at NOK 96.74 as of October 30, 2020. 
8.3 Sensitivity analysis  
The entire valuation chapter concludes with sensitivity analyses. The tool is installed to 
analyze how the independent variables' different values affect our final valuation under the set 
conditions. The sensitivity analysis is instrumental when output is an opaque function of 
several inputs and makes the relationship between the inputs and outputs easier to 
understand. Our estimation of Aker BioMarine's fundamental value has required numerous 
assumptions about its future performance and development. The sensitivity 
analysis illustrates how sensitive the obtained stock price is to these changes.  
8.3.1 Sensitivity analyses of input factors 
The cost of capital and the growth rate are the two most common elements to adopt in a 
sensitivity analysis, as they significantly impact the company's continuing value. The WACC 
consists of three unique elements that rely on assumptions and projections, and possible 
deviations illustrated in the sensitivity analysis and the growth rate. A change in the WACC 
may occur due to one of these three main reasons:  
i. The cost of equity consists of three elements; the beta, return on the market portfolio, 
and the risk-free rate. The proportion of equity in Aker BioMarine is 
high; consequently, the cost of equity will significantly impact the WACC.  
ii. If the cost of debt increases, so will the WACC, ceteris paribus. Hence, changes in the 
cost of debt are likely to affect the market value of Aker BioMarine, which again 
affects the debt-to-equity ratio used in the WACC calculations.  
iii. A change in the target capital structure will change the debt-to-equity ratio, which 
changes the WACC, provided that the cost of debt- and equity is unaffected.  
A sensitivity analysis of the continuing growth rate is also implemented, as much of 
the enterprise's value will be derived from this input. As discussed above, the realistic growth 
rates lie between 0~5%, and the input installed should reflect the realistic assumptions about 
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growth. As we utilized a 3.08% rate, it is useful to investigate how different growth rates affect 
the stock price's final estimation.  
Exhibit 60 illustrates how the fair market price per share would change based on different 
growth- and WACC rates. The difference between the best and worst cases is ~510%, 
demonstrating how sensitive the estimated price is to these inputs. 











5.8 % 114.53 126.83 142.98 164.22 197.29 248.41 342.14 
6.3 % 99.59 108.65 120.15 134.67 155.96 186.06 233.88 
6.8 % 87.52 94.33 102.76 113.06 127.54 146.81 174.83 
7.3 % 77.57 82.77 89.07 96.74 106.08 119.82 137.65 
7.8 % 69.22 73.23 78.01 83.60 91.00 100.12 112.09 
8.3 % 62.12 65.23 68.90 73.10 78.56 85.11 93.44 
8.8 % 56.00 58.43 61.25 64.44 68.51 73.30 79.23 
 
In addition to the sensitivity analysis of CV growth and WACC, we deployed a tornado 
analysis, including six more variables that affect the valuation of Aker BioMarine. The 
illustration in figure 37 displays how the share price changes with a 100bps decrease (increase) 
in the different variables. 
The variable that affects the price estimate the most is the risk-free rate. The estimation of the 
net risk-free rate is 1.93% in the CV, such that an increase (decrease) of 100bps would pose a 
change in the risk-free rate of ~52%. This rate is also one of the most ambiguous variables, as 
the interest rates are problematic to forecast. Thus, it is essential to demonstrate the effects of 
the risk-free rate on a 100bps change. Further, the cost of equity has been estimated through 
comparable firms' asset beta and adjusted for the projected capital structure, making it 
susceptible to any changes in the equity beta. The market risk premium is also assumed to be 
5.1%, which is in line with Knivsflå (2020d). However, if it were to change with 100bps, it 
would significantly impact the price. All the mentioned factors have an enormous impact on 
the valuation through the WACC. The ROIC is an element in the final discount rate to find the 
appropriate discount rate in the continuing value. The ROIC is estimated to be ~13.5%, and a 
100bps change would not be as large a percentage change in this ratio as the other elements. 
Thus, it is not surprising that the effect on the final valuation is minuscule. 
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Finally, the last two elements affect the valuation through either the cash flow or the discount 
rate. An increase in the COGS as a percentage of revenues would cap the estimation with 
almost NOK 11, while a decrease will increase the value with almost NOK 11. The changes 
are close to symmetric either it goes up or down. A change in the operating tax would affect 
the cash flow in the same way as COGS do. An increase (decrease) in the ratios implies a 
lower (higher) cash flow. 































100bps increase 100bps decrease
 181 












A relative valuation analysis, or a multiple analysis, is a simplified valuation technique in 
which the value estimate of an asset or a company is derived by comparing its valuation with 
other similar assets or companies. Consequently, just like the discounted cash flow analysis, a 
multiple analysis can be used to value both private and publicly listed businesses. A 
comparable multiple analysis is performed through three necessary steps: (i) selecting the 
appropriate comparable companies, (ii) selecting the correct multiple, and lastly (iii) to apply 
the multiple to the relevant earnings base (Gaughan, 2020). Along with this outline, we will 
use Damodaran (2012), Knivsflå (2020f), and Koller et al. (2020) as the relevant theoretical 
grounding to support our multiple analysis. In a relative valuation analysis, the choice of 
multiples and comparable companies is of great significance for the value estimate that is 
ultimately derived from the analysis. Hence, we believe a broad theoretical backing is of 
considerable importance in producing a meaningful valuation estimate from our multiple 
analysis of Aker BioMarine. 
9.1 Choice of multiples 
To assess the value of Aker BioMarine in comparison with peers, we will utilize financial 
multiples that are commonly used in relative valuation. In our case, this is important as our 
comparable companies are not directly linked to the krill industry. This implies that the use of 
certain industry-specific multiples, i.e., EV/KG, commonly used in the seafood industry, 
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Chapter 9: 
Relative valuation 
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Accordingly, we have selected four flexible, and in our view highly relevant valuation 
multiples as the basis for our relative valuation analysis. Below is a summary of our selected 
multiples. 
Price-to-Earnings 
Price-to-Earnings multiple is a widely used and easy-to-interpret equity valuation multiple that 
uses the company’s market value of equity as the numerator and divides it by the firm’s 
earnings. Using this comparative valuation ratio, one can assess the market value of a firm 
based on a fundamental indicator of firm performance, in this case, earnings. Although the P/E 
multiple perhaps is the most used peer valuation multiple, it also has several pitfalls to be kept 
in mind while assessing the valuation output. Firstly, the P/E multiple is distorted by capital 
structure, which is not accounted for in the metric. Furthermore, the P/E multiple uses 
accounting-based earnings as its denominator, which may be subject to influence from 
accounting rules like historical cost in inventory valuation and depreciation (Bodie et al., 
2018). Ergo, analysts should proceed with caution when using Price-to-Earnings multiple. 
Enterprise value-to-EBIT 
As we discussed briefly in section 3.2, enterprise value multiples are widely recognized by 
analysts as they allow for analysis across companies without influences from differences in 
the capital structure. Accordingly, we have selected three multiples based on total enterprise 
value. To obtain the EV-to-EBIT ratio, the total market value of a company’s equity and 
financial debt, separate from any cash and marketable securities, is to be divided by the firm’s 
earnings before financial items. 
Enterprise value-to-EBITDA 
This multiple takes the company’s EBITDA and divides it by the enterprise value of the 
company. As this EV-multiple is based on the earnings measure before subtracting financing 
items, depreciation, and amortization, it gives us valuable insights into the underlying’s of the 
company’s operational performance. The EV-to-EBITDA multiple is applicable for the 
valuation of a broader range of companies, as such (Berk & DeMarzo, 2020). 
Enterprise value-to-Sales 
Our fourth multiple is also a valuation multiple based on firm value. This multiple deploys the 
firm’s top line, sales, and divides it by its value. The EV-to-Sales multiple is useful in assessing 
firm valuations when the industry is characterized as unstable or has negative profits. EV-to-
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Sales helps value industries such as start-ups with negative profits and in industries where 
margins tend to be highly volatile. Nonetheless, it is used as a supplement to a broader peer 
valuation as it does not account for essential fundamentals in a firm’s valuation, such as 
margins, growth, and return on invested capital (Koller et al., 2020). 
Forward-looking multiples 
Aker BioMarine has recently made an acquisition as well as significant structural changes to 
their operations, making multiples based on historical profits less relevant (Koller et al., 2020). 
Besides, this choice is also motivated by historical empirical evidence showcasing that forward 
multiples have predicted the future value of the company’s more accurately than backward-
looking multiples (Liu, Nissim, & Thomas, 2002). More so, forward-looking multiples has 
received wide-spread acceptance among professional financial analysts in recent decades. The 
use of several forward-looking and backward-looking multiples will also allow us to produce 
a range of valuation estimates of how Aker BioMarine is priced based on crucial future and 
historical financial indicators, compared to that of just a single valuation estimate. Hence, we 
deem the inclusion of forward-looking multiples as key to a successful relative valuation 
analysis. Thus, our selection of multiples will include multiples based on sales, earnings, 
EBIT, and EBITDA for the latest fiscal year (2019), as well as forward-looking multiples 
based on consensus estimates for 2020E, 2021E, and 2022E. All equity analyst consensus 
estimates are collected from the Bloomberg Terminal on October 30, 2020, and are converted 
into US dollars. 
9.1.2 Choice of comparable companies and other considerations 
Selection of comparable companies 
Based on the arguments presented regarding our selection of comparable companies in chapter 
5, we selected ten comparable companies within the Ingredients and Brands segments for our 
relative valuation analysis. Our selection of companies has mainly been motivated by 
comparable companies' growth characteristics, operational profitability, and geographical 
position. In total, our peer group consists of five Brands companies and five companies within 
the Ingredients segment. 
Out of the ten companies selected for our relative valuation analysis, we have chosen DSM, 
Novozymes, Probi, Biogaia, and AAK in the Ingredients segment. The companies we have 
grouped in the Brands segment are Orkla, Procter & Gamble, Nestlé, Midsona, and Glanbia. 
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Consistent with previous peer analysis, Ingredients companies are colored in blue and Brands 
companies in green. 
Multi-business multiple valuation 
For multi-business companies, a valuation using multiples needs to be valued through a sum-
of-the-parts approach, in which each business unit is valued at a multiple appropriate to its 
peers and performance (Koller et al., 2020, p. 369). This implies that the different business 
units should be valued with different multiples to reflect their differences in marketplace 
valuation. As we have decided to split our peer group into companies in two different 
segments, we have decided to use a weighting to derive our final valuation estimate. Today, 
Aker BioMarine reports that out of their USD 246mn revenue in 2019, 68% was attributable 
to the Ingredients segment, and 32% came from the Brands segment. Therefore, in deciding 
on our final valuation estimate, we will apply this weighting to our estimates. 
Other considerations 
We have also made considerations in terms of which multiples that will be the most relevant 
for our final valuation estimate. First and foremost, we will include multiples on both actual 
2019 numbers and 2020-2022 consensus estimates. These are mainly included to provide 
quantitative backing to our assumptions, accompany discussions, and reveal potential 
irregularities or abnormalities in our final relative valuation estimate. This will provide us with 
a relatively wide range of valuation estimates, and due to Aker BioMarine’s growth 
characteristics and our assumptions of considerable revenue and margins to be captured within 
the coming years, we have concluded that the 2021E multiples provide the best basis for a 
single conclusion on our relative valuation. As we have argued previously, empirical evidence 
showcases that future multiples may allow for better future operations forecasts.  
Therefore, we decide that future 2021E multiples are to provide the basis for our final 
valuation estimate. We have summarized our general assumptions for Aker BioMarine’s share 






Exhibit 61: General assumption for the relative valuation analysis 
General assumptions in Aker BioMarine's relative valuation 
Price per share 30.10.20 (NOK) 82.00 
Shares outstanding (Million) 87.59 
NOK/USD FX rate 30.10.20 (NOK) 9.48 
  
Weighting in Ingredients 68% 
Weighting in Brands 32% 
                    Source: Bloomberg LP (October 30, 2020) 
9.2 Relative valuation analysis 
Before we start our relative valuation analysis, we collect the necessary financial information 
of our comparable companies. This includes calculating the firms’ enterprise value, which 
requires financial information such as market capitalization, financial debt, minority interest, 
and cash and marketable securities. Given the time we have at hand to complete our master 
thesis and consideration of costs and benefits, we decided not to perform a full reorganization 
of the ten comparable firms' financial statements. We dug into each company’s financial 
statements and collected relevant market values to extract the information relevant for our 
comparable company analysis. This includes the market value of equity as of October 30, 
2020, and the latest financial data publicly available for each firm to estimate enterprise value 
on the same date. Moreover, we also extracted the latest available equity analyst consensus 
estimates for forward-looking EBITDA, earnings, and sales from the Bloomberg Terminal on 
October 30, 2020. 
Exhibit 62: Enterprise value calculation Ingredients segment (USD thousands) 
Enterprise value calculation: Ingredients comparable companies 
In USD thousands ($)   DSM Novozymes Probi Biogaia AAK 
       
Relevant USD FX rate (30.10.20)  1.17 0.16 0.11 0.11 0.11 
       
Price per share (30.10.20)  160.2 60.1 43.5 47.6 19.5 
Shares outstanding  181 430 286 600 11 394 17 336 254 391 
Market capitalization   29 067 960 17 211 486 495 830 824 484 4 953 709 
       
Financial debt  4 388 597 853 358 6 446 2 003 550 944 
Cash & marketable securities  (2 011 877) (133 836) (23 556) (32 835) (128 359) 
Non-controlling interest   106 072 1 720 - 0.2 10 219 
       
Enterprise value   31 550 752 17 932 729 478 720 793 652 5 386 513 
Source: Annual and quarterly reports for all companies, 2020 
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Exhibit 63: Enterprise value calculation Brands segment (USD thousands) 
Enterprise value calculation: Brand comparable companies 
In USD thousands ($)   Orkla P&G Nestlé Midsona Glanbia 
       
Relevant USD FX rate (30.10.20)  0.11 n.a. 1.09 0.11 1.17 
       
Price per share (30.10.20)  9.5 137.1 112.4 7.2 9.5 
Shares outstanding  1 015 000 2 625 800 2 934 000 65 005 295 281 
Market capitalization   9 644 641 359 997 180 329 641 337 470 121 2 794 812 
       
Financial debt  1 088 186 34 720 000 41 838 388 167 327 860 818 
Cash & marketable securities  (205 485) (16 181 000) (5 494 469) (15 497) (102 109) 
Minority interest  48 523 357 000 946 984 - - 
       
Enterprise value   10 575 865 378 893 180 366 932 240 621 951 3 553 521 
Source: Annual and quarterly reports for all companies, 2020 
9.2.1 Price-to-Earnings 
 𝑃𝑟𝑖𝑐𝑒 − 𝑡𝑜 − 𝐸𝑎𝑟𝑛𝑖𝑛𝑔𝑠 =  
𝑃𝑟𝑖𝑐𝑒 𝑝𝑒𝑟 𝑠ℎ𝑎𝑟𝑒
𝐸𝑎𝑟𝑛𝑖𝑛𝑔𝑠 𝑝𝑒𝑟 𝑠ℎ𝑎𝑟𝑒 ("EPS")
 Eq.28 
The first multiple in our relative valuation analysis is the Price-to-Earnings ratio. This multiple 
is one of the most frequently used peer valuation metrics among financial analysts and other 
finance practitioners. Firstly, in our P/E analysis, we extract the earnings per share consensus 
estimates from the Bloomberg Terminal along with the price per share data on October 30.  
Exhibit 64: Actual EPS ’19 and forward-looking consensus estimates ’20-’21-’22 
Peer valuation: Price-to-Earnings 
In USD Basis (Price)   P/E '19 P/E '20E P/E '21E P/E '22E 
       
DSM 160.2  33.3x 35.2x 25.2x 24.8x 
Novozymes 60.1  36.4x 37.1x 34.3x 31.7x 
Probi 43.5  54.5x 42.7x 37.2x 32.3x 
Biogaia 47.6  41.6x 40.3x 36.4x 32.1x 
AAK 19.5  32.1x 28.1x 25.0x 22.8x 
Median ingredients     36.4x 37.1x 34.3x 31.7x 
       
Orkla 9.5  21.8x 20.1x 18.7x 18.0x 
Procter & Gamble 137.1  27.6x 24.8x 23.1x 21.4x 
Nestlé 112.4  26.0x 25.1x 24.3x 22.6x 
Midsona 7.2  33.8x 25.4x 20.0x 16.6x 
Glanbia 9.5  13.9x 16.6x 12.2x 10.5x 
Median Brands     26.0x 24.8x 20.0x 18.0x 
        
Aker BioMarine 8.6   - - 39.7x 30.0x 
Source: Bloomberg LP (October 30, 2020) 
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We calculate P/E as in Eq. 28 by dividing price per share over EPS, showcased in exhibit 64. 
The relevant input for each computation is presented in appendix 7. It is worth noting that 
Aker BioMarine did not deliver positive earnings in 2019 and is not expected to do so in our 
2020 estimates. Further, since we anticipate that 2021 is the first year of positive net income 
for the company, our estimates are relatively conservative, and the firm is priced in the 
marketplace at the highest 2021 forward-looking multiple among its peers. 
To compute our final price per share based on P/E multiples, we multiply Aker BioMarine’s 
estimated earnings with the corresponding median multiple for both segments in each given 
year. In our selected year of analysis, 2021, Aker BioMarine’s implied valuation is NOK 70.8 
per share on Ingredients multiples and as low as NOK 41.2 on Brands multiples. After 
applying the weights introduced in our introduction, we arrive at a final weighted stock price 
of NOK 61.3 per share. The full range of valuation estimates of Aker BioMarine’s market 
value of equity per share based on historical and future earnings are presented in exhibit 65. 
2021E multiples are highlighted as this is our primary year of analysis. 
Exhibit 65: Price-to-Earnings relative valuation analysis of Aker BioMarine 
Aker BioMarine: Price-to-Earnings relative valuation 
In USD   2019A 2020E 2021E 2022E 
       
Aker BioMarine EPS basis  - - 0.22 0.29 
Ingredients median multiple  36.4x 37.1x 34.3x 31.7x 
Brands median multiple  26.0x 24.8x 20.0x 18.0x 
       
Aker BioMarine implied USD price 
(Ingredients)* 
  - - 7.5 9.1 
Aker BioMarine implied USD price 
(Brands)* 
 - - 4.4 5.2 
       
Price per share: Ingredients (NOK)*  - - 70.8 86.6 
Price per share: Brands (NOK)*  - - 41.2 49.1 
       
Weighted price per share (NOK)   - - 61.3 74.6 





 𝐸𝑉 − 𝑡𝑜 − 𝑆𝑎𝑙𝑒𝑠 =  
𝑇ℎ𝑒 𝑚𝑎𝑟𝑘𝑒𝑡 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑒𝑞𝑢𝑖𝑡𝑦 +  𝑁𝑒𝑡 𝑓𝑖𝑛𝑎𝑛𝑐𝑖𝑎𝑙 𝑑𝑒𝑏𝑡
𝑆𝑎𝑙𝑒𝑠
 Eq.29 
Exhibit 66: Actual sales ’19 and forward-looking consensus estimates ’20-’21-’22 
Peer valuation: EV-to-Sales 
In USD thousands Basis (EV)   EV/Sales '19A EV/Sales '20E EV/Sales '21E EV/Sales '22E 
       
DSM 31 550 752  3.1x 3.1x 2.9x 2.8x 
Novozymes 17 932 729  8.3x 8.0x 7.7x 7.4x 
Probi 478 720  7.2x 5.9x 5.5x 5.1x 
Biogaia 793 652  9.8x 9.5x 8.6x 7.7x 
AAK 5 386 513  1.8x 1.7x 1.6x 1.5x 
Median ingredients     7.2x 5.9x 5.5x 5.1x 
       
Orkla 10 575 865  2.1x 2.1x 2.0x 2.0x 
Procter & Gamble 378 893 180  5.3x 5.1x 5.0x 4.8x 
Nestlé 366 932 240  3.9x 3.9x 3.9x 3.7x 
Midsona 621 951  1.9x 1.5x 1.3x 1.3x 
Glanbia 3 553 521  0.8x 0.8x 0.8x 0.7x 
Median Brands     2.1x 2.1x 2.0x 2.0x 
        
Aker BioMarine 1 099 345   4.5x 3.7x 2.7x 2.3x 
 
EV-to-Sales is an enterprise value multiple frequently used in the relative valuation of firms 
that operate in industries with volatile or negative profits, such as start-up industries or cyclical 
industries. In its traditional sense, the krill industry is not new, but due to heavy growth and 
investments in recent years to become commercially viable and potentially highly profitable, 
it shares the same characteristics as industries in its early phases. All peer group multiples 
based on actual sales and forward-looking consensus estimates are summarized in exhibit 66 
above. 
The final estimate of Aker BioMarine’s share price based on EV-to-Sales multiples is 
determined in three steps. First, we multiply the company’s sales in each given year by the 
corresponding segment median multiple to get the enterprise value. From this, we add the 
firm’s excess cash and marketable securities and subtract the market value of debt to get the 
implied value of Aker BioMarine’s equity. Finally, we divide the implied market value of 
equity by the shares outstanding and convert the price to NOK to get the NOK price per share. 
Aker BioMarine’s implied price per share of NOK 209.5 in 2021 on Ingredients multiples is 
significantly higher than the NOK 51.4 based on median Brands EV-to-Sales multiples. Our 
final weighted valuation estimates for 2021 is NOK 158.9 per share. 
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Exhibit 67: EV-to-Sales relative valuation analysis of Aker BioMarine 
Aker BioMarine: EV-to-Sales relative valuation 
In USD thousands   2019A 2020E 2021E 2022E 
       
Aker BioMarine sales basis  246 170 298 367 414 023 484 666 
Ingredients median multiple  7.2x 5.9x 5.5x 5.1x 
Brands median multiple  2.1x 2.1x 2.0x 2.0x 
       
Aker BioMarine EV (Ingredients)  1 778 782 1 754 776 2 284 204 2 457 344 
Aker BioMarine EV (Brands)  524 943 612 284 824 058 945 479 
       
Cash and marketable securities  6 485 6 485 6 485 6 485 
Financial debt  (355 354) (355 354) (355 354) (355 354) 
Minority interest  - - - - 
Implied equity value (Ingredients)   1 429 913 1 405 907 1 935 335 2 108 476 
Implied equity value (Brands)  176 074 263 415 475 189 596 611 
       
Price per share: Ingredients (NOK)  154.8 152.2 209.5 228.2 
Price per share: Brands (NOK)  19.1 28.5 51.4 64.6 
       
Weighted price per share   111.3 112.6 158.9 175.8 
 
9.2.3 EV-to-EBIT 
 𝐸𝑉 − 𝑡𝑜 − 𝐸𝐵𝐼𝑇 =  
𝑇ℎ𝑒 𝑚𝑎𝑟𝑘𝑒𝑡 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑒𝑞𝑢𝑖𝑡𝑦 +  𝑁𝑒𝑡 𝑓𝑖𝑛𝑎𝑛𝑐𝑖𝑎𝑙 𝑑𝑒𝑏𝑡
𝐸𝐵𝐼𝑇
 Eq.30 
Exhibit 68: Actual EBIT ’19 and forward-looking consensus estimates ’20-’21-’22 
Peer valuation: EV-to-EBIT 
In USD thousands Basis (EV)   EV/EBIT '19 EV/EBIT '20E EV/EBIT '21E EV/EBIT '22E 
       
DSM 31 550 752  26.2x 27.3x 23.4x 21.1x 
Novozymes 17 932 729  29.6x 30.1x 28.5x 27.0x 
Probi 478 720  40.6x 32.7x 29.1x 25.5x 
Biogaia 793 652  30.9x 29.5x 25.8x 22.8x 
AAK 5 386 513  23.6x 22.0x 19.7x 18.3x 
Median ingredients     29.6x 29.5x 25.8x 22.8x 
       
Orkla 10 575 865  18.3x 18.5x 16.8x 16.3x 
Procter & Gamble 378 893 180  23.5x 21.4x 20.3x 19.0x 
Nestlé 366 932 240  22.4x 22.3x 21.8x 20.7x 
Midsona 621 951  34.6x 22.0x 15.8x 14.3x 
Glanbia 3 553 521  14.7x 19.5x 15.5x 13.5x 
Median Brands     22.4x 21.4x 16.8x 16.3x 
        
Aker BioMarine 1 099 345   108.8x 70.6x 23.5x 18.4x 
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EV-to-EBIT is an enterprise value multiple measuring EV on top of earnings before financial 
items and is one of the most used multiples by practitioners (Knivsflå, 2020f). Due to the 
inclusion of depreciation and amortization, this ratio takes into account the future need for 
maintenance and re-investments. Our peer group multiples will be calculated as in Eq. 30. 
As with the Price-to-Earnings multiple, it is worth noting that Aker BioMarine trades at 
significantly inflated multiples on actual 2019 EBIT and 2020 estimates compared to its peers. 
Some of the share price computations in 2019 and 2020 earnings will consequently come back 
as negative values, and these are excluded from our analysis and visualization of estimates in 
exhibit 69. Nonetheless, this does not affect our final value estimate based on 2021 earnings. 
From our forecasted EBIT basis of ~USD 46.80mn in 2021, we ultimately obtain a price per 
share of NOK 78.3 based on our selected comparable companies' market value. 
Exhibit 69: EV-to-EBIT relative valuation analysis of Aker BioMarine 
Aker BioMarine: EV-to-EBIT relative valuation 
In USD thousands   2019A 2020E 2021E 2022E 
         
EBIT basis  10 108 15 581 46 797 59 905 
Ingredients median multiple  29.6x 29.5x 25.8x 22.8x 
Brands median multiple  22.4x 21.4x 16.8x 16.3x 
         
Aker Bio EV range (Ingredients)  299 304 458 912 1 207 315 1 366 034 
Aker Bio EV range (Brands)  226 648 332 646 785 046 974 721 
         
Cash and marketable securities  6 485 6 485 6 485 6 485 
Financial debt  (355 354) (355 354) (355 354) (355 354) 
Minority interest  - - - - 
Implied equity value (Ingredients)*   - 110 044 858 446 1 017 166 
Implied equity value: (Brands)*  - - 436 178 625 852 
         
Price per share: Ingredients (NOK)*  - 11.9 92.9 110.1 
Price per share: Brands (NOK)*  - - 47.2 67.7 
         
Weighted price per share (NOK)   - 11.9 78.3 96.5 




 𝐸𝑉 − 𝑡𝑜 − 𝐸𝐵𝐼𝑇𝐷𝐴 =  
𝑇ℎ𝑒 𝑚𝑎𝑟𝑘𝑒𝑡 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑒𝑞𝑢𝑖𝑡𝑦 +  𝑁𝑒𝑡 𝑓𝑖𝑛𝑎𝑛𝑐𝑖𝑎𝑙 𝑑𝑒𝑏𝑡
𝐸𝐵𝐼𝑇𝐷𝐴
 Eq.31 
Exhibit 70: Actual EBITDA ’19 and forward-looking consensus estimates ’20-’21-’22 
Relative valuation: EV-to-EBITDA  
In USD thousands Basis (EV)   EV/EBITDA '19 EV/EBITDA '20E EV/EBITDA '21E EV/EBITDA '22E 
       
DSM 31 550 752  16.7x 16.9x 15.2x 14.1x 
Novozymes 17 932 729  22.6x 22.9x 22.0x 20.9x 
Probi 478 720  24.7x 20.2x 18.9x 17.3x 
Biogaia 793 652  29.1x 27.5x 24.2x 21.4x 
AAK 5 386 513  17.9x 16.3x 14.9x 14.1x 
Median ingredients     22.6x 20.2x 18.9x 17.3x 
       
Orkla 10 575 865  13.6x 13.4x 12.5x 12.2x 
Procter & Gamble 378 893 180  19.8x 18.2x 17.3x 16.2x 
Nestlé 366 932 240  17.8x 17.9x 17.4x 16.7x 
Midsona 621 951  20.3x 13.8x 11.1x 10.3x 
Glanbia 3 553 521  9.8x 11.2x 9.6x 8.7x 
Median Brands     17.8x 13.8x 12.5x 12.2x 
       
Aker BioMarine 1 099 345   20.7x 17.3x 12.2x 9.9x 
 
The final enterprise value multiple included in our relative valuation analysis is the EV-to-
EBITDA multiple. The EV-to-EBITDA peer valuation input and median multiples are 
summarized in exhibit 70. To see our full range of forward-looking inputs to derive the 
multiples, we refer to appendix C. As with the previous multiple valuation ratios, Ingredient 
peers are consistently trading at notably higher multiples in comparison to Brands companies 
and Aker BioMarine. We explain this with the considerable growth expected in the ingredients 
market in coming years, leading to a high multiple for companies in this peer group.  
Further, a relative valuation of the firm’s price per share on EV-to-EBITDA multiples is 
computed in the same manner as for EV-to-Sales multiples. From an EBITDA basis of USD 
90.06mn in 2021E, Aker BioMarine is priced at NOK 146.8 per share on the Ingredients 
median and NOK 84.5 on the median multiple of peers in the Brands segment. As seen in 




Exhibit 71: EV-to-EBITDA relative valuation analysis of Aker BioMarine 
9.3 Summary of relative valuation estimates 
As we stated in chapter 3, we have decided to use the relative valuation methodology as a 
complementary valuation method to our discounted cash flow-based valuation. In sum, it has 
provided us with valuable insight as to how the marketplace is assessing the fair valuation of 
assets with similar characteristics as Aker BioMarine. Figure 38 provides a visual summary 
of the high-to-low range of our relative valuation estimates for all years included and all 
companies included in our analysis, with the Ingredients and Brands peer group medians 
marked by blue and green dots, respectively. 
Figure 38: Summary of relative valuation estimates 
* Negative values removed for visual purposes 
Aker BioMarine: EV-to-EBITDA relative valuation 
In USD thousands   2019A 2020E 2021E 2022E 
       
Aker BioMarine EBITDA basis  53 039 63 581 90 060 111 259 
Ingredients median multiple  22.6x 20.2x 18.9x 17.3x 
Brands median multiple  17.8x 13.8x 12.5x 12.2x 
       
Aker BioMarine implied EV (Ingredients)  1 198 663 1 283 742 1 705 598 1 921 066 
Aker BioMarine implied EV (Brands)  941 875 874 826 1 129 159 1 355 486 
       
Cash and marketable securities  6 485 6 485 6 485 6 485 
Financial debt  (355 354) (355 354) (355 354) (355 354) 
Minority interest  - - - - 
Implied equity value (Ingredients)   849 794 934 873 1 356 730 1 572 197 
Implied equity value: (Brands)  593 007 525 958 780 291 1 006 618 
       
Price per share: Ingredients (NOK)  92.0 101.2 146.8 170.2 
Price per share: Brands (NOK)  64.2 56.9 84.5 109.0 
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From our visualization of valuation estimates, it is evident that Aker BioMarine’s stock price 
of NOK 82.00 per share today is well below our final relative valuation estimates of 2021E 
EV/EBITDA and EV/Sales estimated to be NOK 126.9 and NOK 158.9, respectively. The 
firm is priced lower on the peer group’s median on 2021E EV/EBIT with a share price of NOK 
78.3 and Price/Earnings multiples with our weighted price estimate of NOK 61.3 per share. 
This is partially due to our moderate forecasts of earnings and EBIT in the two coming years, 
as we believe that Aker BioMarine’s earnings will be limited in these years due to the firm’s 
intensive revenue growth prospects. More so, this is also reflected in the high valuation on 
EV/Sales multiples. 
If Aker BioMarine is to be priced in the upper end of peer companies in the Ingredients 
segment, it could expect a upside to its stock price as of October 30. However, we note that 
pricing in this peer group spans widely, and pricing for companies in the lower end of this peer 
group is more or less equal to Aker BioMarine’s pricing as of today. Overall, we see a clear 
trend from our visualization in figure 38 that the implied share prices based on the brand 
median (green diamonds) are lower than the black dotted line that resembles Aker BioMarine’s 
stock price of today. On the other hand, the Ingredients median pricing (blue diamonds) is 
consistently above the current share price. While Aker BioMarine trades slightly above the 
Brands peer group on trailing multiples, our estimates of steep growth in financial indicators 
in coming years make the company’s relative valuation converge with Brands on forward-
looking multiples.  
These findings confirm our discussion that a valuation of Aker BioMarine at the higher end of 
its peer groups may not be entirely justified as of today. We argue that should Aker BioMarine 
be successful in transforming a higher amount of its krill meal into high-profit krill oil, a 
valuation somewhere closer to its Ingredient peers may very well be warranted. 
9.4 Final relative valuation estimate 
As we have mentioned, consistent with Koller et al. (2020), we have concluded that 2021E 
enterprise multiples best provide the basis to obtain our ultimate relative value estimate. We 
recognize the three metrics as equally essential and thus arrive at a final stock price by 
weighting the three enterprise multiple valuation estimates on equal weights. As discussed 
previously, we consider price multiples to be less relevant for our analysis as it does not 
recognize the firms’ capital structure, and we decide not to weight the P/E multiple in our final 
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estimate. Further, we have chosen to use median multiples as opposed to average multiples 
for the two peer groups, as the median value is less exposed to outliers in our comparable 
group than mean values (Knivsflå, 2020f). We obtain a final estimate of Aker BioMarine’s 
stock price of NOK 121.4 per share with our selected weights. This share price constitutes a 
48.0% upside to the current share price of NOK 82.0 per share. The final value estimate based 
on average multiples is also presented in exhibit 72 for comparison. 
Exhibit 72: Calculation of final weighted relative valuation estimate 
Final relative valuation estimate 
    Stock Prices 
Multiple  Average Median Weighting 
Price-to-Earnings   NOK     57.4   NOK     61.3  0% 
EV-to-EBIT   NOK     78.6   NOK     78.3  33.3% 
EV-to-EBITDA   NOK   130.9   NOK   126.9  33.3% 
EV-to-Sales   NOK   159.7   NOK   158.9  33.3% 
        
The final weighted estimate of the stock price (NOK)   NOK   123.1   NOK   121.4  100% 
 
In simple terms, our estimated stock price suggests that Aker BioMarine is undervalued in the 
stock market as of October 30, 2020. However, we argue that several factors make it 
challenging to draw an unambiguous conclusion on our valuation estimate. Firstly, none of 
our comparable firms can be said to be directly comparable to Aker BioMarine.  
All these companies are operating in the same end-markets as Aker BioMarine, but none are 
making ingredients or branded products with krill as their primary input. Consequently, our 
peer groups do not share the exact characteristics such as metrics as growth, cash flow 
potential, and riskiness. Moreover, as an extension of this, we acknowledge that our final 
valuation estimate is influenced by the choices we have made to determine the peer group and 
select relevant comparable companies. Further, the significant growth implied in our future 
financial estimates for Aker BioMarine also makes peer valuation on future estimates a 
challenging task. 
In conclusion, there are several potential pitfalls in relative valuation analysis, and the relative 
valuation methodology has its weaknesses as any other valuation methodology. Despite this, 
we have undertaken a conventional approach and have attempted to be transparent in our 
assumptions and consistent in our calculations. Hence, to the best of our knowledge, our 
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relative valuation gives us a highly relevant estimate of how the market assesses the market 
value of assets with similar characteristics as Aker BioMarine. 











Current price: NOK 82.0
Relative valuation: NOK 121.4
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This master thesis aims to answer the research question: “What is the intrinsic value of Aker 
BioMarine's equity on October 30, 2020?”. Based on analyses of the financial performance 
and strategic outlook, we have estimated the future financial performance and cost of capital 
of Aker BioMarine to value the equity of the company. We have installed both fundamental 
models and relative valuations to estimate the fair share price. In this chapter, the thesis's vital 
findings are summarized, and, lastly, we recommend a trading strategy for the stock. 
10.1 Summary 
The master thesis consists of two components. The first component includes chapters 2, 3, 4, 
and 5. The second chapter is the introduction to both Aker BioMarine and the krill industry. 
The third chapter introduced relevant theories and frameworks applied later in the thesis and 
argued why the fundamental valuation would carry the most weight in the valuation. It was 
further elaborated that the relative valuation would be supplementary to the fundamental 
valuation. 
The fourth chapter was an extensive and detailed strategic analysis of the krill industry and 
Aker BioMarine. The external analysis revealed that the krill industry's competitive 
environment is moderate, attributed to the considerable entry barriers and limited close 
competitors. The findings from the external industry analysis indicate that it is possible to 





























cost of capital 
Chapter 9: 
Relative valuation 
Step: 1 Step: 2 Step: 3 Step: 4 Step: 5 
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The internal-oriented analysis indicated that the brand name, value chain, patents, and strategic 
collaborations represent some of the most critical competitive advantages for Aker BioMarine. 
It was reasoned that the stated resources provide a short-term competitive advantage, but all 
the resources are replicable, making a competitive advantage limited. The fifth chapter 
presents the historical financial analysis of Aker BioMarine. The financial statements were 
presented, reorganized, and adjusted. The financial statement analysis was limited to three 
years, as Aker BioMarine was only required to disclose the past three years associated with 
the initial public offering at Merkur Market. It would be possible to derive more information 
about the previous years, but as we regard Aker BioMarine to be a high-growth company, we 
consider the historical financials to have limited importance. 
The second component of the thesis includes chapters 6, 7, 8, 9 and 10. The sixth chapter 
presented the projected financial statements of Aker BioMarine in the coming ten years based 
on the strategic- and financial analyses in the previous chapters. The seventh chapter presented 
the cost of capital we expect the company will have in the coming years. The WACC estimate 
is dynamic until reaching a steady state. 
The forecasted statements were utilized in the eight chapter to estimate the equity's fair market 
value with two different valuation techniques, DCF and EVA. These valuation techniques 
indicated a fair share price of NOK 96.74. The chapter concluded with a sensitivity analysis 
of the WACC and growth that illustrated our estimates' sensitivity. The ninth chapter contained 
the relative valuation where we deployed the multiples EV/EBIT, EV/EBITDA, EV/Sales, 
and P/E. Based on the enterprise multiples, the median estimate of the fair share price was at 
NOK 121.40. We decided to weigh the multiple analysis and fundamental analysis with 20.0% 






10.2 Trading strategy 
Based on the final estimation of the fundamental value of Aker BioMarine as of October 30, 
2020, we present a trading strategy. To evaluate whether the Aker BioMarine stock is 
underpriced (overpriced) as of October 30, 2020, the estimated value of NOK 101.67 must be 
compared with the closing price the same day. Due to our estimates' uncertainties, it is decided 
to present a trading strategy with a buy, hold, or sell recommendation with a deviation of +/- 
10% of the value estimation. With this deviation implemented in the strategy, a hold-
recommendation will be in the interval of NOK [91.50,111.84].  
If the closing price is below NOK 91.50, we recommend buying, is it above NOK 111.84, we 
recommend selling. If the closing price is in the interval, we recommend holding. As of 
October 30, 2020, the closing price was at NOK 82.00, which is well below our final valuation 
estimate. Thus, we recommend BUYING Aker BioMarine on October 30, 2020, as we see a 
potential upside of 23.98%. 










SELL HOLD BUY 
Lower bound: NOK 91.50 Upper bound: NOK 111.84 
Closing price on October 30   
NOK 82.00 
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10.3 Closing thoughts 
To conclude our thesis, we want to leave the reader with our closing thoughts on three 
interesting topics and how they can be the basis for though-provoking discussions on why the 
fair value may differ in the viewpoint of different investors. Firstly, we take a brief glance at 
how professional equity research analysts are assessing the fair value of the Aker BioMarine 
share price. Further, we also want to address the significant stock price development that 
occurred after the cut-off date of our analysis. Finally, we wrap up the chapter with our closing 
thoughts on the “ESG premium” and its implications for the intrinsic value of a firm. 
10.3.1 Analyst target prices as of October 30, 2020 
Compared with analyst target prices as of October 30, 2020, our analysis is placed at the low 
end of the selected range of analysts. On average, the equity analyst's target price is as high as 
NOK 150.0. At the top of this range, Arctic Securities issued a target price of NOK 185.0. 
This represents an upside of 125.6% on the October 30 market value. The most conservative, 
DNB Markets, has issued the lowest target price of NOK 120.0, a reiteration of their initial 
NOK 130.0 target price in September. 
Figure 40: Analyst target prices as of October 30, 2020 
Source: Bloomberg LP (October 30, 2020) 
Interestingly, although our price estimate constitutes a 23.98% upside to Aker BioMarine’s 
pricing in the market as of today, we have issued a target price 15.27% below the lowest price 
target among the industry analysts. As reasoned throughout our thesis, we believe that the firm 
is too ambitious on specific projections and metrics, reflected in an overall underperformance 
























SEB Equities DNB Markets Lindberg &
Rasmussen
 200
the consensus bracket as it is evident that the equity research analysts seemingly view the 
magnitude of future growth opportunities and risk differently. 
10.3.2 Aker BioMarine’s price development after our cut-date 
Aker BioMarine’s price development since its Merkur Market listing on July 6, 2020, can be 
characterized as volatile. On the first day of trading on the platform, the stock closed at NOK 
104.7. From this date until our cut-off date on October 30, the stock fell to NOK 82.0, hovering 
between a high in the period of NOK 110.0 and a low of NOK 78.2. After drifting around the 
NOK 80 mark during October and until mid-November, the stock surged by 34% to a price of 
NOK 109.9 as of closing on December 7, 2020. 
Figure 41: Aker BioMarine’s total return before and after the cut-off date (Indexed to 100) 
Source: Bloomberg LP (October 30, 2020) 
We see two primary reasons for the significant surge: firstly, on November 24, Aker 
BioMarine launched an all-new business segment called Lysoveta. This segment is intended 
to produce commercially viable krill-based products with a broad range of applications and 
health benefits primarily for brain and eye health to a large and fast-growing market (Aker 
BioMarine, 2020d). In the week following the announcement, the company’s stock price rose 
by more than 20%.  
Second, as illustrated in figure 41, the broader stock market in Norway has been steadily 
increasing since our cut-off date, and some of the day-to-day stock price increases in Aker 
BioMarine may also be attributable to the overall positive sentiment in the Norwegian stock 
market. This overall positive stock market uptick is likely to be closely linked to recent news 
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10.3.3 Growing evidence of a potential ESG premium 
As discussed in the strategical analysis in chapter 4, several finance academics and 
practitioners argue that one can observe a premium in the marketplace today on stocks that 
perform well on specific ESG metrics. This effect has picked up pace in recent years, and there 
is a growing collection of empirical evidence that works in favor of this viewpoint (Ciciretti, 
Dalò, & Dam, 2019). More so, more money than ever is flowing into sustainability-linked 
investments. As of October 25, ESG ETFs has seen an inflow of more than USD 22bn this 
year. Despite this, the ESG label is not under the policy by most global regulators as of today 
(Wagner & Ballentine, 2020). 
However, although formal mechanisms are not fully implemented by the government and 
regulators to incentivize sustainability and climate action today, an increasing investor 
attention towards ESG performance is driving the transition from conventional to sustainable 
finance. Aker BioMarine’s business model answers several of the UN’s 17 Sustainable 
Development Goals, and the company has been vocal about including them as a part of their 
mission statement. In a sense, this may leave an additional upside to Aker BioMarine’s 
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Appendix A: Peer group historical financial 
performance 
Appendix 1: Probi AB adjusted historical financial highlights 
In SEK thousands   2017 2018 2019 
     
Revenue  612 244 604 117 626 192 
EBITA  145 535 143 402 173 615 
EBITA, adjusted  146 935 143 402 173 615 
NOPAT  109 960 110 942 136 147 
     
Invested capital, incl. goodwill   1 055 983 1 153 180 1 226 574 
Invested capital, excl. goodwill   776 277 848 619 910 372 
     
Operating margin   24,0% 23,7% 27,7% 
Capital turnover, incl. goodwill  0,6 0,5 0,5 
Capital turnover, excl. goodwill  0,8 0,7 0,7 
Operating taxes   25,2% 22,6% 21,6% 
     
Return on invested capital, incl. goodwill   10,4% 9,6% 11,1% 
Return on invested capital, excl. goodwill   14,2% 13,1% 15,0% 
Source: Probi AB annual report 2019 (2020) 
Appendix 2: DSM Koninklijke adjusted historical financial highlights 
In EUR thousands   2017 2018 2019 
     
Revenue  8 632 000 9 267 000 9 010 000 
EBITA  1 030 000 1 434 000 1 189 000 
EBITA, adjusted  1 147 000 1 534 000 1 310 000 
NOPAT  969 230 1 273 864 1 079 002 
     
Invested capital, incl. goodwill   9 794 000 10 666 000 10 672 000 
Invested capital, excl. goodwill   7 861 000 8 757 000 8 389 000 
     
Operating margin   13,3% 16,6% 14,5% 
Capital turnover, incl. goodwill  0,9 0,9 0,8 
Capital turnover, excl. goodwill  1,1 1,1 1,1 
Operating taxes   15,5% 17,0% 17,6% 
     
Return on invested capital, incl. goodwill   9,9% 11,9% 10,1% 
Return on invested capital, excl. goodwill   12,3% 14,5% 12,9% 
Source: DSM Koninklijke annual report 2019 (2020) 
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Appendix 3: Midsona AB adjusted historical financial highlights 
In SEK thousands   2017 2018 2019 
     
Revenue  2 146 000 2 852 000 3 081 000 
EBITA  160 000 213 000 252 000 
EBITA, adjusted  182 000 226 000 258 000 
NOPAT  136 500 178 859 215 741 
     
Invested capital, incl. goodwill   2 379 000 3 045 000 4 102 000 
Invested capital, excl. goodwill   1 145 000 1 637 000 2 292 000 
     
Operating margin   8,5% 7,9% 8,4% 
Capital turnover, incl. goodwill  0,9 0,9 0,8 
Capital turnover, excl. goodwill  1,9 1,7 1,3 
Operating taxes   25,0% 20,9% 16,4% 
     
Return on invested capital, incl. goodwill   5,7% 5,9% 5,3% 
Return on invested capital, excl. goodwill   11,9% 10,9% 9,4% 
Source: Midsona AB annual report 2019 (2020) 
Appendix 4: Glanbia PLC adjusted historical financial highlights 
In EUR thousands   2017 2018 2019 
     
Revenue  2 387 100 3 170 500 3 875 700 
EBITA  278 400 284 900 237 700 
EBITA, adjusted  283 900 287 700 261 900 
NOPAT  237 152 252 331 237 039 
     
Invested capital, incl. goodwill   2 094 400 2 617 300 2 830 700 
Invested capital, excl. goodwill   1 698 200 2 067 500 2 256 400 
     
Operating margin   11,9% 9,1% 6,8% 
Capital turnover, incl. goodwill  1,1 1,2 1,4 
Capital turnover, excl. goodwill  1,4 1,5 1,7 
Operating taxes   16,5% 12,3% 9,5% 
     
Return on invested capital, incl. goodwill   11,3% 9,6% 8,4% 
Return on invested capital, excl. goodwill   14,0% 12,2% 10,5% 
Source: Glanbia PLC annual report 2019 (2020) 
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Appendix B: Aker BioMarine beta calculations 
Appendix 5: Aker BioMarine’s equity beta calculations 
 
Appendix 6: Aker BioMarine’s equity beta regression statistics 
Regression Statistics        
Multiple R 0.3614        
R Square 0.1306        
Adjusted R 
Square 0.1222        
Standard Error 0.0253        
Observations 106        
         
  df SS MS F Significance F    
Regression 1 0.0100 0.0100 15.6229 0.0001    
Residual 104 0.0666 0.0006       
Total 105 0.0766          
         
  Coefficients 
Standard 







Intercept -0.0003 0.0025 -0.1385 0.8901 -0.0052 0.0046 -0.0052 0.0046 
OSE all shares 0.8446 0.2137 3.9526 0.0001 0.4209 1.2684 0.4209 1.2684 
 






















Appendix C: Bloomberg consensus for relative 
valuation 
Appendix 7: Bloomberg consensus estimates: Earnings per share 
In USD thousands EPS '19 EPS '20E EPS '21E EPS '22E 
      
Ingredients           
DSM  4.82 4.55 6.37 6.45 
Novozymes  1.65 1.62 1.75 1.89 
Probi  0.80 1.02 1.17 1.35 
Biogaia  1.14 1.18 1.30 1.48 
AAK  0.61 0.69 0.78 0.85 
        
Brands           
Orkla  0.44 0.47 0.51 0.53 
Procter & Gamble 4.96 5.53 5.93 6.42 
Nestlé  4.33 4.47 4.62 4.96 
Midsona  0.21 0.28 0.36 0.43 
Glanbia   0.68 0.57 0.78 0.90 
Source: Bloomberg LP (October 30, 2020) 
Appendix 8: Bloomberg consensus estimates: Sales 
In USD thousands Sales '19 Sales '20E Sales '21E Sales '22E 
      
Ingredients           
DSM   10 086 585 10 193 176 10 725 701 11 268 296 
Novozymes   2 155 275 2 247 811 2 324 125 2 424 585 
Probi   66 251 81 397 86 770 94 419 
Biogaia   81 291 83 680 92 550 102 842 
AAK   3 016 364 3 179 652 3 370 103 3 487 590 
            
Brands           
Orkla   4 959 515 5 153 632 5 313 524 5 421 334 
Procter & Gamble 70 950 000 74 041 059 76 363 235 79 450 364 
Nestlé   93 161 973 93 246 386 94 930 799 98 207 013 
Midsona   325 970 412 517 477 851 490 044 
Glanbia   4 337 531 4 538 203 4 704 011 4 960 811 





Appendix 9: Bloomberg consensus estimates: EBIT 
In USD thousands EBIT '19 EBIT '20E EBIT '21E EBIT '22E 
      
Ingredients           
DSM   1 203 449 1 153 996 1 349 734 1 492 374 
Novozymes   605 618 594 856 628 691 662 976 
Probi   11 797 14 647 16 444 18 738 
Biogaia   25 658 26 945 30 763 34 804 
AAK   228 211 244 889 273 964 294 877 
            
Brands           
Orkla   578 563 571 329 630 427 649 983 
Procter & Gamble 16 143 000 17 746 750 18 643 500 19 936 000 
Nestlé   16 364 334 16 419 479 16 834 287 17 707 689 
Midsona   17 986 28 223 39 466 43 493 
Glanbia   241 627 181 971 229 921 263 958 
Source: Bloomberg LP (October 30, 2020) 
Appendix 10: Bloomberg consensus estimates: EBITDA 
In USD thousands EBITDA '19 EBITDA '20E EBITDA '21E EBITDA '22E 
      
Ingredients           
DSM   1 885 217 1 862 946 2 076 247 2 242 092 
Novozymes   793 496 784 344 816 661 859 348 
Probi   19 404 23 710 25 278 27 725 
Biogaia   27 307 28 817 32 821 37 050 
AAK   300 896 330 486 360 765 381 673 
            
Brands           
Orkla   776 761 790 910 843 517 868 073 
Procter & Gamble 19 156 000 20 814 000 21 892 000 23 382 778 
Nestlé   20 662 739 20 508 392 21 055 710 22 035 211 
Midsona   30 682 45 202 56 142 60 472 
Glanbia   363 615 317 969 369 086 407 663 
Source: Bloomberg LP (October 30, 2020) 
 
 
